<SEC-DOCUMENT>0001193125-25-139517.txt : 20250612
<SEC-HEADER>0001193125-25-139517.hdr.sgml : 20250612
<ACCEPTANCE-DATETIME>20250612060529
ACCESSION NUMBER:		0001193125-25-139517
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20250611
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250612
DATE AS OF CHANGE:		20250612

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cabaletta Bio, Inc.
		CENTRAL INDEX KEY:			0001759138
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			AZ
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39103
		FILM NUMBER:		251041600

	BUSINESS ADDRESS:	
		STREET 1:		2929 ARCH STREET
		STREET 2:		SUITE 600
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
		BUSINESS PHONE:		(267) 759-3100

	MAIL ADDRESS:	
		STREET 1:		2929 ARCH STREET
		STREET 2:		SUITE 600
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d828604d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:caba="http://www.cabalettabio.com/20250611" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-351">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-06-11_to_2025-06-11">0001759138</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="caba-20250611.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-06-11_to_2025-06-11"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-06-11</xbrli:startDate> <xbrli:endDate>2025-06-11</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-362">8-K</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-06-11_to_2025-06-11" format="ixt:datemonthdayyearen" id="ixv-363">June 11, 2025</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-364">CABALETTA BIO, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-06-11_to_2025-06-11" format="ixt-sec:stateprovnameen" id="ixv-365">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-366">001-39103</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-367">82-1685768</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-368">2929 Arch Street</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-369">Suite 600</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-370">Philadelphia</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-06-11_to_2025-06-11" format="ixt-sec:stateprovnameen" id="ixv-371">Pennsylvania</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-372">19104</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-373">(267)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-374">759-3100</ix:nonNumeric></span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-06-11_to_2025-06-11" format="ixt-sec:boolballotbox" id="ixv-375">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-06-11_to_2025-06-11" format="ixt-sec:boolballotbox" id="ixv-376">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-06-11_to_2025-06-11" format="ixt-sec:boolballotbox" id="ixv-377">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-06-11_to_2025-06-11" format="ixt-sec:boolballotbox" id="ixv-378">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-379">Common Stock, par value $0.00001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-380">CABA</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-06-11_to_2025-06-11" format="ixt-sec:exchnameen" id="ixv-381">The Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;&#8201;240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-06-11_to_2025-06-11" format="ixt-sec:boolballotbox" id="ixv-382">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;1.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;11, 2025, Cabaletta Bio, Inc. (the &#8220;Company&#8221;) entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Jefferies LLC, TD Securities (USA) LLC and Cantor Fitzgerald &amp; Co. (collectively, the &#8220;Underwriters&#8221;), relating to an underwritten offering (the &#8220;Offering&#8221;) of (i) 39,200,000 shares (the &#8220;Shares&#8221;) of the Company&#8217;s common stock, $0.00001 par value per share (the &#8220;Common Stock&#8221;), (ii) in lieu of Common Stock to certain investors, <span style="white-space:nowrap">pre-funded</span> warrants to purchase an aggregate of 10,800,000 shares of Common Stock (the <span style="white-space:nowrap">&#8220;Pre-Funded</span> Warrants&#8221;) and (iii)&#160;accompanying warrants to purchase an aggregate of 50,000,000 shares of Common Stock (or <span style="white-space:nowrap">pre-funded</span> warrants in lieu thereof) (the &#8220;Common Stock Warrants,&#8221; and together with the <span style="white-space:nowrap">&#8220;Pre-Funded</span> Warrants,&#8221; the &#8220;Warrants&#8221;, and the Common Stock issuable upon exercise of the Warrants, the &#8220;Warrant Shares&#8221;). Cabaletta also granted the underwriters a <span style="white-space:nowrap">30-day</span> option to purchase up to an additional 15,000,000 shares of common stock and/or warrants at the public offering price, less underwriting discounts and commissions. All of the Shares and the Warrants in the Offering were sold by the Company. The Common Stock and <span style="white-space:nowrap">Pre-Funded</span> Warrants were sold in combination with an accompanying Common Stock Warrant to purchase one share of Common Stock (or a <span style="white-space:nowrap">pre-funded</span> warrant in lieu thereof) for each share of Common Stock or <span style="white-space:nowrap">Pre-Funded</span> Warrant sold. Each Share was offered and sold together with an accompanying Common Stock Warrant at a combined offering price of $2.00, and each <span style="white-space:nowrap">Pre-Funded</span> Warrant was offered and sold together with an accompanying Common Stock Warrant at a combined offering price of $1.99999, which is equal to the combined offering price per share of Common Stock and accompanying Common Stock Warrant less the $0.00001 exercise price of each <span style="white-space:nowrap">Pre-Funded</span> Warrant. The offering is expected to close on June&#160;12, 2025, subject to customary closing conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each <span style="white-space:nowrap">Pre-Funded</span> Warrant has an initial exercise price per share of $0.00001, subject to certain adjustments. The <span style="white-space:nowrap">Pre-Funded</span> Warrants are exercisable immediately and may be exercised at any time until all of the <span style="white-space:nowrap">Pre-Funded</span> Warrants are exercised in full. Each Common Stock Warrant has an initial exercise price per share of $2.50, subject to certain adjustments. The Common Stock Warrants are immediately exercisable from the date of issuance and will expire fifteen months from the date of issuance. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Warrants, the Company may not effect the exercise of any Warrant, and a holder will not be entitled to exercise any portion of any Warrant (i)&#160;if immediately prior to the exercise, holder (together with its affiliates), beneficially own an aggregate number of shares of Common Stock greater than 4.5%, 4.99% or 9.99%, as applicable (the &#8220;Maximum Percentage&#8221;) of the total number of issued and outstanding shares of Common Stock of the Company without taking into account any Warrant Shares, or (ii)&#160;to the extent that immediately following the exercise, holder (together with its affiliates) would beneficially own in excess of the Maximum Percentage of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such shares of Common Stock, which such percentage may be changed at the holder&#8217;s election to a higher or lower percentage not in excess of 19.99% upon 61 days&#8217; notice to the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Common Stock Warrants include certain rights upon &#8220;fundamental transactions&#8221; as described in the Common Stock Warrants, including the right of the holders thereof to receive from the Company or a successor entity the same type or form of consideration (and in the same proportion) that is being offered and paid to the holders of Common Stock in such fundamental transaction in the amount of the Black Scholes Value (as described in such Common Stock Warrants) of the unexercised portion of the applicable Common Stock Warrants on the date of the consummation of such fundamental transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company estimates that the net proceeds from the Offering will be approximately $94.0&#160;million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, or $108.1&#160;million, if the underwriters exercise their option in full. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Shares and the Warrants were issued pursuant to a shelf registration statement on Form <span style="white-space:nowrap">S-3</span> (File <span style="white-space:nowrap">No.&#160;333-278126),</span> as amended by that certain Post-Effective Amendment No.&#160;1 to Form <span style="white-space:nowrap">S-3</span> (No. <span style="white-space:nowrap">333-278126)</span> and that certain Post-Effective Amendment No.&#160;2 to Form <span style="white-space:nowrap">S-3</span> (No. <span style="white-space:nowrap">333-278126),</span> as filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;31, 2025 and declared effective on March&#160;31, 2025. A prospectus supplement relating to the Offering has been filed with the SEC dated June&#160;11, 2025 and a final prospectus supplement dated June&#160;11, 2025. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Underwriting Agreement contains customary representations, warranties, covenants, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, and other obligations of the parties. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties. The foregoing is only a brief description of the terms of the Underwriting Agreement, does not purport to be a complete statement of the rights and obligations of the parties under the Underwriting Agreement and the transactions contemplated thereby, and is qualified in its entirety by reference to the Underwriting Agreement, which is filed as Exhibit 1.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing is only a brief description of the terms of the form of Warrants, does not purport to be a complete statement of the rights and obligations of the parties thereto and the transactions contemplated thereby, and is qualified in its entirety by reference to the form of <span style="white-space:nowrap">Pre-Funded</span> Warrant and form of Common Stock Warrant that are filed as Exhibit 4.1 and Exhibit 4.2, respectively, to this Current Report on Form <span style="white-space:nowrap">8-K</span> and are incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the legal opinion of Goodwin Procter LLP relating to the issuance and sale of the Shares and the Warrants in the Offering is filed as Exhibit 5.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is filed with reference to, and is hereby incorporated by reference into, the Registration Statement. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;8.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The full text of the press release announcing the pricing of the underwritten offering on June&#160;11, 2025 is attached as Exhibit 99.1 hereto and is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company currently intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, primarily to fund the expanded clinical development of <span style="white-space:nowrap">rese-cel</span> in multiple indications including the initiation of potentially registrational studies, and to further advance its manufacturing capabilities in preparation for late-stage clinical trials and commercial readiness for <span style="white-space:nowrap">rese-cel,</span> in addition to working capital and general corporate purposes. Based upon the Company&#8217;s current operating plan, the Company believes that the net proceeds from the offering, excluding any exercise of the underwriters&#8217; option, together with the Company&#8217;s existing cash and cash equivalents, will enable it to fund its operating expenses and capital expenditure requirements into the second half of 2026. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:3%"/>
<td style="width:94%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">1.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d828604dex11.htm">Underwriting Agreement, dated June&#160;11, 2025, between Cabaletta Bio, Inc. and Jefferies LLC, TD Securities (USA) LLC and Cantor Fitzgerald &amp; Co. as representatives of the several underwriters named therein. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d828604dex41.htm">Form of <span style="white-space:nowrap">Pre-Funded</span> Warrant. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">4.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d828604dex42.htm">Form of Common Stock Warrant. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d828604dex51.htm">Opinion of Goodwin Procter LLP. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d828604dex51.htm">Consent of Goodwin Procter LLP (included in Exhibit&#160;5.1). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d828604dex991.htm">Press Release dated June&#160;11, 2025. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL Document).</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top;text-align:left">*</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation <span style="white-space:nowrap">S-K.</span> A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request. </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">CABALETTA BIO, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: June 12, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Steven Nichtberger</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Steven Nichtberger</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer and President</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Executive Officer)</p></td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d828604dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>39,200,000 Shares of Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to purchase 10,800,000 Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Warrants to Purchase 50,000,000 Shares of Common Stock (or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants in lieu thereof)
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>UNDERWRITING AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">June&nbsp;11, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TD SECURITIES (USA) LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CANTOR FITZGERALD&nbsp;&amp; CO. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of the several Underwriters </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o JEFFERIES
LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o TD SECURITIES (USA) LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1 Vanderbilt Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o CANTOR FITZGERALD&nbsp;&amp; CO.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">110 East 59th Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Introductory.</B>
Cabaletta Bio, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), proposes to issue and sell to the several underwriters named in <U>Schedule A</U> (the &#147;<B>Underwriters</B>&#148;) an aggregate of (i) 39,200,000 shares (the
&#147;<B>Shares</B>&#148;) of its common stock, par value $0.00001 per share (the &#147;<B>Common Stock</B>&#148;), (ii) <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants of the Company to purchase an aggregate of 10,800,000 shares of
Common at an exercise price equal to $0.00001 per share (the &#147;<B><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants</B>&#148;) and (iii)&nbsp;common warrants to purchase up to 50,000,000 shares of Common Stock of the Company (or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants in lieu thereof) at an exercise price equal to $2.50 per share (the &#147;<B>Warrants</B>&#148;). The 39,200,000 Shares to be sold by the Company are called the &#147;<B>Firm Shares</B>&#148; and
the Warrants to purchase 50,000,000 Shares to be sold by the Company are called the &#147;<B>Firm Warrants</B>.&#148; As used herein, &#147;<B>Firm Securities</B>&#148; means the Firm Shares, the Firm Warrants and the
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. In addition, the Company has granted to the Underwriters an option to purchase up to an additional 7,500,000 Shares and/or warrants to purchase an additional 7,500,000 shares of Common
Stock (the &#147;<B>Optional Warrants</B>&#148; and together with the Firm Warrants, the &#147;<B>Offered Warrants</B>&#148;), as provided in Section&nbsp;2. The additional 7,500,000 Shares to be sold by the Company pursuant to such option are
called the &#147;<B>Optional Shares</B>&#148; and together with the Optional Warrants, are collectively called the &#147;<B>Optional Securities</B>.&#148; The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are
collectively called the &#147;<B>Offered Shares</B>&#148;, and together with the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, the Firm Warrants and, if and to the extent such option is exercised, the Optional Warrants are
collectively referred to as the &#147;<B>Offered Securities</B>.&#148; Jefferies LLC (&#147;<B>Jefferies</B>&#148;), TD Securities (USA) LLC (&#147;<B>TD Cowen</B>&#148;) and Cantor Fitzgerald&nbsp;&amp; Co. (&#147;<B>Cantor</B>&#148;) have </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreed to act as representatives of the several Underwriters (in such capacity, the &#147;<B>Representatives</B>&#148;) in connection with the offering and sale of the Offered Securities. To the
extent there are no additional underwriters listed on <U>Schedule A</U>, the term &#147;Representatives&#148; as used herein shall mean you, as Underwriters, and the term &#147;Underwriters&#148; shall mean either the singular or the plural, as the
context requires. As used herein, &#147;<B>Warrant Shares</B>&#148; means the shares of Common Stock issuable upon the exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and the Offered Warrants. Each Share and each <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant are being sold with one Warrant to purchase one share of Common Stock or, in each case, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants in lieu thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has prepared and filed with the Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) a shelf registration
statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3ASR,</FONT> File <FONT STYLE="white-space:nowrap">No.&nbsp;333-278126,</FONT> including a base prospectus (the &#147;<B>Base Prospectus</B>&#148;), as amended by Post-Effective Amendment
No.&nbsp;1 and Post-Effective Amendment No.&nbsp;2 thereto, to be used in connection with the public offering and sale of the Offered Securities. Such registration statement, as amended, including the financial statements, exhibits and schedules
thereto, in the form in which it became effective under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder (collectively, the &#147;<B>Securities Act</B>&#148;), including all documents incorporated or
deemed to be incorporated by reference therein and any information deemed to be a part thereof at the time of effectiveness pursuant to Rule&nbsp;430A or 430B under the Securities Act, is called the &#147;<B>Registration Statement</B>.&#148; Any
registration statement filed by the Company pursuant to Rule 462(b) under the Securities Act in connection with the offer and sale of the Offered Securities is called the &#147;<B>Rule 462(b) Registration Statement</B>,&#148; and from and after the
date and time of filing of any such Rule 462(b) Registration Statement the term &#147;Registration Statement&#148; shall include the Rule 462(b) Registration Statement. The preliminary prospectus supplement dated June&nbsp;11, 2025 describing the
Offered Securities and the offering thereof (the &#147;<B>Preliminary Prospectus Supplement</B>&#148;), together with the Base Prospectus, is called the &#147;<B>Preliminary Prospectus</B>,&#148; and the Preliminary Prospectus and any other
prospectus supplement to the Base Prospectus in preliminary form that describes the Offered Securities and the offering thereof and is used prior to the filing of the Prospectus (as defined below), together with the Base Prospectus, is called a
&#147;<B>preliminary prospectus</B>.&#148; As used herein, the term &#147;<B>Prospectus</B>&#148; shall mean the final prospectus supplement to the Base Prospectus that describes the Offered Securities and the offering thereof (the &#147;<B>Final
Prospectus Supplement</B>&#148;), together with the Base Prospectus, in the form first used by the Underwriters to confirm sales of the Offered Securities or in the form first made available to the Underwriters by the Company to meet requests of
purchasers pursuant to Rule 173 under the Securities Act. References herein to the Preliminary Prospectus, any preliminary prospectus and the Prospectus shall refer to both the prospectus supplement and the Base Prospectus components of such
prospectus. As used herein, &#147;<B>Applicable Time</B>&#148; is 8:15 a.m. (New York City time) on June&nbsp;11, 2025. As used herein, &#147;<B>free writing prospectus</B>&#148; has the meaning set forth in Rule 405 under the Securities Act, and
&#147;<B>Time of Sale Prospectus</B>&#148; means the Preliminary Prospectus, as amended or supplemented immediately prior to the Applicable Time, together with the free writing prospectuses, if any, identified in <U>Schedule B</U> hereto. As used
herein, <B>&#147;</B><B>Road Show</B><B>&#148;</B> means a &#147;road show&#148; (as defined in Rule 433 under the Securities Act) relating to the offering of the Offered Securities contemplated hereby that is a &#147;written communication&#148; (as
defined in Rule 405 under the Securities Act). As used herein, &#147;<B>Section</B><B></B><B>&nbsp;5(d) Written Communication</B>&#148; means each written communication (within the meaning of Rule 405 under the Securities Act) that is made in
reliance on Section&nbsp;5(d) of the Securities Act by the Company or any person authorized to act on behalf of the Company to one or more potential investors that are qualified institutional buyers (&#147;<B>QIBs</B>&#148;) and/or institutions that
are accredited investors (&#147;<B>IAIs</B>&#148;), as such terms are respectively defined in Rule 144A and Rule 501(a) under the Securities Act, to determine whether such investors might have an interest in the offering of the Offered Securities;
&#147;<B>Section</B><B></B><B>&nbsp;5(d) Oral Communication</B>&#148; means each oral communication, if any, made in reliance on Section&nbsp;5(d) of the Securities Act by the Company or any person authorized to act on behalf of the Company made to
one or more QIBs and/or one or more IAIs to determine whether such investors might have an interest in the offering of the Offered Securities; &#147;<B>Marketing Materials</B>&#148; means any materials or information provided to investors by, or
with the approval of, the Company in connection with the marketing of the offering of the Offered Securities, including any roadshow or investor presentations made to investors by the Company (whether in person or electronically); and
&#147;<B>Permitted Section</B><B></B><B>&nbsp;5(d) Communication</B>&#148; means the Section&nbsp;5(d) Written Communication(s) and Marketing Materials listed on Schedule C attached hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references in this Agreement to the Registration Statement, the Preliminary Prospectus,
any preliminary prospectus, the Base Prospectus and the Prospectus shall include the documents incorporated or deemed to be incorporated by reference therein. All references in this Agreement to financial statements and schedules and other
information which are &#147;contained,&#148; &#147;included&#148; or &#147;stated&#148; in, or &#147;part of&#148; the Registration Statement, the Rule 462(b) Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base
Prospectus, the Time of Sale Prospectus or the Prospectus, and all other references of like import, shall be deemed to mean and include all such financial statements and schedules and other information which is or is deemed to be incorporated by
reference in the Registration Statement, the Rule 462(b) Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, the Time of Sale Prospectus or the Prospectus, as the case may be. All references in this
Agreement to amendments or supplements to the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, the Time of Sale Prospectus or the Prospectus shall be deemed to mean and include the filing of any
document under the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (collectively, the &#147;<B>Exchange Act</B>&#148;) that is or is deemed to be incorporated by reference in the Registration
Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, or the Prospectus, as the case may be. All references in this Agreement to (i)&nbsp;the Registration Statement, the Preliminary Prospectus, any preliminary
prospectus, the Base Prospectus or the Prospectus, any amendments or supplements to any of the foregoing, or any free writing prospectus, shall include any copy thereof filed with the Commission pursuant to its Electronic Data Gathering, Analysis
and Retrieval System (&#147;<B>EDGAR</B>&#148;) and (ii)&nbsp;the Prospectus shall be deemed to include any &#147;electronic Prospectus&#148; provided for use in connection with the offering of the Offered Securities as contemplated by
Section&nbsp;3(n) of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the Company has only one subsidiary, then all references herein to
&#147;subsidiaries&#148; of the Company shall be deemed to refer to such single subsidiary, <U>mutatis</U> <U>mutandis</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
hereby confirms its agreements with the Underwriters as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;1. Representations and Warranties.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company hereby represents, warrants and covenants to each Underwriter, as of the date of this Agreement, as of the First Closing Date (as
hereinafter defined) and as of each Option Closing Date (as hereinafter defined), if any, as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><I>Compliance with
Registration Requirements</I></B><B>.</B> The Registration Statement has become effective under the Securities Act. The Company has complied, to the Commission&#146;s satisfaction, with all requests of the Commission for additional or supplemental
information, if any. No stop order suspending the effectiveness of the Registration Statement is in effect and no proceedings for such purpose have been instituted or are pending or, to the knowledge of the Company, are contemplated or threatened by
the Commission. At the time the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2024 (the &#147;<B>Annual Report</B>&#148;) was filed with the Commission, or, if later, at the
time the Registration Statement was originally filed with the Commission, the Company met the then-applicable requirements for use of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act. The Company meets the requirements for
use of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act specified in the Financial Industry Regulatory Authority (&#147;<B>FINRA</B>&#148;) Conduct Rule 5110(B)(7)(C)(i). The documents incorporated or deemed to be
incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus, at the time they were or hereafter are filed with the Commission, or became effective under the Exchange Act, as the case may be, complied or
will comply, as applicable, in all material respects with the requirements of the Exchange Act at such time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><I>Disclosure</I></B><B>.</B> Each preliminary prospectus and the Prospectus
when filed complied in all material respects with the Securities Act and, if filed by electronic transmission pursuant to EDGAR, was identical (except as may be permitted by <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-T</FONT> under the
Securities Act) to the copy thereof delivered to the Underwriters for use in connection with the offer and sale of the Offered Securities. Each of the Registration Statement and any post-effective amendment thereto, at the time it became or becomes
effective until such time as the Underwriters are no longer required to deliver a Prospectus in order to confirm sales of the Offered Securities, complied and will comply in all material respects with the Securities Act and did not and will not
contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. As of the Applicable Time, the Time of Sale Prospectus did not, and at the
First Closing Date (as defined in Section&nbsp;2) and at each applicable Option Closing Date (as defined in Section&nbsp;2), as then amended or supplemented by the Company, will not, contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Prospectus as amended or supplemented as of its date, did not, and at the First Closing Date and at each
applicable Option Closing Date, as then amended or supplemented by the Company, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading. The representations and warranties set forth in the three immediately preceding sentences do not apply to statements in or omissions from the Registration Statement or any post-effective
amendment thereto, or the Prospectus or the Time of Sale Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity with written information relating to any Underwriter furnished to the Company in writing by the
Representatives expressly for use therein, it being understood and agreed that the only such information consists of the information described in Section&nbsp;9(b) below. There are no contracts or other documents required to be described in the Time
of Sale Prospectus or the Prospectus or to be filed as an exhibit to the Registration Statement which have not been described or filed as required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><I>Free Writing Prospectuses; Road Show</I></B><B>.</B> As of the determination date referenced in Rule 164(h) under the
Securities Act, the Company was not, is not or will not be (as applicable) an &#147;ineligible issuer&#148; in connection with the offering of the Offered Securities pursuant to Rules 164, 405 and 433 under the Securities Act. Each free writing
prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the Securities Act. Each free writing prospectus that the Company
has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies or will comply in all material respects with the requirements of Rule 433
under the Securities Act, including timely filing with the Commission, retention and legending, as applicable, and each such free writing prospectus, as of its issue date and at all subsequent times through the completion of the public offer and
sale of the Offered Securities did not, does not and will not include any information that conflicted, conflicts or will conflict with the information contained in the Registration Statement, the Prospectus or any preliminary prospectus unless such
information has been superseded or modified as of such time. The representations and warranties set forth in the immediately preceding sentence do not apply to statements made in reliance upon and in conformity with written information relating to
any Underwriter furnished to the Company in writing by the Representatives expressly for use therein, it being understood and agreed that the only such information consists of the information described in Section&nbsp;9(b) below. Except for the free
writing prospectuses, if any, identified in <U>Schedule B</U>, and electronic road shows, if any, furnished to the Representatives before first use, the Company has not prepared, used or referred to, and will not, without the prior written consent
of the Representatives (such consent not to be unreasonably withheld, conditioned or delayed), prepare, use or refer to, any free writing prospectus. Each Road Show, when considered together with the Time of Sale Prospectus, did not, as of the
Applicable Time, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><I>Distribution of Offering Material By the Company</I></B><B>.</B> Prior to
the later of (i)&nbsp;the expiration or termination of the option granted to the Underwriters in Section&nbsp;2 and (ii)&nbsp;the completion of the Underwriters&#146; distribution of the Offered Securities, the Company has not distributed and will
not distribute any offering material in connection with the offering and sale of the Offered Securities other than the Registration Statement, the Time of Sale Prospectus, the Prospectus or any free writing prospectus reviewed and consented to by
the Representatives, the free writing prospectuses, if any, identified on <U>Schedule B</U> hereto and any Permitted Section&nbsp;5(d) Communications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><I>The Underwriting Agreement</I></B><B>.</B> This Agreement has been duly authorized, executed and delivered by the Company.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B><I>Authorization of the Offered </I></B><B><I>Securities</I></B><B>.</B> The Offered Shares have been duly and validly
authorized for issuance and sale pursuant to this Agreement and, when issued and delivered by the Company against payment therefor pursuant to this Agreement, will be validly issued, fully paid and nonassessable, and the issuance and sale of the
Offered Shares is not subject to any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase the Offered Shares. The Offered Warrants and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants have been
duly authorized for issuance and sale pursuant to this Agreement and, when issued and delivered by the Company against payment therefor pursuant to this Agreement, will be validly issued, and the issuance and sale of the Offered Warrants and <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are not subject to any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase the Offered Warrants or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT>
Warrants. The Warrant Shares have been duly authorized and validly reserved for issuance upon the exercise of the Offered Warrants and the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants in a number sufficient to meet the current
exercise requirements. The Warrant Shares, when issued and delivered upon exercise of the Offered Warrants and the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants in accordance therewith, will be validly issued, fully paid and
nonassessable, and the issuance of the Warrant Shares is not subject to any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase the Warrant Shares. The Offered Securities, when issued, will conform to the
descriptions thereof the Registration Statement, the Time of Sale Prospectus and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B><I>No Applicable
Registration or Other Similar Rights</I></B><B>.</B> There are no persons with registration or other similar rights to have any equity or debt securities registered for sale under the Registration Statement or included in the offering contemplated
by this Agreement, except for such rights as have been duly waived. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B><I>No Material Adverse Change</I></B><B>.</B> Except as
otherwise disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, subsequent to the respective dates as of which information is given in the Registration Statement, the Time of Sale Prospectus and the Prospectus:
(i)&nbsp;there has been no Material Adverse Change; (ii)&nbsp;the Company and its subsidiaries, considered as one entity, have not incurred any material liability or obligation, indirect, direct or contingent, not in the ordinary course of business
nor entered into any material transaction or agreement not in the ordinary course of business: and (iii)&nbsp;there has been no dividend or distribution of any kind declared, paid or made by the Company or, except for regular quarterly dividends
publicly announced by the Company or dividends paid to the Company or other subsidiaries, by any of its subsidiaries on any class of capital stock or repurchase or redemption by the Company or any of its subsidiaries of any class of capital stock
(any such change being referred to herein as a &#147;<B>Material Adverse Change</B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B><I>Independent Accountants</I></B><B>.</B> Ernst&nbsp;&amp; Young LLP, who has
expressed its opinion with respect to the financial statements (which term as used in this Agreement includes the related notes thereto) and supporting schedules filed with the Commission or incorporated by reference as a part of the Time of Sale
Prospectus and the Prospectus, is an independent registered public accounting firm as required by the Securities Act and the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B><I>Financial Statements</I></B><B>.</B> The financial statements filed with the Commission as a part of or incorporated by
reference in the Time of Sale Prospectus and the Prospectus present fairly, in all material respects, the consolidated financial position of the Company and its subsidiaries as of and at the dates indicated and the results of their operations and
cash flows for the periods specified. The supporting schedules included in or incorporated in the Time of Sale Prospectus and the Prospectus present fairly, in all material respects, the information required to be stated therein. Such financial
statements and supporting schedules have been prepared in conformity with generally accepted accounting principles as applied in the United States applied on a consistent basis throughout the periods involved, except as may be expressly stated in
the related notes thereto, or, in the case of unaudited interim financial statements, for normal <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments and the omission of certain footnotes as permitted by the applicable rules of the
Commission. No other financial statements or supporting schedules are required to be included in or incorporated in the Time of Sale Prospectus and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> <B><I>Company</I></B><B><I>&#146;</I></B><B><I>s Accounting System</I></B><B>.</B> The Company and each of its subsidiaries
maintains a system of &#147;internal control over financial reporting&#148; (as such term is defined in Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> of the General Rules and Regulations under the Exchange Act (the &#147;<B>Exchange Act
Rules</B>&#148;)) that is designed to comply with the requirements of the Exchange Act and has been designed by their respective principal executive and principal financial officers, or under their supervision, to provide reasonable assurances that
(i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain
accountability for assets; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization; (iv)&nbsp;the recorded accountability for assets is compared with existing assets at reasonable
intervals and appropriate action is taken with respect to any differences and (v)&nbsp;interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the
Commission&#146;s rules and guidelines applicable thereto. The Company&#146;s internal control over financial reporting is effective. Except as described in the Prospectus and the Time of Sale Prospectus, since the end of the Company&#146;s most
recent audited fiscal year, there has been (A)&nbsp;no material weakness in the Company&#146;s internal control over financial reporting (whether or not remediated) and (B)&nbsp;no change in the Company&#146;s internal control over financial
reporting that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> <B><I>Disclosure Controls and Procedures; Deficiencies in or Changes to Internal Control Over Financial Reporting</I></B><B>.</B>
The Company and its subsidiaries maintain disclosure controls and procedures (as such is defined in Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> of the Exchange Act Rules) that comply with the requirements of the Exchange Act; such
disclosure controls and procedures have been designed to ensure that information required to be disclosed by the Company and its subsidiaries in reports that they file or submits under the Exchange Act is recorded, processed, summarized and reported
within the time periods specified in the Commission&#146;s rules and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company&#146;s management to allow timely decisions
regarding disclosures. The Company and its subsidiaries have conducted evaluations of the effectiveness of its disclosure controls as required by Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> of the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> <B><I>Incorporation and Good Standing of the Company</I></B><B>.</B> The Company
and each of its subsidiaries (as defined in Section&nbsp;16) have been duly organized and are validly existing as corporations or other legal entities. The Company and, to its knowledge, each of its subsidiaries, are in good standing (or the foreign
equivalent thereof) under the laws of their respective jurisdictions of organization, except where the failure to be in good standing would not have a Material Adverse Effect (as defined below). The Company and each of its subsidiaries are duly
qualified to do business and, with respect to its subsidiaries, to its knowledge, are in good standing as foreign corporations or other legal entities in each jurisdiction in which their respective ownership or lease of property or the conduct of
their respective businesses requires such qualification and have all power and authority (corporate or other) necessary to own or hold their respective properties and to conduct the businesses in which they are engaged, except where the failure to
so qualify or have such power or authority would not (i)&nbsp;have, singularly or in the aggregate, a material adverse effect on the business, properties, management, financial position, stockholders&#146; equity, results of operations or prospects
of the Company and its subsidiaries taken as a whole, or (ii)&nbsp;impair in any material respect the ability of the Company to perform its obligations under this Agreement or to consummate any transactions contemplated by this Agreement, the Time
of Sale Prospectus or the Prospectus (any such effect as described in clauses (i)&nbsp;or (ii), a &#147;<B>Material Adverse Effect</B>&#148;). The Company has two subsidiaries: Cabaletta Bio GmbH, incorporated in Switzerland, and Cabaletta Bio
(Germany) GmbH, incorporated in Germany. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> <B><I>Capitalization and Other Capital Stock Matters</I></B><B>.</B> The capital
stock conforms in all material respects to the description thereof contained in the Time of Sale Prospectus and the Prospectus. All of the Company&#146;s options, warrants and other rights to purchase or exchange any securities for shares of the
Company&#146;s capital stock have been duly authorized and validly issued, are fully paid and nonassessable and were issued in compliance with federal and state securities laws. None of the outstanding shares of Common Stock were issued in violation
of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company. As of the date set forth in the Time of Sale Prospectus, there were no authorized or outstanding shares of capital
stock, options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company or any of its subsidiaries other
than those described above or accurately described in all material respects in the Time of Sale Prospectus and the Prospectus. The description of the Company&#146;s stock option, stock bonus and other stock plans or arrangements, and the options or
other rights granted thereunder, as described in the Time of Sale Prospectus and the Prospectus, accurately and fairly present in all material respects the information required to be shown with respect to such plans, arrangements, options and
rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> <B><I>Stock Exchange Listing</I></B><B>.</B> The Company is subject to and in compliance in all material respects with
the reporting requirements of Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act. The Common Stock is registered pursuant to Section&nbsp;12(b) or 12(g) of the Exchange Act and is listed on the Nasdaq Global Select Market, and the Company has
taken no action designed to, or reasonably likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or delisting the Common Stock from the Nasdaq Global Select Market, nor has the Company received any
notification that the Commission or FINRA is contemplating terminating such registration or listing. The Company has complied in all material respects with the applicable requirements of Nasdaq for maintenance of inclusion of the Common Stock
thereon. The Company has filed or will file an application to include the Offered Shares and the Warrant Shares on Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B>
<B><I><FONT STYLE="white-space:nowrap">Non-Contravention</FONT> of Existing Instruments; No Further Authorizations or Approvals Required</I></B><B>.</B> Neither the Company nor any of its subsidiaries is in violation of its charter or <FONT
STYLE="white-space:nowrap">by-laws</FONT> or is in default (or, with the giving of notice or lapse of time, would be in default) (&#147;<B>Default</B>&#148;) under any indenture, mortgage, loan or credit agreement, note, contract, franchise, lease
or other instrument to which the Company or any of its subsidiaries is a party or by which it or any of them may be bound, or to which any of the property or assets of the Company or any of its subsidiaries is subject (each, an &#147;<B>Existing
Instrument</B>&#148;), except for such Defaults as would not, individually or in the aggregate, result in a Material </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Adverse Change, or any development that could reasonably be expected to result in a Material Adverse Change. The Company&#146;s execution, delivery and performance of this Agreement and the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, and consummation of the transactions contemplated hereby and thereby and by the Time of Sale Prospectus and Prospectus (i)&nbsp;have been duly authorized by all necessary corporate action and
will not result in any violation of the provisions of the charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> of the Company or any subsidiary, (ii)&nbsp;will not conflict with or constitute a breach of, or Default under, or result in the
creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of its subsidiaries pursuant to, or require the consent of any other party to, any Existing Instrument, except for such conflicts, breaches,
Defaults, liens, charges or encumbrances as would not, individually or in the aggregate, result in a Material Adverse Change and (iii)&nbsp;will not result in any violation of any law, administrative regulation or administrative or court decree
applicable to the Company or any subsidiary. No consent, approval, authorization or other order of, or registration or filing with, any court or other governmental or regulatory authority or agency, is required for the Company&#146;s execution,
delivery and performance of this Agreement and consummation of the transactions contemplated hereby and by the Time of Sale Prospectus and the Prospectus, except such as have been obtained or made by the Company and are in full force and effect
under the Securities Act, applicable state securities or blue sky laws, the Nasdaq Global Select Market in connection with the purchase and distribution of the Offered Securities by the Underwriters and the listing of the Offered Securities on the
Nasdaq Global Select Market and from FINRA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> <B><I>Compliance with Laws</I></B><B><I>.</I></B> The Company and each of its
subsidiaries are in compliance with all applicable laws, rules and regulations of the jurisdictions in which they are conducting business, except where failure to be so in compliance would not result in a Material Adverse Change. Each of the Company
and its subsidiaries: (A)&nbsp;is and at all times has been in compliance with all statutes, rules, or regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling,
promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by the Company or its subsidiaries (&#147;<B>Applicable Laws</B>&#148;), except as would not reasonably be expected to result in a
Material Adverse Effect; (B)&nbsp;has not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or written notice from the FDA or any other governmental authority alleging or asserting
noncompliance in any material respect with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws
(&#147;<B>Authorizations</B>&#148;); (C) possesses all material Authorizations and such Authorizations are valid and in full force and effect and are not in material violation of any term of any such Authorizations; (D)&nbsp;has not received written
notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any governmental authority or third party alleging that any product operation or activity is in violation of any Applicable Laws or
Authorizations and has no knowledge that any such governmental authority or third party claim, litigation, arbitration, action, suit, investigation or proceeding is pending; (E)&nbsp;has not received notice that any governmental authority has taken,
is taking or intends to take action to limit, suspend, or revoke any Authorizations and has no knowledge that any such governmental authority is considering such action; and (F)&nbsp;has filed, obtained, maintained or submitted all material reports,
documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions
and supplements or amendments were complete and correct in all material respects on the date filed (or were corrected or supplemented by a subsequent submission); and (G)&nbsp;has not, either voluntarily or involuntarily, initiated, conducted, or
issued or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, &#147;dear healthcare provider&#148; letter, or other notice or action relating to the alleged lack of safety or efficacy of any
product or any alleged product defect or violation and, to the Company&#146;s knowledge, no third party has initiated, conducted or intends to initiate any such notice or action.. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> <B><I>No Material Actions or Proceedings</I></B><B>.</B> Except as disclosed in
the Time of Sale Prospectus and the Prospectus, there are no legal or governmental actions, suits or proceedings pending or, to the Company&#146;s knowledge, threatened (i)&nbsp;against or affecting the Company or any of its subsidiaries,
(ii)&nbsp;which has as the subject thereof any officer or director of, or property owned or leased by, the Company or any of its subsidiaries or (iii)&nbsp;relating to environmental or discrimination matters, where in any such case (A)&nbsp;there is
a reasonable possibility that such action, suit or proceeding might be determined adversely to the Company or such Subsidiary and (B)&nbsp;any such action, suit or proceeding, if so determined adversely, would reasonably be expected to result in a
Material Adverse Change or adversely affect the consummation of the transactions contemplated by this Agreement. No material labor dispute with the employees of the Company or any of its subsidiaries exists or, to the Company&#146;s knowledge, is
threatened or imminent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B> <B><I>Intellectual Property Rights</I></B><B>.</B><B></B>&nbsp;The Company and its subsidiaries own or
possess the valid license to use all (i)&nbsp;patents, patent applications, trademarks, trademark registrations, service marks, service mark registrations, Internet domain name registrations, copyrights, copyright registrations, licenses, trade
secret rights (&#147;<B>Intellectual Property Rights</B>&#148;) described in the Time of Sale Prospectus and the Prospectus and (ii)&nbsp;inventions, software, works of authorships, trademarks, service marks, trade names, databases, formulae, know
how, Internet domain names and other intellectual property (including trade secrets and other unpatented and/or unpatentable proprietary confidential information, systems, or procedures) (collectively, &#147;<B>Intellectual Property
Assets</B>&#148;) necessary to conduct their respective businesses as currently conducted, and as proposed to be conducted and described in the Time of Sale Prospectus and the Prospectus. The Company and its subsidiaries have not received any
opinion from their legal counsel concluding that any activities of their respective businesses infringe, misappropriate, or otherwise violate, valid and enforceable Intellectual Property Rights of any other person, and have not received written
notice of any challenge, which is to their knowledge still pending, by any other person to the rights of the Company and its subsidiaries with respect to any Intellectual Property Rights or Intellectual Property Assets owned or used by the Company
or its subsidiaries. To the Company&#146;s knowledge, the Company and its subsidiaries&#146; respective businesses as now conducted do not give rise to any infringement of, any misappropriation of, or other violation of, any valid and enforceable
Intellectual Property Rights of any other person. To the Company&#146;s knowledge, all licenses for the use of the Intellectual Property Rights described in the Time of Sale Prospectus and the Prospectus are valid, binding upon, and enforceable by
or against the parties thereto in accordance to their terms. The Company has complied in all material respects with, and is not in breach nor has received any asserted or threatened claim of breach of any Intellectual Property license, and the
Company has no knowledge of any breach or anticipated breach by any other person to any Intellectual Property license. Except as described in the Time of Sale Prospectus and the Prospectus, no claim has been made against the Company alleging the
infringement by the Company of any patent, trademark, service mark, trade name, copyright, trade secret, license in or other intellectual property right or franchise right of any person. The Company has taken all reasonable steps to protect,
maintain and safeguard its Intellectual Property Rights, including the execution of appropriate nondisclosure and confidentiality agreements. The consummation of the transactions contemplated by this Agreement will not result in the loss or
impairment of or payment of any additional amounts with respect to, nor require the consent of any other person in respect of, the Company&#146;s right to own, use, or hold for use any of the Intellectual Property Rights as owned, used or held for
use in the conduct of the business as currently conducted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B> <B><I>All Necessary Permits, etc</I></B><B>.</B> The Company and
each subsidiary possess such valid and current certificates, authorizations or permits issued by the appropriate state, federal or foreign regulatory agencies or bodies necessary to conduct their respective businesses, other than those the failure
to possess or own would not result in a Material Adverse Change, and neither the Company nor any subsidiary has received any notice of proceedings relating to the revocation or modification of, or
<FONT STYLE="white-space:nowrap">non-compliance</FONT> with, any such certificate, authorization or permit which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would result in a Material Adverse Change.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u)</B> <B><I>Title to Properties</I></B><B>.</B> The Company does not own any real
property. The Company and each of its subsidiaries have valid and marketable rights to lease or otherwise use, all items of personal property which are material to the business of the Company and its subsidiaries taken as a whole, in each case free
and clear of all liens, encumbrances, security interests, claims and defects that (i)&nbsp;do not, singularly or in the aggregate, materially affect the value of such property and do not materially interfere with the use made and proposed to be made
of such property by the Company or any of its subsidiaries or (ii)&nbsp;could not reasonably be expected, singularly or in the aggregate, to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> <B><I>Tax Law Compliance</I></B><B>.</B> The Company and its consolidated subsidiaries have filed all necessary federal, state and
foreign income, property and franchise tax returns, or extensions thereof, which have been required to be filed and have paid all taxes required to be paid by any of them and, if due and payable, any related or similar assessment, fine or penalty
levied against any of them except as may be being contested in good faith and by appropriate proceedings or where the failure to do so would not reasonably be expected to result in a Material Adverse Change. The Company has made adequate charges,
accruals and reserves in the applicable financial statements referred to in Section&nbsp;1 (i) above in respect of all federal, state and foreign income, property and franchise taxes for all periods as to which the tax liability of the Company or
any of its consolidated subsidiaries has not been finally determined. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w)</B> <B><I>Insurance</I></B><B>.</B> Except as otherwise
described in the Time of Sale Prospectus and the Prospectus, each of the Company and its subsidiaries are insured by insurers of recognized financial responsibility with policies in such amounts and with such deductibles and covering such risks as
the Company believes are generally deemed prudent and customary for the business for which it is engaged including, but not limited to, policies covering real and personal property owned or leased by the Company and its subsidiaries against theft,
damage, destruction, acts of vandalism and earthquakes. The Company has no reason to believe that it or any Subsidiary will not be able (i)&nbsp;to renew its existing insurance coverage as and when such policies expire or (ii)&nbsp;to obtain
comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not result in a Material Adverse Change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> <B><I>Compliance with Environmental Laws</I></B><B>.</B> Except as otherwise described in the Prospectus, and except as would not,
individually or in the aggregate, result in a Material Adverse Change (i)&nbsp;neither the Company nor any of its subsidiaries is in violation of any federal, state, local or foreign law or regulation relating to pollution or protection of human
health or the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including without limitation, laws and regulations relating to emissions, discharges, releases or
threatened releases of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum and petroleum products (collectively, &#147;<B>Materials of Environmental Concern</B>&#148;), or otherwise relating to the
manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Materials of Environmental Concern (collectively, &#147;<B>Environmental Laws</B>&#148;), which violation includes, but is not limited to,
noncompliance with any permits or other governmental authorizations required for the operation of the business of the Company or its subsidiaries under applicable Environmental Laws, or noncompliance with the terms and conditions thereof, nor has
the Company or any of its subsidiaries received any written communication, whether from a governmental authority, citizens group, employee or otherwise, that alleges that the Company or any of its subsidiaries is in violation of any Environmental
Law; (ii)&nbsp;there is no claim, action or cause of action filed with a court or governmental authority, no investigation with respect to which the Company has received written notice, and no written notice by any person or entity alleging
potential liability for investigatory costs, cleanup costs, governmental responses costs, natural resources damages, property damages, personal injuries, attorneys&#146; fees or penalties arising </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
out of, based on or resulting from the presence, or release into the environment, of any Material of Environmental Concern at any location owned, leased or operated by the Company or any of its
subsidiaries, now or in the past (collectively, &#147;<B>Environmental Claims</B>&#148;), pending or, to the Company&#146;s knowledge, threatened against the Company or any of its subsidiaries or any person or entity whose liability for any
Environmental Claim the Company or any of its subsidiaries has retained or assumed either contractually or by operation of law; and (iii)&nbsp;to the Company&#146;s knowledge, there are no past or present actions, activities, circumstances,
conditions, events or incidents, including, without limitation, the release, emission, discharge, presence or disposal of any Material of Environmental Concern, that would reasonably be expected to result in a violation of any Environmental Law or
form the basis of a potential Environmental Claim against the Company or any of its subsidiaries or against any person or entity whose liability for any Environmental Claim the Company or any of its subsidiaries has retained or assumed either
contractually or by operation of law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y)</B> <B><I>ERISA Compliance</I></B><B>.</B> No &#147;prohibited transaction&#148; (as defined
in Section&nbsp;406 of the Employee Retirement Income Security Act of 1974, as amended, including the regulations and published interpretations thereunder (&#147;<B>ERISA</B>&#148;), or Section&nbsp;4975 of the Internal Revenue Code of 1986, as
amended from time to time (the &#147;<B>Code</B>&#148;)) or &#147;accumulated funding deficiency&#148; (as defined in Section&nbsp;302 of ERISA) or any of the events set forth in Section&nbsp;4043(b) of ERISA (other than events with respect to which
the thirty <FONT STYLE="white-space:nowrap">(30)-day</FONT> notice requirement under Section&nbsp;4043 of ERISA has been waived) has occurred or could reasonably be expected to occur with respect to any employee benefit plan of the Company or any of
its subsidiaries which could, singularly or in the aggregate, have a Material Adverse Effect. Each employee benefit plan of the Company or any of its subsidiaries is in compliance in all material respects with applicable law, including ERISA and the
Code. The Company and its subsidiaries have not incurred and could not reasonably be expected to incur liability under Title IV of ERISA with respect to the termination of, or withdrawal from, any pension plan (as defined in ERISA). Each pension
plan for which the Company or any of its subsidiaries would have any liability that is intended to be qualified under Section&nbsp;401(a) of the Code is so qualified, and nothing has occurred, whether by action or by failure to act, which could,
singularly or in the aggregate, cause the loss of such qualification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(z)</B> <B><I>Company Not an
</I></B><B><I>&#147;</I></B><B><I>Investment Company.</I></B><B><I>&#148;</I></B> The Company has been advised of the rules and requirements under the Investment Company Act of 1940, as amended (the &#147;<B>Investment Company Act</B>&#148;). The
Company is not, and after receipt of payment for the Offered Securities will not be, an &#147;investment company&#148; within the meaning of the Investment Company Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aa)</B> <B><I>No Price Stabilization or Manipulation</I></B><B><I>; Compliance with Regulation M</I></B><B>.</B> The Company has not taken
and will not take, directly or indirectly, any action designed to or that would be reasonably expected to cause or result in stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Offered
Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bb)</B> <B><I>Related-Party Transactions</I></B><B>.</B> There are no business relationships or related-party
transactions involving the Company or any subsidiary or any other person required to be described in the Prospectus which have not been described as required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(cc)</B> <B><I>FINRA Matters</I></B><B>.</B> All of the information provided to the Underwriters or to counsel for the Underwriters by the
Company, its counsel, its officers and directors and, to the Company&#146;s knowledge, the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection with the offering of the Offered Securities is
true, complete, correct and compliant in all material respects with FINRA&#146;s rules and any letters, filings or other supplemental information provided to FINRA pursuant to FINRA Rules or NASD Conduct Rules is true, complete and correct in all
material respects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(dd)</B> <B><I>Parties to <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Agreements</I></B><B>.</B> The Company has furnished to the Underwriters a letter agreement in the form attached hereto as <U>Exhibit</U><U></U><U>&nbsp;A</U> (the &#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement</B>&#148;) from
each of the persons listed on <U>Exhibit</U><U></U><U>&nbsp;B</U>. Such <U>Exhibit</U><U></U><U>&nbsp;B</U> lists under an appropriate caption the directors and executive officers of the Company. If any additional persons shall become directors or
executive officers of the Company prior to the end of the Company <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period (as defined below), the Company shall cause each such person, prior to or contemporaneously with their appointment or election
as a director or executive officer of the Company, to execute and deliver to the Representatives a <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement.<B></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ee)</B> <B><I>Statistical and Market-Related Data</I></B><B>.</B> The statistical and market related data included in the Registration
Statement, the Time of Sale Prospectus and the Prospectus are based on or derived from sources that the Company believes to be reliable and accurate, and such data agree with the sources from which they are derived. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ff)</B> <B><I>Sarbanes-Oxley Act.</I></B> There is and has been no failure on the part of the company or, to the Company&#146;s Knowledge,
any of the Company&#146;s officers or directors, in their capacities as such, to comply with any provision of the Sarbanes-Oxley Act of 2002 (the &#147;<B>Sarbanes-Oxley Act</B>&#148;) and the rules and regulations promulgated in connection
therewith, including Section&nbsp;402 related to loans and Sections 302 and 906 related to certifications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(gg)</B> <B><I>No Unlawful
Contributions or Other Payments</I></B><B>.</B> Neither the Company nor any of its subsidiaries nor, to the Company&#146;s knowledge, any employee or agent of the Company or any subsidiary, has made any contribution or other payment to any official
of, or candidate for, any federal, state or foreign office in violation of any applicable law or of the character required to be disclosed in the Registration Statement, the Time of Sale Prospectus or the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(hh)</B> <B><I>Anti-Corruption and Anti-Bribery Laws</I></B><B>.</B> Neither the Company nor any of its subsidiaries nor, to the
Company&#146;s knowledge, any directory, officer, employee, agent, affiliate or other person acting on behalf of the Company or any subsidiary, has (i)&nbsp;used any corporate funds for any unlawful contribution, gifts, entertainment or other
unlawful expenses relating to political activity, (ii)&nbsp;made any direct or indirect unlawful payment to foreign or domestic government officials or employees, political parties or campaigns, political party officials, or candidates for political
office from corporate funds, (iii)&nbsp;violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or any applicable anti-corruption laws, rules, or regulation of any other jurisdiction in which the
Company or any subsidiary conducts business, or (iv)&nbsp;made any other unlawful bribe, rebate, payoff, influence payment, kickback, or other unlawful payment to any person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B><I>Money Laundering Laws</I></B><B>.</B> The operations of the Company and its subsidiaries are and have been conducted at all
times in material compliance with all applicable financial recordkeeping and reporting requirements, including those of the U.S. Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools
Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), and the applicable anti-money laundering statutes of jurisdictions where the Company and its subsidiaries conduct business, the rules and regulations thereunder and any
related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#147;<B>Anti-Money Laundering Laws</B>&#148;), and no action, suit or proceeding by or before any court or
governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(jj)</B> <B><I>Sanctions</I></B><B>.</B> (A)&nbsp;Neither the Company nor any of its
subsidiaries, nor any director, officer or employee thereof, nor, to the Company&#146;s knowledge, any agent, affiliate, representative or other person acting on behalf of the Company or any of its subsidiaries, is an individual or entity
(&#147;<B>Person</B>&#148;) that is, or is owned or controlled by a Person that is: (i)&nbsp;the subject of any sanctions administered or enforced by the U.S. Department of Treasury&#146;s Office of Foreign Assets Control (&#147;<B>OFAC</B>&#148;),
the United Nations Security Council, the European Union, His Majesty&#146;s Treasury, or other relevant sanctions authority (collectively, &#147;<B>Sanctions</B>&#148;), nor (ii)&nbsp;located, organized or resident in a country or territory that is
the subject of a U.S. government embargo (including, without limitation, the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic, the <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic, the
Crimea Region of Ukraine, Cuba, Iran, North Korea, Syria and the <FONT STYLE="white-space:nowrap">non-government</FONT> controlled areas of the Zaporizhzhia and Kherson Regions). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(B) The Company will not, directly or indirectly, use the proceeds of the offering, or lend, contribute or otherwise make available such
proceeds to any subsidiary, joint venture partner or other Person: (i)&nbsp;to fund or facilitate any activities or business of or with any Person that, at the time of such funding or facilitation, is the subject of Sanctions, or in any country or
territory that, at the time of such funding or facilitation, is the subject of a U.S. government embargo; or (ii)&nbsp;in any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the
offering, whether as underwriter, advisor, investor or otherwise). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(C) For the past five (5)&nbsp;years, the Company and its subsidiaries
have not knowingly engaged in, are not now knowingly engaged in, and will not engage in, any direct or indirect dealings or transactions with any Person that at the time of the dealing or transaction is or was the subject of Sanctions or any country
or territory that, at the time of the dealing or transaction is or was the subject of a U.S. government embargo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(kk)</B>
<B><I>Brokers</I></B><B>.</B> Except for the Representatives, there is no broker, finder or other party that is entitled to receive from the Company any brokerage or finder&#146;s fee or other fee or commission as a result of any transactions
contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ll)</B> <B><I>Forward-Looking Statements.</I></B> No forward-looking statement (within the meaning of
Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act) contained in either the Time of Sale Prospectus or the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(mm)</B> <B><I>No Outstanding Loans or Other Extensions of Credit</I></B>. The Company does not have any outstanding extension of
credit, in the form of a personal loan, to or for any director or executive officer (or equivalent thereof) of the Company except for such extensions of credit as are expressly permitted by Section&nbsp;13(k) of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(nn)</B> <B><I>Cybersecurity</I></B>. There has been no material security breach, attack or other compromise of any Personal Data and/or
any of the Company&#146;s and its subsidiaries&#146; information technology and computer systems, networks, hardware and software used to store and/or process any Personal Data, software, data (including the data of their respective customers,
employees, suppliers, vendors and any third party data maintained by or on behalf of them), equipment or technology (collectively, &#147;<B>IT Systems and Data</B>&#148;), and (y)&nbsp;the Company and its subsidiaries have not been notified of, and
have no knowledge of any event or condition that would reasonably be expected to result in any material security breach, attack or compromise to their IT Systems and Data, (ii)&nbsp;the Company and each of its subsidiaries have taken appropriate
steps reasonably designed to ensure material compliance with, all applicable Privacy Laws relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation
or modification, except as would not, in the case of this clause (ii), individually or in the aggregate, result in a Material Adverse Change, and (iii)&nbsp;the Company and each of its subsidiaries have implemented backup and disaster recovery
technology consistent with industry standards and practice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(oo)</B> <B><I>Compliance with Data Privacy Laws</I></B>. The Company and each of its
subsidiaries are, and at all times since January&nbsp;1, 2017 were, in material compliance with all applicable data privacy and security laws and regulations (collectively, &#147;<B>Privacy Laws</B>&#148;). To ensure compliance with the Privacy
Laws, the Company and each of its subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects with their policies and procedures relating to data privacy and security and the
collection, storage, use, disclosure, handling and analysis of Personal Data (the &#147;<B>Policies</B>&#148;). The Company provides accurate notice of its Policies to individuals from whom Personal Data are collected, to the extent that such notice
is required by applicable Privacy Laws. The Policies provide accurate and sufficient notice of the Company&#146;s then-current privacy practices relating to its subject matter and such Policies do not contain any material omissions of the
Company&#146;s then-current privacy practices. &#147;<B>Personal Data</B>&#148; means (i)&nbsp;a natural persons&#146; name, street address, telephone number, email address, photograph, social security number, bank information, or customer or
account number; (ii)&nbsp;any information which is regulated by applicable Privacy Laws; and (iii)&nbsp;any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis
of any data related to an identified person&#146;s health or sexual orientation. None of such disclosures made or contained in any of the Policies have been inaccurate, misleading, deceptive or in violation of any Privacy Laws or Policies in any
material respect. The execution, delivery and performance of this Agreement, or any other agreement referred to in this Agreement will not result in a breach of any Privacy Laws or Policies. Neither the Company nor any of its subsidiaries,
(i)&nbsp;has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to result in any
such notice; (ii)&nbsp;is currently conducting or paying for, in whole or in part, any investigation, remediation or other corrective action pursuant to any Privacy Law; or (iii)&nbsp;is a party to any order, decree, or agreement that imposed any
obligation or liability under any Privacy Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(pp) </B><B><I>[Reserved].</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(qq)</B> <B><I>Communications.</I></B> The Company (a)&nbsp;has not alone engaged in communications with potential investors in reliance on
Section&nbsp;5(d) of the Securities Act with the consent of the Representatives with entities that are qualified institutional buyers within the meaning of Rule 144A under the Securities Act or institutions that are accredited investors within the
meaning of Rule 501 under the Securities Act and (b)&nbsp;has not authorized anyone other than the Representatives to engage in such communications. The Company reconfirms that the Representatives have been authorized to act on its behalf in
undertaking Marketing Materials, Section&nbsp;5(d) Oral Communications and Section&nbsp;5(d) Written Communications. The Company has not distributed any Section&nbsp;5(d) Written Communications other than those listed on <U>Schedule C </U>hereto.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(rr)</B> <B><I>Clinical Data and Regulatory Compliance.</I></B> To the Company&#146;s knowledge, the studies, tests and preclinical
and clinical investigations conducted by or on behalf of the Company and described in the Prospectus were and, if still pending, are, in all material respects, being conducted in accordance with established protocols, procedures and controls
pursuant to, where applicable, accepted professional scientific standards for products or product candidates comparable to those being developed by the Company, and all Applicable Laws (as defined below) and Authorizations (as defined below),
including, without limitation, the Federal Food, Drug, and Cosmetic Act and implementing regulations including good laboratory practice (&#147;<B>GLP</B>&#148;) regulations (21 C.F.R. Part 58) if any such studies, tests or preclinical and clinical
investigations are being conducted pursuant to GLP, and good clinical practice and Investigational New Drug Application (&#147;<B>IND</B>&#148;) requirements (21 C.F.R. Parts 50, 54, 56, and 312) if any such studies, tests or preclinical and
clinical investigations were or are subject to good clinical practice regulations or were or are being conducted under an IND; the descriptions of the results of such studies, tests and trials contained in the Registration Statement and the
Prospectus are accurate in all material respects and fairly present the data derived from such studies, tests and trials; except to the extent disclosed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the Registration Statement and the Prospectus, the Company is not aware of any studies, tests or trials the results of which the Company believes reasonably call into question, in any material
respect, the study, test, or trial results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described and the clinical state of development; and neither the Company nor
any of its subsidiaries have received any written notices or correspondence from any governmental authority requiring the termination, suspension or material modification of any studies, tests or preclinical or clinical investigations conducted by
or on behalf of the Company or any of its subsidiaries. Except as set forth in the Registration Statement and the Prospectus, the Company and each of its subsidiaries have such permits, licenses, patents, franchises, certificates of need and other
approvals and other authorizations (the &#147;<B>Regulatory Permits</B>&#148;) issued by the appropriate domestic or foreign regional, federal, state, or local regulatory agencies or bodies necessary to conduct the business of the Company,
including, without limitation, any IND, as required by the U.S. Food and Drug Administration (&#147;<B>FDA</B>&#148;), or any other authorizations issued by domestic or foreign regional, federal, state, or local agencies or bodies engaged in the
regulation of pharmaceuticals such as those being developed by the Company and its subsidiaries, except for any of the foregoing that would not reasonably be expected to, individually or in the aggregate, have a Material Adverse Change; the Company
is in compliance in all material respects with the requirements of the Regulatory Permits, and all of the Regulatory Permits are valid and in full force and effect, in each case in all material respects, except where any invalidity, individually or
in the aggregate, would not reasonably be expected to have a Material Adverse Change; the Company has not received any written notice of proceedings relating to the revocation, termination, modification or impairment of rights of any of the
Regulatory Permits that, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would reasonably be expected to result in a Material Adverse Change; the Company has not failed to submit to the FDA any IND
necessary to conduct the business of the Company, any such filings that were required to be made were in material compliance with applicable laws when filed, and no material deficiencies have been asserted by the FDA with respect to any such filings
or submissions that were made.<B>&nbsp;</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ss)</B> <B><I>Regulatory Filings</I></B>. Except as disclosed in the Registration
Statement and the Prospectus, neither the Company nor any of its subsidiaries has failed to file with the applicable regulatory authorities (including, without limitation, the FDA, or any foreign, federal, state, provincial or local governmental or
regulatory authority performing functions similar to those performed by the FDA) any required filing, declaration, listing, registration, report or submission, except for such failures that, individually or in the aggregate, would not reasonably be
expected to have a Material Adverse Change; except as disclosed in the Registration Statement and the Prospectus, all such filings, declarations, listings, registrations, reports or submissions were in compliance with applicable laws when filed and
no deficiencies have been asserted by any applicable regulatory authority with respect to any such filings, declarations, listings, registrations, reports or submissions, except for any deficiencies that, individually or in the aggregate, would not
reasonably be expected to have a Material Adverse Change. The Company has operated and currently is, in all material respects, in compliance with the United States Federal Food, Drug, and Cosmetic Act, all applicable rules and regulations of the FDA
and other federal, state, local and foreign governmental bodies exercising comparable authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(tt)</B> <B><I>Export and Import
Law</I></B>. Each of the Company and the subsidiaries, and, to the Company&#146;s knowledge, each of their affiliates and any director, officer, agent or employee of, or other person associated with or acting on behalf of, the Company has, for the
past five (5)&nbsp;years, acted in compliance in all material respects with applicable Export and Import Laws (as defined below), in each case, while acting on behalf of the Company or its subsidiaries. There are no claims, complaints, charges,
investigations or proceedings pending or expected or, to the knowledge of the Company, threatened between the Company or any of the subsidiaries and any governmental authority under any Export or Import Laws. The term &#147;<B>Export and Import
Laws</B>&#148; means the Arms Export Control Act, the International Traffic in Arms Regulations, the Export Administration Act of 1979, as amended, the Export Administration Regulations, and all other laws and regulations of the United States
government regulating the export and import of articles or information from and to the United States of America, and all similar laws and regulations of any foreign government applicable to the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any certificate signed by any officer of the Company or any of its subsidiaries and
delivered to any Underwriter or to counsel for the Underwriters in connection with the offering, or the purchase and sale, of the Offered Securities shall be deemed a representation and warranty by the Company to each Underwriter as to the matters
covered thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has a reasonable basis for making each of the representations set forth in this Section&nbsp;1. The Company
acknowledges that the Underwriters and, for purposes of the opinions to be delivered pursuant to Section&nbsp;6 hereof, counsel to the Company and counsel to the Underwriters, will rely upon the accuracy and truthfulness of the foregoing
representations and hereby consents to such reliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.</B> <B>Purchase, Sale and Delivery of the Offered
</B><B>Securities</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><I>The Firm </I></B><B><I>Securities</I></B><B>.</B> Upon the terms herein set forth, (i)&nbsp;the
Company agrees to issue and sell to the several Underwriters an aggregate of 39,200,000 Firm Shares and accompanying Firm Warrants and 10,800,000 <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and accompanying Firm Warrants. On the
basis of the representations, warranties and agreements herein contained, and upon the terms but subject to the conditions herein set forth, the Underwriters agree, severally and not jointly, to purchase from the Company the respective number of
Firm Securities set forth opposite their names on <U>Schedule</U><B> </B><U>A</U>. The combined purchase price per Firm Share and accompanying Firm Warrant to be paid by the several Underwriters to the Company shall be $1.88 per unit, which shall be
allocated as $1.879999 per Firm Share and $0.000001 per Firm Warrant. The combined purchase price per <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant and accompanying Firm Warrant to be paid by the several Underwriters to the Company
shall be $1.87999 per unit, which shall be allocated as $1.879989 per <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant and $0.000001 per Firm Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><I>The First Closing Date</I></B><B>.</B> Delivery of the Firm Shares, Firm Warrants and 10,800,000 <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to be purchased by the Underwriters and payment therefor shall be made at the offices of Duane Morris LLP (or such other place as may be agreed to by the Company and the Representatives) at 9:00
a.m. New York City time, on June&nbsp;12, 2025<B>,</B> or such other time and date not later than 1:30&nbsp;p.m. New York City time, on June&nbsp;23, 2025 as the Representatives shall designate by notice to the Company (the time and date of such
closing are called the &#147;<B>First Closing Date</B>&#148;). The Company hereby acknowledges that circumstances under which the Representatives may provide notice to postpone the Closing Date as originally scheduled include, but are not limited
to, any determination by the Company or the Representatives to recirculate to the public copies of an amended or supplemented Prospectus or a delay as contemplated by the provisions of Section&nbsp;11. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><I>The Optional Securities; Option Closing Date</I></B><B>.</B> In addition, on the basis of the representations, warranties and
agreements herein contained, and upon the terms but subject to the conditions herein set forth, the Company hereby grants an option to the several Underwriters to purchase, severally and not jointly, up to an aggregate of 7,500,000 Optional Shares
from the Company at the purchase price per share to be paid by the Underwriters for the Firm Shares and/or 7,500,000 Optional Warrants at the purchase price per share to be paid by the Underwriters for the Firm Warrants. The option granted hereunder
may be exercised at any time and from time to time in whole or in part upon notice by the Representatives to the Company, which notice may be given at any time within 30&nbsp;days from the date of this Agreement. Such notice shall set forth
(i)&nbsp;the aggregate number of Optional Shares and/or Optional Warrants as to which the Underwriters are exercising the option and (ii)&nbsp;the time, date and place at which the Optional Shares and/or Optional Warrants will be delivered (which
time and date may be simultaneous with, but not earlier than, the First Closing Date; and in the event that such time and date are simultaneous </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with the First Closing Date, the term &#147;<B>First Closing Date</B>&#148; shall refer to the time and date of delivery of the Firm Securities and such Optional Securities). Any such time and
date of delivery, if subsequent to the First Closing Date, is called an &#147;<B>Option Closing Date</B>,&#148; and shall be determined by the Representatives and shall not be earlier than two or later than five full business days after delivery of
such notice of exercise. If any Optional Shares and/or Optional Warrants are to be purchased, each Underwriter agrees, severally and not jointly, to purchase the number of Optional Shares and/or Optional Warrants (subject to such adjustments to
eliminate fractional shares as the Representatives may determine) that bears the same proportion to the total number of Optional Securities to be purchased as the number of Firm Securities set forth on <U>Schedule A</U> opposite the name of such
Underwriter bears to the total number of Firm Securities. The Representatives may cancel the option at any time prior to its expiration by giving written notice of such cancellation to the Company.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><I>Public Offering of the Offered </I></B><B><I>Securities</I></B><B>.</B> The Representatives hereby advise the Company that
the Underwriters intend to offer for sale to the public, initially on the terms set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus, their respective portions of the Offered Securities as soon after this Agreement
has been executed as the Representatives, in their sole judgment, have determined is advisable and practicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><I>Payment
for the Offered </I></B><B><I>Securities</I></B><B>.</B> Payment for the Offered Securities to be sold by the Company shall be made at the First Closing Date (and, if applicable, at each Option Closing Date) by wire transfer of immediately available
funds to the order of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is understood that the Representatives have been authorized, for their own account and the accounts
of the several Underwriters, to accept delivery of and receipt for, and make payment of the purchase price for, the Firm Securities and any Optional Securities the Underwriters have agreed to purchase. Each of Jefferies, TD Cowen and Cantor,
individually and not as the Representatives of the Underwriters, may (but shall not be obligated to) make payment for any Offered Securities to be purchased by any Underwriter whose funds shall not have been received by the Representatives by the
First Closing Date or the applicable Option Closing Date, as the case may be, for the account of such Underwriter, but any such payment shall not relieve such Underwriter from any of its obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B><I>Delivery of the Offered </I></B><B><I>Securities</I></B><B>.</B> The Company shall (i)&nbsp;deliver, or cause to be delivered
through the facilities of Depositary Trust Company (&#147;<B>DTC</B>&#148;) unless the Representatives shall otherwise instruct, to the Representatives for the accounts of the several Underwriters, the Firm Shares, and (ii)&nbsp;deliver, or cause to
be delivered, to the purchasers thereof the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and the Firm Warrants in accordance with the Underwriters&#146; instructions to be sold by them at the First Closing Date, against release of a
wire transfer of immediately available funds for the amount of the purchase price therefor. The Company shall also (i)&nbsp;deliver, or cause to be delivered through the facilities of DTC unless the Representatives shall otherwise instruct, to the
Representatives for the accounts of the several Underwriters, the Optional Shares and (ii)&nbsp;deliver, or cause to be delivered, to the purchasers thereof the Optional Warrants the Underwriters have agreed to purchase from them at the First
Closing Date or the applicable Option Closing Date, as the case may be, against the release of a wire transfer of immediately available funds for the amount of the purchase price therefor. If Jefferies so elects, delivery of the Offered Shares may
be made by credit to the accounts designated by Jefferies through The Depository Trust Company&#146;s full fast transfer or DWAC programs. If Jefferies so elects, the Offered Shares shall be registered in such names and denominations as the
Representatives shall have requested at least two full business days prior to the First Closing Date (or the applicable Option Closing Date, as the case may be) and shall be made available for inspection on the business day preceding the First
Closing Date (or the applicable Option Closing Date, as the case may be) at a location in New York City as the Representatives may designate; provided, however, that if the Company, upon the instruction of the Representatives, registers the Offered
Warrants or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants in the name of any person or entity to whom any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Underwriter intends to sell such Offered Warrants or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, then such Underwriter shall have the right to thereafter request the <FONT
STYLE="white-space:nowrap">re-registration</FONT> of such Offered Warrants or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants (and the Company shall be required to <FONT STYLE="white-space:nowrap">re-register</FONT> such Offered Warrants
or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants) in the name of any other person or entity (it being understood that such <FONT STYLE="white-space:nowrap">re-registration</FONT> is intended to permit an Underwriter to resell such
Offered Warrants or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants in the event that the person or entity to whom such Underwriter originally intended to sell such Offered Warrants or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT>
Warrants shall fail to pay the purchase price of such Offered Warrants or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants). Time shall be of the essence, and delivery at the time and place specified in this Agreement is a further
condition to the obligations of the Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3. Additional Covenants of the Company.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company further covenants and agrees with each Underwriter as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><I>Delivery of Registration Statement, Time of Sale Prospectus and Prospectus</I></B><B><I>.</I></B><I> </I>To the extent not
available on EDGAR, upon the request of the Representatives, the Company agrees to furnish promptly to the Representatives and to counsel for the Underwriters a signed copy of the Registration Statement as originally filed with the Commission, and
of each amendment thereto filed with the Commission, including all consents and exhibits filed therewith </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>
<B><I>Representatives</I></B><B><I>&#146;</I></B><B><I> Review of Proposed Amendments and Supplements</I></B><B><I>.</I></B><I> </I>During the period when a prospectus relating to the Offered Securities is required by the Securities Act to be
delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule), the Company (i)&nbsp;will furnish to the Representatives for review, a reasonable period of time prior to the proposed time of filing of
any proposed amendment or supplement to the Registration Statement, a copy of each such amendment or supplement and (ii)&nbsp;will not amend or supplement the Registration Statement (including any amendment or supplement through incorporation of any
report filed under the Exchange Act) without the Representatives&#146; prior written consent, which will not be unreasonably withheld, conditioned or delayed. Prior to amending or supplementing any preliminary prospectus, the Time of Sale Prospectus
or the Prospectus (including any amendment or supplement through incorporation of any report filed under the Exchange Act), the Company shall furnish to the Representatives for review, a reasonable amount of time prior to the time of filing or use
of the proposed amendment or supplement, a copy of each such proposed amendment or supplement. The Company shall not file or use any such proposed amendment or supplement without the Representatives&#146; prior written consent, which will not be
unreasonably withheld, conditioned or delayed. The Company shall file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><I>Free Writing Prospectuses</I></B><B><I>.</I></B><I> </I>The Company represents and agrees that, unless it obtains the prior
consent of the Representatives, and each Underwriter represents and agrees that, unless it obtains the prior consent of the Company and the Representatives, it has not made and will not, other than the final term sheet prepared and filed pursuant to
Section&nbsp;4(d) hereof, make any offer relating to the Offered Securities that would constitute a &#147;free writing prospectus&#148; as defined in Rule 405 of the Rules and Regulations unless the prior written consent of the Representatives has
been received (each, a &#147;<B>Permitted Free Writing Prospectus</B>&#148;); <I>provided</I> that the prior written consent of the Representatives hereto shall be deemed to have been given in respect of the Free Writing Prospectuses included in
<U>Schedule B</U> hereto. The Company represents that it has treated and agrees that it will treat each Permitted Free Writing Prospectus as a Free Writing Prospectus, comply with the requirements of Rules 164 and 433 of the Rules and Regulations
applicable to any Free Writing Prospectus, including the requirements relating to timely filing with the Commission, legending and record keeping and will not take any action that would result in an Underwriter or the Company being required to file
with the Commission pursuant to Rule 433(d) of the rules and regulations of the Securities Act a free writing prospectus prepared by or on behalf of such Underwriter that such Underwriter otherwise would not have been required to file thereunder.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><I>Filing of Underwriter Free Writing Prospectuses.</I></B><I> </I>The Company
shall not take any action that would result in an Underwriter or the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of such Underwriter that such
Underwriter otherwise would not have been required to file thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><I>Amendments and Supplements to Time of Sale
Prospectus</I></B><B><I>.</I></B><I> </I>If the Time of Sale Prospectus is being used to solicit offers to buy the Offered Securities at a time when the Prospectus is not yet available to prospective purchasers, and any event shall occur or
condition exist as a result of which it is necessary to amend or supplement the Time of Sale Prospectus so that the Time of Sale Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order
to make the statements therein, in the light of the circumstances when delivered to a prospective purchaser, not misleading, or if any event shall occur or condition exist as a result of which the Time of Sale Prospectus conflicts with the
information contained in the Registration Statement, or if, in the reasonable opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law, the Company shall (subject to
Section&nbsp;3(b) and Section&nbsp;3(c) hereof) promptly prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that
the statements in the Time of Sale Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
when delivered to a prospective purchaser, not misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with the information contained in the Registration Statement, or so that the Time of Sale
Prospectus, as amended or supplemented, will comply with applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B><I>Certain Notifications and Required
Actions</I></B><B>.</B> After the date of this Agreement, the Company shall, upon request, during the period of five (5)&nbsp;years from the date hereof, to deliver to each of the Underwriters, (i)&nbsp;as soon as they are available, copies of all
reports or other communications (financial or other) furnished to stockholders, and (ii)&nbsp;as soon as they are available, copies of any reports and financial statements furnished or filed with the Commission or any national securities exchange on
which the Offered Securities are listed. However, so long as the Company is subject to the reporting requirements of either Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act and is timely filing reports EDGAR, it is not required to furnish
such reports or statements to the Underwriters. The Company shall also supply the Underwriters with copies of all correspondence to and from, and all documents issued to and by, the Commission in connection with the registration of the Offered
Securities under the Securities Act or any of the Registration Statement or the Prospectus, or any amendment or supplement thereto or document incorporated by reference therein. Prior to the Closing Date, the Company shall not to issue any press
release or other communication directly or indirectly or hold any press conference with respect to the Company, its condition, financial or otherwise, or earnings, business affairs or business prospects (except for routine oral marketing
communications in the ordinary course of business and consistent with the past practices of the Company and of which the Representatives is notified), without the prior consent of the Representatives, unless in the judgment of the Company and its
counsel, and after notification to the Representatives, such press release or communication is required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B>
<B><I>Amendments and Supplements to the Prospectus and Other Securities Act Matters</I></B><B><I>.</I></B> If any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Prospectus so that the Prospectus
does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered (whether physically or through compliance
with Rule 172 under the Securities Act </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or any similar rule) to a purchaser, not misleading, or if in the reasonable opinion of the Representatives or counsel for the Underwriters it is otherwise necessary to amend or supplement the
Prospectus to comply with applicable law, the Company agrees (subject to Section&nbsp;3(b) and Section&nbsp;3(c) hereof) to promptly prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon
request, amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances when the Prospectus is delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) to a purchaser, not misleading or so that the Prospectus, as
amended or supplemented, will comply with applicable law. Neither the Representatives&#146; consent to, nor delivery of, any such amendment or supplement shall constitute a waiver of any of the Company&#146;s obligations under Section&nbsp;3(b) or
Section&nbsp;3(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B><I>Blue Sky Compliance</I></B><B>.</B> The Company shall take promptly from time to time such actions as
the Representatives may reasonably request to qualify the Offered Securities for offering and sale under the securities or Blue Sky laws of such jurisdictions (domestic or foreign) as the Representatives may reasonably designate and to continue such
qualifications in effect, and to comply with such laws, for so long as required to permit the offer and sale of Stock in such jurisdictions; <I>provided</I> that the Company and its subsidiaries shall not be obligated to (i)&nbsp;qualify as foreign
corporations in any jurisdiction in which they are not so qualified, (ii)&nbsp;file a general consent to service of process in any jurisdiction or (iii)&nbsp;subject itself to taxation in any such jurisdiction if it is not otherwise so subject. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B><I>Use of Proceeds</I></B><B>.</B> The Company shall apply the net proceeds from the sale of the Offered Securities sold by it
in the manner described under the caption &#147;Use of Proceeds&#148; in the Registration Statement, the Time of Sale Prospectus and the Prospectus, and except as disclosed in the Registration Statement, the Company does not intend to use any of the
proceeds from the sale of the Offered Securities hereunder to repay any outstanding debt owed to any affiliate of any Underwriter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B><I>Transfer Agent</I></B><B>.</B> The Company shall maintain, at its expense, a registrar and transfer agent for the Offered
Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> <B><I>Earnings Statement</I></B><B>.</B> The Company will make generally available to its security holders and to
the Representatives as soon as practicable, but in any event not later than sixteen (16)&nbsp;months after the effective date of the Registration Statement (as defined in Rule 158(c) of the rules and regulations of the Securities Act), an earnings
statement of the Company and its subsidiaries (which need not be audited) complying with Section&nbsp;11(a) of the Securities Act (including, at the option of the Company, Rule 158). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> <B><I>Continued Compliance with Securities Laws</I></B><B>.</B> The Company will comply with the Securities Act and the Exchange
Act so as to permit the completion of the distribution of the Offered Securities as contemplated by this Agreement<B>, </B>the Registration Statement, the Time of Sale Prospectus and the Prospectus. Without limiting the generality of the foregoing,
the Company will, during the period when a prospectus relating to the Offered Securities is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule), file on
a timely basis with the Commission and the NASDAQ all reports and documents required to be filed under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B>
<B><I>Listing</I></B><B>.</B> The Company will use its reasonable best efforts to list, subject to notice of issuance, the Offered Shares and the Warrant Shares on the NASDAQ. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> <B><I>Agreement Not to Offer or Sell Additional Shares</I></B><B>.</B> During the
period commencing on and including the date hereof and continuing through and including the 90<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day following the date of the Prospectus (such period, being referred to herein as the &#147;<B><FONT
STYLE="white-space:nowrap">Lock-up</FONT> Period</B>&#148;), the Company will not, without the prior written consent of Jefferies and TD Cowen (which consent may be withheld in sole discretion of Jefferies and TD Cowen), directly or indirectly:
(i)&nbsp;sell, offer to sell, contract to sell or lend any Shares or Related Securities (as defined below); (ii) effect any short sale, or establish or increase any &#147;put equivalent position&#148; (as defined in Rule <FONT
STYLE="white-space:nowrap">16a-1(h)</FONT> under the Exchange Act) or liquidate or decrease any &#147;call equivalent position&#148; (as defined in <FONT STYLE="white-space:nowrap">Rule&nbsp;16a-1(b)</FONT> under the Exchange Act) of any Shares or
Related Securities; (iii)&nbsp;pledge, hypothecate or grant any security interest in any Shares or Related Securities; (iv)&nbsp;in any other way transfer or dispose of any Shares or Related Securities; (v)&nbsp;enter into any swap, hedge or similar
arrangement or agreement that transfers, in whole or in part, the economic risk of ownership of any Shares or Related Securities, regardless of whether any such transaction is to be settled in securities, in cash or otherwise; (vi)&nbsp;announce the
offering of any Shares or Related Securities (other than as contemplated by this Agreement with respect to the Offered Securities); (vii) submit or file any registration statement under the Securities Act in respect of any Shares or Related
Securities (other than as contemplated by this Agreement with respect to the Offered Securities); (viii) effect a reverse stock split, recapitalization, share consolidation, reclassification or similar transaction affecting the outstanding Shares;
or (ix)&nbsp;publicly announce the intention to do any of the foregoing; <I>provided, however</I>, that the Company may (A)&nbsp;effect the transactions contemplated hereby, (B)&nbsp;issue Shares or options to purchase Shares, or issue Shares upon
exercise of options, pursuant to any stock option, stock bonus or other stock plan or arrangement described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, (C)&nbsp;issue Shares pursuant to the conversion of securities
or the exercise of warrants, which securities or warrants are outstanding on the date hereof and described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, (D)&nbsp;adopt a new equity incentive plan, including an
inducement plan, and file a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act to register the offer and sale of securities to be issued pursuant to such new equity incentive plan, and press releases,
if applicable pursuant to an inducement plan, and issue securities pursuant to such new equity incentive plan (including, without limitation, the issuance of Shares upon the exercise of options or other securities issued pursuant to such new equity
incentive plan), provided that (1)&nbsp;such new equity incentive plan satisfies the transaction requirements of General Instruction A.1 of Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act and (2)&nbsp;this clause
(D)&nbsp;shall not be available unless each recipient, if such person is an officer or director of the Company, of Shares or Related Securities, pursuant to such new equity incentive plan shall be contractually prohibited from selling, offering,
disposing of or otherwise transferring any such Shares or Related Securities during the remainder of the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period; (E)&nbsp;issue Shares to one or more counterparties in connection with the consummation
of a strategic partnership, joint venture, collaboration, merger, <FONT STYLE="white-space:nowrap">co-promotion</FONT> or distribution arrangement, or the acquisition, <FONT STYLE="white-space:nowrap">in-licensing</FONT> or <FONT
STYLE="white-space:nowrap">out-licensing</FONT> of any business products or technologies; provided, that prior to such issuance, each recipient of such Shares under this clause (E)&nbsp;shall execute and deliver to the Representatives a <FONT
STYLE="white-space:nowrap">Lock-up</FONT> Agreement substantially in the form of Exhibit A hereto; (F)&nbsp;facilitate the transfer of Shares under a trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act
(a &#147;Trading Plan&#148;) that is existing on the date hereof which has been provided to the Representative or its legal counsel (G)&nbsp;facilitate the establishment of a trading plan on behalf of a shareholder, officer or director of the
Company pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of Shares, provided that (x)&nbsp;such plan does not provide for the transfer of Shares during the
<FONT STYLE="white-space:nowrap">Lock-up</FONT> Period and (y)&nbsp;to the extent a public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by the Company regarding the establishment of such plan, such
announcement or filing shall include a statement to the effect that no transfer of Shares may be made under such plan during the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period and (H)&nbsp;issue Shares pursuant to an existing or future at
the market sales agreement with TD Securities (USA) LLC (as successor to Cowen and Company, LLC), through which the Company can sell shares of common stock by means of at the market offerings from time to time. For purposes of the foregoing,
&#147;<B>Related Securities</B>&#148; shall mean any options or warrants or other rights to acquire Shares or any securities exchangeable or exercisable for or convertible into Shares, or to acquire other securities or rights ultimately exchangeable
or exercisable for, or convertible into, Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> <B><I>Future Reports to the
Representative</I></B><B><I>s</I></B><B><I>.</I></B><I> </I>During the period of five years hereafter, the Company will furnish to the Representatives, c/o Jefferies, at 520 Madison Avenue, New York, New York 10022, Attention: Global Head of
Syndicate: (i)&nbsp;as soon as practicable after the end of each fiscal year, copies of the Annual Report of the Company containing the balance sheet of the Company as of the close of such fiscal year and statements of income, stockholders&#146;<I>
</I>equity and cash flows for the year then ended and the opinion thereon of the Company&#146;s independent public or certified public accountants; (ii)&nbsp;as soon as practicable after the filing thereof, copies of each proxy statement, Annual
Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or other public report filed by the Company with
the Commission, FINRA or any securities exchange; and (iii)&nbsp;as soon as available, copies of any report or communication of the Company furnished or made available generally to holders of its capital stock; <I>provided, however,</I> that the
requirements of this Section&nbsp;3(o) shall be satisfied to the extent that such reports, statements, communications, financial statements or other documents are available on EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> <B><I>Investment Limitation</I></B><B>.</B> The Company shall not invest or otherwise use the proceeds received by the Company from
its sale of the Offered Securities in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment Company Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> <B><I>No Stabilization or Manipulation</I></B><B><I>; Compliance with Regulation M</I></B><B>. </B>Until the Underwriters shall
have notified the Company of the completion of the resale of the Offered Securities, that the Company will not, and will use its reasonable best efforts to cause its affiliated purchasers (as defined in Regulation M under the Exchange Act) not to,
either alone or with one or more other persons, bid for or purchase, for any account in which it or any of its affiliated purchasers has a beneficial interest, any Offered Securities, or attempt to induce any person to purchase any Offered
Securities; and not to, and to use its reasonable best efforts to cause its affiliated purchasers not to, make bids or purchase for the purpose of creating actual, or apparent, active trading in or of raising the price of the Offered Securities..
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> <B><I>Enforce <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</I></B><B><I>s</I></B><B>.</B> During the <FONT
STYLE="white-space:nowrap">Lock-up</FONT> Period, the Company will enforce all agreements between the Company and any of its officers and directors that restrict or prohibit, expressly or in operation, the offer, sale or transfer of Shares or
Related Securities or any of the other actions restricted or prohibited under the terms of the form of <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement. In addition, the Company will direct the transfer agent to place stop transfer
restrictions upon any such securities of the Company that are bound by such <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements for the duration of the periods contemplated in such agreements, including, without limitation, <FONT
STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements entered into by the Company&#146;s officers and directors pursuant to Section&nbsp;6(i) hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B> <B><I>Company to Provide Interim Financial Statements</I></B><B>.</B> Prior to the First Closing Date and each Applicable Option
Closing Date, the Company will furnish to the Underwriters, as soon as reasonably practicable after they have been prepared by or are available to the Company, a copy of any unaudited interim financial statements of the Company for any period
subsequent to the period covered by the most recent financial statements appearing in the Registration Statement and the Prospectus; provided however, that the requirements of this Section&nbsp;3(s) shall be satisfied to the extent that such
reports, statements, communications, financial statements or other documents are available on EDGAR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B> <B><I>Amendments and
Supplements to Permitted Section</I></B><B><I></I></B><B><I>&nbsp;5(d) Communications. </I></B><I></I>If at any time following the distribution of any Permitted Section&nbsp;5(d) Communication and prior to the later of (i)&nbsp;the expiration or
termination of the option granted to the Underwriters in Section&nbsp;2 and (ii)&nbsp;the completion of the Underwriters&#146; distribution of the Offered Shares, there occurred or occurs an event or development as a result of which such Permitted
Section&nbsp;5(d) Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that
subsequent time, not misleading, the Company will promptly notify the Representatives and, upon the reasonable request of the Representatives, will promptly amend or supplement, at its own expense, such Permitted Section&nbsp;5(d) Communication to
eliminate or correct such untrue statement or omission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u) </B><B><I>[Reserved].</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> <B><I>Maintenance of Registration.</I></B> The Company shall, at all times while the Company is subject to the reporting
requirements of Section&nbsp;13 or 15(d) of the Exchange Act and any <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are outstanding, use its best efforts to maintain a registration statement covering the issuance and sale of the Warrant
Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w)</B> <B><I>Warrant Shares Reserved.</I></B> The Company shall, at all times while any
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants or Firm Warrants are outstanding, reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved shares of Common Stock, solely for the purpose of
enabling it to issue Warrant Shares upon exercise of such <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants or Firm Warrants, the number of Warrant Shares that are initially issuable and deliverables upon the exercise of the
then-outstanding <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants or Firm Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> <B><I>Performance of Covenants
and Satisfaction of Conditions</I></B><B>.</B> The Company agrees to use its reasonable best efforts to do and perform all things required to be done or performed under this Agreement by the Company prior to each Closing Date and to satisfy all
conditions precedent to the delivery of the Firm Securities and the Optional Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Representatives, on behalf of the several
Underwriters, may, in their sole discretion, waive in writing the performance by the Company of any one or more of the foregoing covenants or extend the time for their performance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.</B> <B>Payment of Expenses</B><B>.</B> The Company agrees to pay all costs, fees and expenses incurred in
connection with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including without limitation (i)&nbsp;all expenses incident to the issuance and delivery of the Offered Securities (including
all printing and engraving costs), (ii)&nbsp;all fees and expenses of the registrar and transfer agent of the Offered Securities, (iii)&nbsp;all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Offered
Securities to the Underwriters, (iv)&nbsp;all fees and expenses of the Company&#146;s counsel, independent public or certified public accountants and other advisors, (v)&nbsp;all costs and expenses incurred in connection with the preparation,
printing, filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Time of Sale Prospectus, the Prospectus, each free writing prospectus prepared
by or on behalf of, used by, or referred to by the Company, and each preliminary prospectus, each Permitted Section&nbsp;5(d) Communication, and all amendments and supplements thereto, and this Agreement, (vi)&nbsp;all filing fees, reasonable and
documented attorneys&#146; fees and expenses incurred by the Company or the Underwriters in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Offered Securities for
offer and sale under the state securities or blue sky laws, and, if requested by the Representatives, preparing and printing a &#147;Blue Sky Survey&#148; or memorandum and a &#147;Canadian wrapper&#148;, and any supplements thereto, advising the
Underwriters of such qualifications, registrations and exemptions (including reasonable and documented attorneys&#146; fees and expenses up to an aggregate amount of $10,000), (vii)&nbsp;the fees, disbursements and expenses of counsel to the
Underwriters up to an aggregate of $35,000, including the costs, fees and expenses incurred by the Underwriters in connection with determining their compliance with the rules and regulations of FINRA related to the Underwriters&#146; participation
in the offering and distribution of the Offered Securities, if applicable, including any related filing fees and the reasonable and documented legal fees of, and disbursements by, counsel to the Underwriters<B>,</B> (viii)&nbsp;the costs and
expenses of the Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
relating to investor presentations on any &#147;road show&#148;, any Permitted Section&nbsp;5(d) Communication or any Section&nbsp;5(d) Oral Communication undertaken in connection with the
offering of the Offered Securities, including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of
any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives, employees and officers of the Company and any such consultants, and the cost of any
aircraft chartered in connection with the road show, provided that the cost of any such chartered aircraft shall be borne 50% by the Company and 50% by the Underwriters (ix)&nbsp;the fees and expenses associated with listing the Offered Shares and
the Warrant Shares on the NASDAQ, and (x)&nbsp;all other fees, costs and expenses of the nature referred to in Item 14 of Part&nbsp;II of the Registration Statement. Except as provided in this Section&nbsp;4 or in Section&nbsp;7, Section&nbsp;9 or
Section&nbsp;10 hereof, the Underwriters shall pay their own expenses, including the fees and disbursements of their counsel and their own travel and lodging expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.</B> <B>Covenant of the Underwriters</B><B>.</B> Each Underwriter severally and not jointly covenants with the
Company not to take any action that would result in the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of such Underwriter that otherwise would
not, but for such actions, be required to be filed by the Company under Rule 433(d). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.</B> <B>Conditions
of the Obligations of the Underwriters</B><B>.</B> The respective obligations of the several Underwriters hereunder to purchase and pay for the Offered Securities as provided herein on the First Closing Date and, with respect to the Optional
Securities, each Option Closing Date, shall be subject to the accuracy of the representations and warranties on the part of the Company set forth in Section&nbsp;1 hereof as of the date hereof and as of the First Closing Date as though then made
and, with respect to the Optional Securities, as of each Option Closing Date as though then made, to the timely performance by the Company of its covenants and other obligations hereunder, and to each of the following additional conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><I>Comfort Letter</I></B><B>.</B> On the date hereof, the Representatives shall have received from Ernst&nbsp;&amp; Young LLP,
independent registered public accountants for the Company, a letter dated the date hereof addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives, containing statements and information of the type
ordinarily included in accountant&#146;s &#147;comfort letters&#148; to underwriters, delivered according to Statement of Auditing Standards No.&nbsp;72 (or any successor bulletin), with respect to the audited and unaudited financial statements and
certain financial information contained in the Registration Statement, the Time of Sale Prospectus, and each free writing prospectus, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><I>Compliance with Registration Requirements; No Stop Order; No Objection from </I></B><B><I>FINRA</I></B><B><I>. </I></B>For
the period from and after the date of this Agreement and through and including the First Closing Date and, with respect to any Optional Securities purchased after the First Closing Date, each Option Closing Date: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Company shall have filed the Prospectus with the Commission (including the information required by Rule 430A under the
Securities Act) in the manner and within the time period required by Rule 424(b) under the Securities Act; or the Company shall have filed a <FONT STYLE="white-space:nowrap">post-effective</FONT> amendment to the Registration Statement containing
the information required by such Rule 430A. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) No stop order suspending the effectiveness of the Registration Statement
or any post-effective amendment to the Registration Statement shall be in effect, and no proceedings for such purpose shall have been instituted or threatened by the Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) If a filing has been made with FINRA, FINRA shall have raised no
objection to the fairness and reasonableness of the underwriting terms and arrangements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><I>No Material Adverse Change or
Ratings Agency Change</I></B><B>.</B> For the period from and after the date of this Agreement and through and including the First Closing Date and, with respect to any Optional Seurities purchased after the First Closing Date, each Option Closing
Date: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) in the judgment of the Representatives there shall not have occurred any Material Adverse Change; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential
downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any &#147;nationally recognized statistical rating
organization&#148; as that term is used in <FONT STYLE="white-space:nowrap">Rule&nbsp;15c3-1(c)(2)(vi)(F)</FONT> under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><I>Opinion and Negative Assurance Letter of Counsel for the Company</I></B><B>.</B> On each of the First Closing Date and each
Option Closing Date, the Representatives shall have received the opinion and negative assurance letter of Goodwin Procter LLP, counsel for the Company, dated as of such date, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><I>Opinion of Intellectual Property Counsel for the Company.</I></B><I> </I>On each of the First Closing Date and each Option
Closing Date, the Representatives shall have received the opinion of Goodwin Procter LLP, counsel for the Company with respect to intellectual property matters, dated as of such date, in form and substance reasonably satisfactory to the
Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B><I>Opinion and Negative Assurance Letter of Counsel for the Underwriters</I></B><B>.</B> On each of the
First Closing Date and each Option Closing Date, the Representatives shall have received the opinion and negative assurance letter of Duane Morris LLP, counsel for the Underwriters in connection with the offer and sale of the Offered Securities, in
form and substance reasonably satisfactory to the Representatives, dated as of such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B>
<B><I>Officers</I></B><B><I>&#146;</I></B><B><I> Certificate</I></B><B>.</B> On each of the First Closing Date and each Option Closing Date, the Representatives shall have received a certificate executed by the Chairman of the Board of the Company
or the President and Chief Financial Officer of the Company, dated as of such date, to the effect set forth in Section&nbsp;6(b)(ii) and further to the effect that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) No stop order suspending the effectiveness of the Registration Statement (including, for the avoidance of doubt, any Rule
462(b) Registration Statement), or any post-effective amendment thereto, shall be in effect and no proceedings for such purpose shall have been instituted or, to their knowledge, threatened by the Commission; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) for the period from and including the date of this Agreement through and including such Closing Date, there has not
occurred any Material Adverse Change; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) to their knowledge, after reasonable investigation, as of such Closing Date,
the representations, warranties and covenants of the Company set forth in this Agreement are true and correct and the Company has complied with all agreements and satisfied all the conditions on its part to be performed or satisfied hereunder at or
prior to such Closing Date; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) there has not been, subsequent to the date of the most recent audited
financial statements included or incorporated by reference in the Prospectus, any Material Adverse Change in the financial position or results of operations of the Company, or any change or development that, singularly or in the aggregate, would
reasonably be expected to involve a Material Adverse Change, except as set forth in the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B><I>Bring-down Comfort
Letter</I></B><B>.</B> On each of the First Closing Date and each Option Closing Date, the Representatives shall have received from Ernst&nbsp;&amp; Young LLP, independent registered public accountants for the Company, a letter dated such date, in
form and substance satisfactory to the Representatives, which letter shall: (i)&nbsp;reaffirm the statements made in the letter furnished by them pursuant to Section&nbsp;6(a), except that the specified date referred to therein for the carrying out
of procedures shall be no more than three business days prior to the First Closing Date or the applicable Option Closing Date, as the case may be; and (ii)&nbsp;cover certain financial information contained in the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</I></B><B><I>.</I></B> On or prior to the date hereof, the Company
shall have furnished to the Representatives an agreement in the form of <U>Exhibit A</U> hereto from each of the persons listed on Exhibit B hereto, and each such agreement shall be in full force and effect on each of the First Closing Date and each
Option Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B><I>Rule</I></B><B><I></I></B><B><I>&nbsp;462(b) Registration Statement</I></B>. In the event that a
Rule&nbsp;462(b) Registration Statement is filed in connection with the offering contemplated by this Agreement, such Rule&nbsp;462(b) Registration Statement shall have been filed with the Commission on the date of this Agreement and shall have
become effective automatically upon such filing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> <B><I>Additional Documents</I></B>. On or before each of the First Closing
Date and each Option Closing Date, the Representatives and counsel for the Underwriters shall have received such information, documents and opinions as they may reasonably request for the purposes of enabling them to pass upon the issuance and sale
of the Offered Securities as contemplated herein, or in order to evidence the accuracy of any of the representations and warranties, or the satisfaction of any of the conditions or agreements, herein contained; and all proceedings taken by the
Company in connection with the issuance and sale of the Offered Securities as contemplated herein and in connection with the other transactions contemplated by this Agreement shall be satisfactory in form and substance to the Representatives and
counsel for the Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any condition specified in this Section&nbsp;6 is not satisfied when and as required to be satisfied
(unless waived by the Representatives), this Agreement may be terminated by the Representatives by notice from Jefferies to the Company at any time on or prior to the First Closing Date and, with respect to the Optional Securities, at any time on or
prior to the applicable Option Closing Date, which termination shall be without liability on the part of any party to any other party, except that Section&nbsp;4, Section&nbsp;7, Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and
shall survive such termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.</B> <B>Reimbursement of Underwriters</B><B>&#146;</B><B> Expenses</B>.
If this Agreement is terminated by the Representatives pursuant to Section&nbsp;6, Section&nbsp;11 or Section&nbsp;12, or if the sale to the Underwriters of the Offered Securities on the First Closing Date is not consummated because of any refusal,
inability or failure on the part of the Company to perform any agreement herein or to comply with any provision hereof, the Company agrees to reimburse the Representative and the other Underwriters (or such Underwriters as have terminated this
Agreement with respect to themselves), severally, upon demand for all reasonably documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses that shall have been reasonably incurred by the
Representatives and the Underwriters in connection with the proposed purchase and the offering and sale of the Offered Securities, including, but not limited to, reasonable and documented fees and disbursements of counsel, printing expenses, travel
expenses, postage, facsimile and telephone charges. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.</B> <B>Effectiveness of this Agreement</B>. This Agreement
shall become effective upon&nbsp;the execution and delivery hereof by the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;9.</B>
<B>Indemnification</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><I>Indemnification of the Underwriters</I></B><B>.</B> The Company agrees to indemnify and hold
harmless each Underwriter, its affiliates, directors, officers, employees and agents, and each person, if any, who controls any Underwriter within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or
expense, as incurred, to which such Underwriter or such affiliate, director, officer, employee, agent or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state statutory law or regulation, or the
laws or regulations of foreign jurisdictions where Offered Securities have been offered or sold or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of the Company),
insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration
Statement, or any amendment thereto, or the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii)&nbsp;any untrue statement or alleged untrue
statement of a material fact included in any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act, any
Marketing Material, any Section&nbsp;5(d) Written Communication or the Prospectus (or any amendment or supplement to the foregoing), or the omission or alleged omission to state therein a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading; and to reimburse each Underwriter and each such affiliate, director, officer, employee, agent and controlling person for any and all expenses (including the
reasonable fees and disbursements of counsel) as such expenses are incurred by such Underwriter or such affiliate, director, officer, employee, agent or controlling person in connection with investigating, defending, settling, compromising or paying
any such loss, claim, damage, liability, expense or action; <I>provided, however</I>, that the foregoing indemnity agreement shall not apply to any loss, claim, damage, liability or expense to the extent, but only to the extent, arising out of or
based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company by the Representatives in writing expressly for
use in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any such free writing prospectus, any Marketing Material, any Section&nbsp;5(d) Written Communication or the Prospectus (or any amendment or supplement
thereto), it being understood and agreed that the only such information consists of the information described in Section&nbsp;9(b) below. The indemnity agreement set forth in this Section&nbsp;9(a) shall be in addition to any liabilities that the
Company may otherwise have. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><I>Indemnification of the Company, its Directors and Officers</I></B>. Each Underwriter agrees,
severally and not jointly, to indemnify and hold harmless the Company, each of its directors, each of its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of the Securities Act or
the Exchange Act, against any loss, claim, damage, liability or expense, as incurred, to which the Company, or any such director, officer or controlling person may become subject, under the Securities Act, the Exchange Act, or other federal or state
statutory law or regulation, or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of such Underwriter), insofar as such loss, claim, damage, liability or expense (or
actions in respect thereof as contemplated below) arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, or any omission or
alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact included in any preliminary
prospectus, the Time of Sale </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Prospectus, any free writing prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433 of the Securities Act, any Section&nbsp;5(d) Written
Communication or the Prospectus (or any such amendment or supplement) or the omission or alleged omission to state therein a material fact necessary in order to make the statements, in the light of the circumstances under which they were made, not
misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, such preliminary prospectus, the Time of Sale Prospectus,
such free writing prospectus, such Section&nbsp;5(d) Written Communication or the Prospectus (or any such amendment or supplement), in reliance upon and in conformity with information relating to such Underwriter furnished to the Company by the
Representatives in writing expressly for use therein; and to reimburse the Company, or any such director, officer or controlling person for any and all expenses (including the fees and disbursements of counsel) as such expenses are incurred by the
Company, or any such director, officer or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action. The Company hereby acknowledges that the only
information that the Representatives have furnished to the Company expressly for use in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the Company has filed, or is required to
file, pursuant to Rule 433(d) of the Securities Act, any Section&nbsp;5(d) Written Communication or the Prospectus (or any amendment or supplement to the foregoing) are the statements set forth in the thirteenth, fourteenth and fifteenth paragraphs
under the caption &#147;Underwriting&#148; in the Preliminary Prospectus Supplement and the Final Prospectus Supplement. The indemnity agreement set forth in this Section&nbsp;9(b) shall be in addition to any liabilities that each Underwriter may
otherwise have. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><I>Notifications and Other Indemnification Procedures</I></B><B>.</B> Promptly after receipt by an
indemnified party under this Section&nbsp;9 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this Section&nbsp;9, notify the indemnifying party
in writing of the commencement thereof, but the omission to so notify the indemnifying party will not relieve the indemnifying party from any liability which it may have to any indemnified party to the extent the indemnifying party is not materially
prejudiced as a proximate result of such failure and shall not in any event relieve the indemnifying party from any liability that it may have otherwise than on account of this indemnity agreement. In case any such action is brought against any
indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it shall elect, jointly with all other indemnifying
parties similarly notified, by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense thereof with counsel reasonably satisfactory to such indemnified party;
<I>provided, however</I>, that if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded based upon the advice of counsel that a conflict may arise
between the positions of the indemnifying party and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and/or other indemnified parties which are different from or additional to
those available to the indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party
or parties. Upon receipt of notice from the indemnifying party to such indemnified party of such indemnifying party&#146;s election to so assume the defense of such action and approval by the indemnified party of counsel, such approval not to be
unreasonably withheld, delayed or conditioned, the indemnifying party will not be liable to such indemnified party under this Section&nbsp;9 for any reasonable and documented legal or other expenses subsequently incurred by such indemnified party in
connection with the defense thereof unless (i)&nbsp;the indemnified party shall have employed separate counsel in accordance with the proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be liable
for the fees and expenses of more than one separate counsel (together with one local counsel for each applicable jurisdiction), representing the indemnified parties who are parties to such action), which counsel (together with such local counsel)
for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the indemnified parties shall be selected by Jefferies (in the case of counsel for the indemnified parties referred to in Section&nbsp;9(a) above) or by the Company (in the case of counsel for
the indemnified parties referred to in Section&nbsp;9(b) above)) or (ii)&nbsp;the indemnifying party shall not have employed counsel reasonably satisfactory to the indemnified party to represent the indemnified party within a reasonable time after
notice of commencement of the action or (iii)&nbsp;the indemnifying party has authorized in writing the employment of counsel for the indemnified party at the expense of the indemnifying party, in each of which cases the fees and expenses of such
counsel shall be at the expense of the indemnifying party and shall be paid as they are incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>
<B><I>Settlements</I></B><B>.</B> The indemnifying party under this Section&nbsp;9 shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for
the plaintiff, the indemnifying party agrees to indemnify the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified
party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by Section&nbsp;9(c) hereof, the indemnifying party shall be liable for any settlement of any proceeding effected
without its written consent if (i)&nbsp;such settlement is entered into more than 30&nbsp;days after receipt by such indemnifying party of the aforesaid request and (ii)&nbsp;such indemnifying party shall not have reimbursed the indemnified party in
accordance with such request prior to the date of such settlement. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or
threatened action, suit or proceeding in respect of which any indemnified party is or could have been a party and indemnity was or could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an
unconditional release of such indemnified party from all liability on claims that are the subject matter of such action, suit or proceeding and does not include an admission of fault or culpability or a failure to act by or on behalf of such
indemnified party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;10.</B> <B>Contribution</B>. If the indemnification provided for in Section&nbsp;9 is
for any reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each indemnifying party shall contribute to the
aggregate amount paid or payable by such indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received
by the Company, on the one hand, and the Underwriters, on the other hand, from the offering of the Offered Securities pursuant to this Agreement or (ii)&nbsp;if the allocation provided by clause&nbsp;(i) above is not permitted by applicable law, in
such proportion as is appropriate to reflect not only the relative benefits referred to in clause&nbsp;(i) above but also the relative fault of the Company, on the one hand, and the Underwriters, on the other hand, in connection with the statements
or omissions which resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, in
connection with the offering of the Offered Securities pursuant to this Agreement shall be deemed to be in the same respective proportions as the total proceeds from the offering of the Offered Securities pursuant to this Agreement (before deducting
expenses) received by the Company, and the total underwriting discounts and commissions received by the Underwriters, in each case as set forth on the front cover page of the Prospectus, bear to the aggregate initial public offering price of the
Offered Securities as set forth on such cover. The relative fault of the Company, on the one hand, and the Underwriters, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement
of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company, on the one hand, or the Underwriters, on the other hand, and the parties&#146; relative intent, knowledge, access to
information and opportunity to correct or prevent such statement or omission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount paid or payable by a party as a result of the losses, claims, damages,
liabilities and expenses referred to above shall be deemed to include, subject to the limitations set forth in Section&nbsp;9(c), any reasonable and documented legal or other fees or expenses reasonably incurred by such party in connection with
investigating or defending any action or claim. The provisions set forth in Section&nbsp;9(c) with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this Section&nbsp;10; <I>provided,
however,</I> that no additional notice shall be required with respect to any action for which notice has been given under Section&nbsp;9(c) for purposes of indemnification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section&nbsp;10 were
determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to in this Section&nbsp;10. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the provisions of this Section&nbsp;10, no Underwriter shall be required to contribute any amount in excess of the
underwriting discounts and commissions received by such Underwriter in connection with the Offered Securities underwritten by it and distributed to the public. No person guilty of fraudulent misrepresentation (within the meaning of
Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#146; obligations to contribute pursuant to this Section&nbsp;10 are several, and
not joint, in proportion to their respective underwriting commitments as set forth opposite their respective names on <U>Schedule A</U>. For purposes of this Section&nbsp;10, each affiliate, director, officer, employee and agent of an Underwriter
and each person, if any, who controls an Underwriter within the meaning of the Securities Act or the Exchange Act shall have the same rights to contribution as such Underwriter, and each director of the Company, each officer of the Company who
signed the Registration Statement, and each person, if any, who controls the Company within the meaning of the Securities Act and the Exchange Act shall have the same rights to contribution as the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;11.</B> <B>Default of One or More of the Several Underwriters</B><I>.</I> If, on the First Closing Date or any
Option Closing Date any one or more of the several Underwriters shall fail or refuse to purchase Offered Securities that it or they have agreed to purchase hereunder on such date, and the aggregate number of Offered Securities which such defaulting
Underwriter or Underwriters agreed but failed or refused to purchase does not exceed 10% of the aggregate number of the Offered Securities to be purchased on such date, the Representatives may make arrangements satisfactory to the Company for the
purchase of such Offered Securities by other persons, including any of the Underwriters, but if no such arrangements are made by such date, the other Underwriters shall be obligated, severally and not jointly, in the proportions that the number of
Firm Securities set forth opposite their respective names on <U>Schedule</U><B> A</B> bears to the aggregate number of Firm Securities set forth opposite the names of all such <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, or
in such other proportions as may be specified by the Representatives with the consent of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, to purchase the Offered Securities which such defaulting Underwriter or Underwriters
agreed but failed or refused to purchase on such date. If, on the First Closing Date or any Option Closing Date any one or more of the Underwriters shall fail or refuse to purchase Offered Securities and the aggregate number of Offered Securities
with respect to which such default occurs exceeds 10% of the aggregate number of Offered Securities to be purchased on such date, and arrangements satisfactory to the Representatives and the Company for the purchase of such Offered Securities are
not made within 48 hours after such default, this Agreement shall terminate without liability of any party (other than the breaching Underwriter or Underwriters) to any other party except that the provisions of Section&nbsp;4, Section&nbsp;7,
Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and shall survive such termination. In any such case either the Representatives or the Company shall have the right to postpone the First Closing Date or the applicable Option
Closing Date, as the case may be, but in no event for longer than seven days in order that the required changes, if any, to the Registration Statement and the Prospectus or any other documents or arrangements may be effected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Agreement, the term &#147;<B>Underwriter</B>&#148; shall be deemed to
include any person substituted for a defaulting Underwriter under this Section&nbsp;11. Any action taken under this Section&nbsp;11 shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;12.</B> <B>Termination of this Agreement</B><I>.</I> Prior to the purchase of the Firm
Securities by the Underwriters on the First Closing Date, this Agreement may be terminated by Jefferies, TD Cowen and Cantor by notice given to the Company if at any time: (i)&nbsp;trading or quotation in any of the Company&#146;s securities shall
have been suspended or limited by the Commission or by the NASDAQ, or trading in securities generally on either the NASDAQ or the NYSE shall have been suspended or limited, or minimum or maximum prices shall have been generally established on any of
such stock exchanges; (ii)&nbsp;a general banking moratorium shall have been declared by any of federal, New York, or Pennsylvania authorities; (iii)&nbsp;there shall have occurred any outbreak or escalation of national or international hostilities
or any crisis or calamity, or any change in the United States or international financial markets, or any substantial change or development involving a prospective substantial change in United States&#146; or international political, financial or
economic conditions, as in the judgment of the Representatives is material and adverse and makes it impracticable to market the Offered Securities in the manner and on the terms described in the Time of Sale Prospectus or the Prospectus or to
enforce contracts for the sale of securities; (iv)&nbsp;in the judgment of the Representatives there shall have occurred any Material Adverse Change; or (v)&nbsp;the Company shall have sustained a loss by strike, fire, flood, earthquake, accident or
other calamity of such character as in the judgment of the Representatives may interfere materially with the conduct of the business and operations of the Company regardless of whether or not such loss shall have been insured. Any termination
pursuant to this Section&nbsp;12 shall be without liability on the part of (a)&nbsp;the Company to any Underwriter, except that the Company shall be obligated to reimburse the expenses of the Representatives and the Underwriters pursuant to
Section&nbsp;4 or Section&nbsp;7 hereof or (b)&nbsp;any Underwriter to the Company; <I>provided, however,</I> that the provisions of Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and shall survive such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;13.</B> <B>No Advisory or Fiduciary Relationship. </B>The Company acknowledges and agrees that (a)&nbsp;the
purchase and sale of the Offered Securities pursuant to this Agreement, including the determination of the public offering price of the Offered Securities and any related discounts and commissions, is an
<FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> commercial transaction between the Company, on the one hand, and the several Underwriters, on the other hand, (b)&nbsp;in connection with the offering contemplated hereby and the process
leading to such transaction, each Underwriter is and has been acting solely as a principal and is not the agent or fiduciary of the Company, or its stockholders, creditors, employees or any other party, (c)&nbsp;no Underwriter has assumed or will
assume an advisory or fiduciary responsibility in favor of the Company with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company on
other matters) and no Underwriter has any obligation to the Company with respect to the offering contemplated hereby except the obligations expressly set forth in this Agreement, (d)&nbsp;the Underwriters and their respective affiliates may be
engaged in a broad range of transactions that involve interests that differ from those of the Company, and (e)&nbsp;the Underwriters have not provided any legal, accounting, regulatory or tax advice with respect to the offering contemplated hereby
and the Company has consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;14.</B> <B>Representations and Indemnities to Survive Delivery</B><I>.</I> The respective indemnities,
agreements, representations, warranties and other statements of the Company, of its officers and of the several Underwriters set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made
by or on behalf of any Underwriter or the Company or any of its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding, will survive delivery of and payment for
the Offered Securities sold hereunder and any termination of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;15.</B> <B>Notices</B>. All communications hereunder shall be
in writing and shall be mailed, emailed, hand delivered or telecopied and confirmed to the parties hereto as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to the
Representatives: &#8195;&#8195;&#8196;&#8195;Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:26%; font-size:10pt; font-family:Times New Roman">[<U>&#8195;&#8195;&#8195; </U><U></U><U></U><U></U>] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:26%; font-size:10pt; font-family:Times New Roman">Facsimile: [<U>&#8195;&#8195;&#8195; </U><U></U><U></U><U></U>] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:26%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:26%; font-size:10pt; font-family:Times New Roman">TD
Securities (USA) LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:26%; font-size:10pt; font-family:Times New Roman">[<U>&#8195;&#8195;&#8195; </U><U></U><U></U><U></U>] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:26%; font-size:10pt; font-family:Times New Roman">Attention: Head of Equity Capital Markets </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:26%; font-size:10pt; font-family:Times New Roman">Facsimile: [<U>&#8195;&#8195;&#8195; </U><U></U><U></U><U></U>] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:26%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:26%; font-size:10pt; font-family:Times New Roman">Facsimile: [<U>&#8195;&#8195;&#8195; </U><U></U><U></U><U></U>] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:26%; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald&nbsp;&amp; Co. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:26%; font-size:10pt; font-family:Times New Roman">[<U>&#8195;&#8195;&#8195; </U><U></U><U></U><U></U>] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:26%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:26%; font-size:10pt; font-family:Times New Roman">Email: [<U>&#8195;&#8195;&#8195; </U><U></U><U></U><U></U>] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy to: &#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8201;&#8201;&#8199;&#8194;Duane Morris LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:26%; font-size:10pt; font-family:Times New Roman">[<U>&#8195;&#8195;&#8195; </U><U></U><U></U><U></U>] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:26%; font-size:10pt; font-family:Times New Roman">Attention: [<U>&#8195;&#8195;&#8195; </U><U></U><U></U><U></U>] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:26%; font-size:10pt; font-family:Times New Roman">Email: [<U>&#8195;&#8195;&#8195; </U><U></U><U></U><U></U>] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to the Company: &#8195;&#8194;&#8195;&#8194;&#8195;&#8194;&#8194;&#8194;Cabaletta Bio, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:26%; font-size:10pt; font-family:Times New Roman">[<U>&#8195;&#8195;&#8195; </U><U></U><U></U><U></U>] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:26%; font-size:10pt; font-family:Times New Roman">Phone: [<U>&#8195;&#8195;&#8195; </U><U></U><U></U><U></U>] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:26%; font-size:10pt; font-family:Times New Roman">Email: [<U>&#8195;&#8195;&#8195; </U><U></U><U></U><U></U>] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:26%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with
a copy to: &#8195;&#8194;&#8194;&#8194;&#8195;&#8195;&#8195;&#8195;&#8194;&#8201;Goodwin Procter LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:26%; font-size:10pt; font-family:Times New Roman">[<U>&#8195;&#8195;&#8195;
</U><U></U><U></U><U></U>] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:26%; font-size:10pt; font-family:Times New Roman">Attention: [<U>&#8195;&#8195;&#8195; </U><U></U><U></U><U></U>] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:26%; font-size:10pt; font-family:Times New Roman">Email: [<U>&#8195;&#8195;&#8195; </U><U></U><U></U><U></U>] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:26%; font-size:10pt; font-family:Times New Roman">Attention: [<U>&#8195;&#8195;&#8195; </U><U></U><U></U><U></U>] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:26%; font-size:10pt; font-family:Times New Roman">Email: [<U>&#8195;&#8195;&#8195; </U><U></U><U></U><U></U>] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any party hereto may change the address for receipt of communications by giving written notice to the others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;16.</B> <B>Successors</B><I>.</I> This Agreement will inure to the benefit of and be binding upon the parties
hereto, including any substitute Underwriters pursuant to Section&nbsp;11 hereof, and to the benefit of the affiliates, directors, officers, employees, agents and controlling persons referred to in Section&nbsp;9 and Section&nbsp;10, and in each
case their respective successors, and no other person will have any right or obligation hereunder. The term &#147;<B>successors</B>&#148; shall not include any purchaser of the Offered Securities as such from any of the Underwriters merely by reason
of such purchase. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;17.</B> <B>Partial Unenforceability</B>. The invalidity or
unenforceability of any section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other section, paragraph or provision hereof. If any section, paragraph or provision of this Agreement is for any reason
determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;18. Recognition of the U.S. Special Resolution Regimes. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime,
the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and
any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> In the event
that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are
permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, (A) &#147;<B>BHC Act Affiliate</B>&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be
interpreted in accordance with, 12 U.S.C. &#167; 1841(k); (B) &#147;<B>Covered Entity</B>&#148; means any of the following: (i)&nbsp;a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167;
252.82(b); (ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or (iii)&nbsp;a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R.
&#167; 382.2(b); (C) &#147;<B>Default Right</B>&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable; and (D) &#147;<B>U.S. Special Resolution
Regime</B>&#148; means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;19.</B> <B>Governing Law Provisions</B><I>.</I> This Agreement shall be governed by and construed in
accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby
(&#147;<B>Related Proceedings</B>&#148;) may be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case located in the Borough
of Manhattan in the City of New York (collectively, the &#147;<B>Specified Courts</B>&#148;), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such
court (a &#147;<B>Related Judgment</B>&#148;), as to which such jurisdiction is <FONT STYLE="white-space:nowrap">non-exclusive)</FONT> of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail
to such party&#146;s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any
suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an
inconvenient forum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;20.</B> <B>General Provisions</B><B>.</B> This Agreement constitutes the entire
agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement may be executed in two or more
counterparts, each one of which shall be an original, with the same effect </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as if the signatures thereto and hereto were upon the same instrument. This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein
(express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit. The section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the parties hereto acknowledges that it is a sophisticated business person who was adequately represented by counsel
during negotiations regarding the provisions hereof, including, without limitation, the indemnification provisions of Section&nbsp;9 and the contribution provisions of Section&nbsp;10, and is fully informed regarding said provisions. Each of the
parties hereto further acknowledges that the provisions of Section&nbsp;9 and&nbsp;Section 10 hereof fairly allocate the risks in light of the ability of the parties to investigate the Company, its affairs and its business in order to assure that
adequate disclosure has been made in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, each free writing prospectus and the Prospectus (and any amendments and supplements to the foregoing), as contemplated by the
Securities Act and the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Follows</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding of our agreement, kindly sign and
return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CABALETTA BIO, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Steven Nichtberger</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name: Steven Nichtberger</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title: Chief Executive Officer and President</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The foregoing Underwriting Agreement is hereby confirmed and accepted by the Representatives in New
York, New York as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>JEFFERIES LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TD SECURITIES (USA) LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CANTOR FITZGERALD&nbsp;&amp; CO.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Acting individually and as Representatives of the several Underwriters named in the attached <U>Schedule A</U>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>JEFFERIES LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Philip Ross</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Philip Ross</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Title: Chairman of Healthcare Investment Banking</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#8195;&#8194;Vice Chairman of Investment Banking</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TD SECURITIES (USA) LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Mariel Healy</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Mariel Healy</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CANTOR FITZGERALD&nbsp;&amp; CO.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jason Fenton</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Jason Fenton</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: <FONT STYLE="white-space:nowrap">Co-Head</FONT> of Equity Capital Markets</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#8195;&#8194;Managing Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule A </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Underwriters</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Firm Shares</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>to&nbsp;be&nbsp;Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number&nbsp;of&nbsp;Firm<BR>Warrants&nbsp;to&nbsp;be<BR>Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Funded&nbsp;Warrants</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>to be Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,072,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,428,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TD Securities (USA) LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,132,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,618,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,996,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,754,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Free Writing Prospectuses Included in the Time of Sale Prospectus </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>None. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Permitted Section&nbsp;5(d) Communications </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>None. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Form of <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June&nbsp;10, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TD Securities (USA) LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald &amp; Co. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;As Representatives of the Several Underwriters </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o TD Securities (USA) LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1 Vanderbilt Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Cantor Fitzgerald &amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">110 East 59th Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10022 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">RE:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cabaletta Bio, Inc. (the &#147;<B>Company</B>&#148;) </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies&nbsp;&amp; Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned is an owner of
shares of common stock, par value $0.00001 per share, of the Company (&#147;<B>Shares</B>&#148;) or of securities convertible into or exchangeable or exercisable for Shares. The Company proposes to conduct a public offering of Shares and/or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase Shares (the &#147;<B><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants</B>&#148; and together with the Shares, the &#147;<B>Securities</B>&#148;) (the
&#147;<B>Offering</B>&#148;) for which Jefferies LLC (&#147;<B>Jefferies</B>&#148;), TD Securities (USA) LLC (&#147;<B>TD Cowen</B>&#148;) and Cantor Fitzgerald &amp; Co. (&#147;<B>Cantor</B>&#148;) will act as the representatives of the
underwriters. The undersigned recognizes that the Offering will benefit each of the Company and the undersigned. The undersigned acknowledges that the underwriters are relying on the representations and agreements of the undersigned contained in
this letter agreement in conducting the Offering and, at a subsequent date, in entering into an underwriting agreement (the &#147;<B>Underwriting Agreement</B>&#148;) and other underwriting arrangements with the Company with respect to the Offering.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annex A sets forth definitions for capitalized terms used in this letter agreement that are not defined in the body of this letter agreement. Those
definitions are a part of this letter agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In consideration of the foregoing, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the undersigned hereby agrees that, during the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, the undersigned will not (and will cause any Family Member not to), without the prior written
consent of Jefferies and TD Cowen, each of which may withhold their consent in their sole discretion: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sell or Offer to Sell any Shares or Related Securities currently or hereafter owned either of record or
beneficially (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) by the undersigned or such Family Member, </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any Swap, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any demand for, or exercise any right with respect to, the registration under the Securities Act of the
offer and sale of any Shares or Related Securities, or cause to be filed a registration statement, prospectus or prospectus supplement (or an amendment or supplement thereto) with respect to any such registration, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicly announce any intention to do any of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing will not apply to the registration of the offer and sale of the Securities, and the sale of the Securities to the underwriters, in each case as
contemplated by the Underwriting Agreement. In addition, the foregoing restrictions shall not apply to the transfer of Shares or Related Securities (i)&nbsp;by gift, or by will or intestate succession to a Family Member or to a trust whose
beneficiaries consist exclusively of one or more of the undersigned and/or a Family Member, (ii)&nbsp;as a bona fide gift to a charity or educational institution, (iii)&nbsp;transfers that occur solely by operation of law pursuant to pursuant to a
court order, qualified domestic order or in connection with a divorce settlement, (iv)&nbsp;if the undersigned is a corporation, partnership, limited liability company or other business entity, any transfers or distributions to any stockholder,
partner or member of, or owner of a similar equity interest in, the undersigned, as the case may be, if, in any such case, such transfer is not for value, or to any investment fund or other entity controlled or managed by the undersigned; including,
for the avoidance of doubt, transfers or distributions to a fund managed by the same manager or managing member or general partner or management company or by an entity controlling, controlled by, or under common control with such manager or
managing member or general partner or management company as the undersigned or who shares a common investment advisor with the undersigned, (v)&nbsp;if the undersigned is a corporation, partnership, limited liability company or other business
entity, any transfer made by the undersigned (a)&nbsp;in connection with the sale or other bona fide transfer in a single transaction of all or substantially all of the undersigned&#146;s capital stock, partnership interests, membership interests or
other similar equity interests, as the case may be, or all or substantially all of the undersigned&#146;s assets, in any such case not undertaken for the purpose of avoiding the restrictions imposed by this letter agreement or (b)&nbsp;to another
corporation, partnership, limited liability company or other business entity so long as the transferee is an affiliate (as defined below) of the undersigned and such transfer is not for value, (vi)&nbsp;acquired in open market transactions after the
completion of the Offering, provided that no filing under Section&nbsp;16(a) of the Exchange Act shall be required or shall be voluntarily made in connection with subsequent sales of Shares or Related Securities acquired in such open market
transactions, (vii)&nbsp;transfers pursuant to a bona fide third party tender offer for shares of the Company&#146;s capital stock made to all holders of the Company&#146;s securities, merger, consolidation or other similar transaction involving a
Change of Control of the Company that is approved by the Board of Directors of the Company, made to all holders of Shares and occurring after the closing of the Offering, provided that in the event that the tender offer, merger, consolidation or
other such transaction is not completed, the Shares or Related Securities owned by the undersigned shall remain subject to the restrictions contained in this letter agreement and title to the undersigned&#146;s shares shall remain with the
undersigned, (viii)&nbsp;the transfer of Shares under a trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act (a &#147;Trading Plan&#148;) that is existing on the date hereof which has been provided to
the Representatives or its legal counsel, (ix)&nbsp;the establishment or modification of a Trading Plan for the transfer of Shares or Related Securities, provided that such plan does not provide for any Sales of Shares or Related Securities during
the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period or (x)&nbsp;the transfer of Shares in connection with the exercise, including by and to the extent necessary to cover any &#147;net&#148; exercise, of any options or warrants to acquire
Shares or the conversion of any convertible security into Shares in accordance with its terms; provided that, in the case of clauses (viii)&nbsp;and (ix) to the extent a public announcement or filing under the Exchange Act, if any, is required of or
voluntarily made by or on behalf of the undersigned or the Company regarding such transfer, such announcement or filing shall include a statement that such transfer is in accordance with an established Trading Plan; <I>provided, however</I>, that in
the case of clauses (i)-(v) and (x)&nbsp;above, it shall be a condition to such transfer that: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each transferee executes and delivers to Jefferies and TD Cowen an agreement in form and substance satisfactory
to Jefferies and TD Cowen stating that such transferee is receiving and holding such Shares and/or Related Securities subject to the provisions of this letter agreement and agrees not to Sell or Offer to Sell such Shares and/or Related Securities,
engage in any Swap or engage in any other activities restricted under this letter agreement except in accordance with this letter agreement (as if such transferee had been an original signatory hereto), and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to the expiration of the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, no public disclosure or
filing under the Exchange Act by any party to the transfer (donor, donee, transferor or transferee) shall be required, or made voluntarily, reporting a reduction in beneficial ownership of Shares in connection with such transfer; provided that if
the undersigned is required to file a report under Section&nbsp;13 or Section&nbsp;16(a) of the Exchange Act reporting a reduction in beneficial ownership during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, the undersigned shall
include a statement in such report detailing the reason for the transaction. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For avoidance of doubt, nothing in this letter agreement
prohibits the undersigned from exercising any Related Securities (which exercises may be effected on a cashless basis to the extent the instruments representing such options or warrants permit exercises on a cashless basis), it being understood that
any Shares issued upon such exercises will be subject to the restrictions of this letter agreement and provided, however, that no public announcement or filing is voluntarily made regarding such exercise during the
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period and provided that if the undersigned is required to file a report under Section&nbsp;16(a) of the Exchange Act reporting a reduction in beneficial ownership of such options or warrants during
the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, the undersigned shall include a statement in such report to the effect that the disposition relates to the exercise of an option or warrant, as applicable, and that the Shares received upon
exercise are subject to the restrictions of this letter agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the undersigned is an officer or director of the Company, the undersigned further
agrees that the foregoing provisions shall be equally applicable to any Company-directed Shares the undersigned may purchase or otherwise receive in the Offering (including pursuant to a directed share program). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned also agrees and consents to the entry of stop transfer instructions with the Company&#146;s transfer agent and registrar against the transfer
of Shares or Related Securities held by the undersigned and the undersigned&#146;s Family Members, if any, except in compliance with the foregoing restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to the Offering only, the undersigned waives any registration rights relating to registration under the Securities Act of the offer and sale of
any Shares and/or any Related Securities owned either of record or beneficially by the undersigned, including any rights to receive notice of the Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned confirms that the undersigned has not, and has no knowledge that any Family Member has, directly or indirectly, taken any action designed to
or that might reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale of the Shares. The undersigned will not, and will cause any Family Member not to take,
directly or indirectly, any such action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that the underwriters have not provided any recommendation or investment
advice nor have the underwriters solicited any action from the undersigned with respect to the Offering and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to the extent deemed appropriate. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whether or not the Offering occurs as currently contemplated or at all depends on market conditions and
other factors. The Offering will only be made pursuant to the Underwriting Agreement, the terms of which are subject to negotiation between the Company and the underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants that the undersigned has full power, capacity and authority to enter into this letter agreement. This letter
agreement is irrevocable and will be binding on the undersigned and the successors, heirs, personal representatives and assigns of the undersigned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything herein to the contrary, if (a)&nbsp;the closing of the Offering has not occurred prior to June&nbsp;30, 2025, (b) after being
executed, the Underwriting Agreement (other than the provisions thereof that survive termination) shall terminate or be terminated prior to payment for and delivery of the Securities to be sold thereunder, or (c)&nbsp;the Company notifies the
Underwriters in writing that it does not intend to proceed with the Offering, then the undersigned shall be released from all obligations under this letter agreement upon the earliest to occur of the events specified above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This letter agreement shall be governed by, and construed in accordance with, the laws of the State of New York. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Printed Name of Person Signing</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>(Indicate capacity of person signing if signing as custodian or trustee, or on behalf of an entity)</I></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain Defined Terms </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Used in <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the letter agreement to which this Annex A is attached and of which it is made a part: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Call Equivalent Position</B>&#148;<B> </B>shall have the meaning set forth in Rule <FONT STYLE="white-space:nowrap">16a-1(b)</FONT>
under the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Change of Control</B>&#148; means the consummation of any bona fide third party tender offer, merger,
consolidation or other similar transaction the result of which is that any &#147;person&#148; (as defined in Section&nbsp;13(d)(3) of the Exchange Act), or group of persons, other than the Company, becomes the beneficial owner (as such term is used
in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> of the Exchange Act) of more than 50% of the total voting power of the voting stock of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Act</B>&#148;<B> </B>shall mean the Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Family Member</B>&#148; shall mean the spouse, including a former spouse, of the undersigned, an immediate family member of the
undersigned or an immediate family member of the undersigned&#146;s spouse, in each case living in the undersigned&#146;s household or whose principal residence is the undersigned&#146;s household (regardless of whether such spouse or family member
may at the time be living elsewhere due to educational activities, health care treatment, military service, temporary internship or employment or otherwise). &#147;<B>Immediate family member</B>&#148; as used above shall have the meaning set forth
in Rule <FONT STYLE="white-space:nowrap">16a-1(e)</FONT> under the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT>
Period</B>&#148; shall mean the period beginning on the date hereof and continuing through the close of trading on the date that is 60 days after the date of the Prospectus (as defined in the Underwriting Agreement). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Put Equivalent Position</B>&#148; shall have the meaning set forth in Rule <FONT STYLE="white-space:nowrap">16a-1(h)</FONT> under the
Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Related Securities</B>&#148; shall mean any options or warrants or other rights to acquire Shares or any securities
exchangeable or exercisable for or convertible into Shares, or to acquire other securities or rights ultimately exchangeable or exercisable for or convertible into Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Securities Act</B>&#148; shall mean the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sell or Offer to Sell</B>&#148; shall mean to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sell, offer to sell, contract to sell or lend, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effect any short sale or establish or increase a Put Equivalent Position or liquidate or decrease any Call
Equivalent Position </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pledge, hypothecate or grant any security interest in, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in any other way transfer or dispose of, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">in each case whether effected directly or indirectly. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Swap</B>&#148; shall mean any swap, hedge or similar arrangement or agreement that transfers, in whole or in part, the economic risk
of ownership of Shares or Related Securities, regardless of whether any such transaction is to be settled in securities, in cash or otherwise. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Capitalized terms not defined in this Annex A shall have the meanings given to them in the body of this
letter agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Directors, Executive Officers and Others </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>&#8195;&#8195;&#8195;Signing <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement&#8195;&#8195;&#8195;&#8195; </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Directors: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scott Brun </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Steven Nichtberger </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark Simon </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Bollard </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Richard Henriques </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shawn Tomasello </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive Officers: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Steven Nichtberger </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gwendolyn K. Binder </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anup Marda </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David J. Chang </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael Gerard </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arun Das </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>d828604dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Form of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT TO PURCHASE COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Number of Shares: [_________] (subject to adjustment) </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Warrant No. [___]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Original Issue Date: June [___], 2025</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cabaletta Bio, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), hereby certifies that, for good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [___________] or its registered assigns (the &#147;<B>Holder</B>&#148;) is entitled, subject to the terms set forth below, to purchase from the Company up to a
total of [______] shares of common stock, $0.00001 par value per share (the &#147;<B>Common Stock</B>&#148;), of the Company (each such share, a &#147;<B>Warrant Share</B>&#148; and all such shares, the &#147;<B>Warrant Shares</B>&#148;) at an
exercise price per share equal to $0.00001 per share (as adjusted from time to time as provided in Section&nbsp;9 herein, the &#147;<B>Exercise Price</B>&#148;) upon surrender of this Warrant to Purchase Common Stock (including any Warrants to
Purchase Common Stock issued in exchange, transfer or replacement hereof, the &#147;<B>Warrant</B>&#148;) at any time and from time to time on or after the date hereof (the &#147;<B>Original Issue Date</B>&#148;), subject to the following terms and
conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <I>Definitions</I>. For purposes of this Warrant, the following terms shall have the following meanings: (a)
&#147;<B>Affiliate</B>&#148; means any Person directly or indirectly controlled by, controlling or under common control with, a Holder, as such terms are used in and construed under Rule 405 under the Securities Act, but only for so long as such
control shall continue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B>Commission</B>&#148; means the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Closing Sale Price</B>&#148; means, for any security as of any date, the last trade price for such security on the Principal
Trading Market for such security, as reported by Bloomberg L.P., or, if such Principal Trading Market begins to operate on an extended hours basis and does not designate the last trade price, then the last trade price of such security prior to 4:00
P.M., New York City time, as reported by Bloomberg L.P., or if the security is not listed for trading on a national securities exchange or other trading market on the relevant date, the last quoted bid price for the security in the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the relevant date as reported by OTC Markets Group Inc. (or a similar organization or agency succeeding to its functions of reporting prices). If
the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually determined by the Company and the Holder.
If the Company and the Holder are unable to agree upon the fair market value of such security, then the Board of Directors of the Company shall use its good faith judgment to determine the fair market value. The Board of Directors&#146;
determination shall be binding upon all parties absent demonstrable error. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation
period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>Marketable Securities</B>&#148; means securities meeting all of the following requirements: (i)&nbsp;the issuer
thereof is then subject to the reporting requirements of Section&nbsp;13 or Section&nbsp;15(d) of the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;), and is then current in its filing of all required reports and
other information under the Securities Act and the Exchange Act; (ii)&nbsp;the class and series of shares or other security of the issuer that would be received by Holder in connection with the Fundamental Transaction (as defined below) were Holder
to exercise this Warrant on or prior to the closing thereof is then traded or quoted on a nationally recognized securities exchange, inter-dealer quotation system or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, and (iii)&nbsp;following the closing of such Fundamental Transaction, the Holder would not be restricted from publicly <FONT
STYLE="white-space:nowrap">re-selling</FONT> all of the issuer&#146;s shares and/or other securities that would be received by the Holder in such Fundamental Transaction were the Holder to exercise or convert this Warrant in full on or prior to the
closing of such Fundamental Transaction. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B>Principal Trading Market</B>&#148; means the national securities exchange or
other trading market on which the Common Stock is primarily listed on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Global Select Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B>Registration Statement</B>&#148; means the Company&#146;s Registration Statement on Form
<FONT STYLE="white-space:nowrap">S-3ASR</FONT> (File No <FONT STYLE="white-space:nowrap">333-278126),</FONT> as amended by that certain Post-Effective Amendment No.&nbsp;1 (No. <FONT STYLE="white-space:nowrap">333-278126)</FONT> and that certain
Post-Effective Amendment No.&nbsp;2 (No. <FONT STYLE="white-space:nowrap">333-278126),</FONT> as filed with the Commission on March&nbsp;31, 2025 and declared effective on March&nbsp;31, 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) &#147;<B>Securities Act</B>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) &#147;<B>Standard Settlement Period</B>&#148; means the standard settlement period, expressed in a number of Trading Days, for the
Company&#146;s primary trading market or quotation system with respect to the Common Stock that is in effect on the date of delivery of an applicable Exercise Notice, which as of the Original Issue Date is &#147;T+1&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) &#147;<B>Trading Day</B>&#148; means any weekday on which the Principal Trading Market is open for trading. If the Common Stock is not
listed or admitted for trading, &#147;Trading Day&#148; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in New York City are authorized or required
by law or other governmental action to close. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) &#147;<B>Transfer Agent</B>&#148; means Equiniti Trust Company, LLC, the Company&#146;s
transfer agent and registrar for the Common Stock, and any successor appointed in such capacity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <I>Issuance of Securities;
Registration of Warrants</I>. The Warrant, as initially issued by the Company, is offered and sold pursuant to the Registration Statement. As of the Original Issue Date, the Warrant Shares are issuable under the Registration Statement. Accordingly,
the Warrant and, assuming issuance pursuant to the Registration Statement or an exchange meeting the requirements of Section&nbsp;3(a)(9) of the Exchange Act as in effect on the Original Issue Date, the Warrant Shares, are not &#147;restricted
securities&#148; under Rule 144 promulgated under the Securities Act. The Company shall register ownership of this Warrant, upon records to be maintained by the Company for that purpose (the &#147;<B>Warrant Register</B>&#148;), in the name of the
record Holder (which shall include the initial Holder or, as the case may be, any assignee to which this Warrant is assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner
hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <I>Registration of Transfers</I>. Subject to compliance with all applicable securities laws, the Company shall, or will cause its Transfer
Agent to, register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer taxes (if any). Upon any such registration or transfer, a new warrant to purchase
Common Stock in substantially the form of this Warrant (any such new warrant, a &#147;<B>New Warrant</B>&#148;) evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining
portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in
respect of the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue and deliver at the Company&#146;s own expense any New Warrant under this Section&nbsp;3. Until due
presentment for registration of transfer, the Company may treat the registered Holder hereof as the owner and holder for all purposes, and the Company shall not be affected by any notice to the contrary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <I>Exercise and Duration of Warrants</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) All or any part of this Warrant shall be exercisable by the registered Holder in the manner set forth in Section&nbsp;10 at any time and
from time to time on or after the Original Issue Date, and such rights shall not expire. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Holder may exercise this Warrant by
delivering to the Company an exercise notice, in the form attached as Schedule 1 hereto (the &#147;<B>Exercise Notice</B>&#148;), completed and duly signed. The date on which such exercise notice is delivered to the Company (as determined in
accordance with the notice provisions hereof) is an <B>&#147;Exercise Date</B>.&#148; The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have
the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares, if any. <B>The </B><B>Holder and any assignee, by acceptance of this Warrant, acknowledge
and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on
the face hereof.</B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <I>Delivery of Warrant Shares</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Upon exercise of this Warrant, the Company shall, or shall cause the Transfer Agent to, promptly (but in no event later than the number of
Trading Days comprising the Standard Settlement Period following the Exercise Date), upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such exercise to the
Holder&#146;s or its designee&#146;s balance account with The Depository Trust Company (&#147;<B>DTC</B>&#148;) through its Deposit Withdrawal Agent Commission system, or if the Transfer Agent is not participating in the Fast Automated Securities
Transfer Program or if the certificates are required to bear a legend regarding restriction on transferability, issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the
Company&#146;s share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise. The Holder, or any natural person or legal entity (each, a
&#147;<B>Person</B>&#148;) so designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date such Warrant Shares are credited to the
Holder&#146;s DTC account or the date of delivery of the certificates evidencing such Warrant Shares, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If the
Company fails to deliver to the Holder a certificate representing the required number of Warrant Shares in the manner required pursuant to <U>Section</U><U></U><U>&nbsp;5(a)</U> or fails to credit the Holder&#146;s DTC account for such number of
Warrant Shares to which the Holder is entitled within the Standard Settlement Period following the Exercise Date, and if after such Standard Settlement Period and prior to the receipt of such Warrant Shares, the Holder purchases (in an open market
transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a
&#147;<B><FONT STYLE="white-space:nowrap">Buy-In</FONT></B>&#148;), then the Company shall, within three (3)&nbsp;Trading Days after the Holder&#146;s request promptly honor its obligation to deliver to the Holder a certificate or certificates
representing such Warrant Shares and pay cash to the Holder in an amount equal to the excess (if any) of Holder&#146;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased in the <FONT
STYLE="white-space:nowrap">Buy-In</FONT> less the product of (A)&nbsp;the number of shares of Common Stock purchased in the <FONT STYLE="white-space:nowrap">Buy-In,</FONT> times (B)&nbsp;the Closing Sale Price of a share of Common Stock on the
Exercise Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To the extent permitted by law and subject to Section&nbsp;5(b), the Company&#146;s obligations to issue and deliver
Warrant Shares in accordance with and subject to the terms hereof (including the limitations set forth in Section&nbsp;11 below) are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or
consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any
other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in
connection with the issuance of Warrant Shares. Subject to Section&nbsp;5(b), nothing herein shall limit the Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of
specific performance and/or injunctive relief with respect to the Company&#146;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <I>Charges, Taxes and Expenses</I>. Issuance and delivery of shares of Common Stock upon exercise of this Warrant shall be made without
charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties) in respect of the issuance of such shares, all of which taxes and expenses shall be paid by the
Company; <I>provided</I>, <I>however</I>, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any Warrant Shares or the Warrants in a name other than that of the Holder
or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <I>Replacement of Warrant</I>. If this Warrant is mutilated, lost, stolen or destroyed,
the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of
such loss, theft or destruction (in such case) and, in each case, a customary and reasonable indemnity and surety bond, if requested by the Company. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable
regulations and procedures and pay such other reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company
as a condition precedent to the Company&#146;s obligation to issue the New Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <I>Reservation of Warrant Shares</I>. The Company
covenants that it will, at all times while this Warrant is outstanding, reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant
Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of
persons other than the Holder (taking into account the adjustments and restrictions of Section&nbsp;9). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price
in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> The Company will take all such action as may be reasonably necessary to assure that such shares of
Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed. The Company further
covenants that it will not, without the prior written consent of the Holder, take any actions to increase the par value of the Common Stock at any time while this Warrant is outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <I>Certain Adjustments</I>. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant (the &#147;<B>Number of
Warrant Shares</B>&#148;) are subject to adjustment from time to time as set forth in this Section&nbsp;9. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Stock Dividends and
Splits</U>. If the Company, at any time while this Warrant is outstanding, (i)&nbsp;pays a stock dividend on its Common Stock that is payable in shares of Common Stock, (ii)&nbsp;subdivides its outstanding shares of Common Stock into a larger number
of shares of Common Stock, (iii)&nbsp;combines its outstanding shares of Common Stock into a smaller number of shares of Common Stock or (iv)&nbsp;issues by reclassification of shares of capital stock any additional shares of Common Stock of the
Company, then in each such case the Number of Warrant Shares shall be multiplied by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately after such event and the denominator of which shall be the
number of shares of Common Stock outstanding immediately before such event. Any adjustment made pursuant to clause (i)&nbsp;of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to
receive such dividend or distribution, provided, however, that if such record date shall have been fixed and such dividend is not fully paid on the date fixed therefor, the Number of Warrant Shares shall be recomputed accordingly as of the close of
business on such record date and thereafter the Number of Warrant Shares shall be adjusted pursuant to this paragraph as of the time of actual payment of such dividends. Any adjustment pursuant to clause (ii), (iii) or (iv)&nbsp;of this paragraph
shall become effective immediately after the effective date of such subdivision, combination or issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Pro Rata
Distributions</U>. If the Company, at any time while this Warrant is outstanding, distributes to all holders of Common Stock for no consideration (i)&nbsp;evidences of its indebtedness, (ii)&nbsp;any security (other than a distribution of Common
Stock covered by the preceding paragraph), (iii) rights or warrants to subscribe for or purchase any security (including Common Stock), or (iv)&nbsp;cash or any other asset (in each case, a &#147;<B>Distribution</B>&#148;), other than a
reclassification as to which Section&nbsp;9(c) applies, then in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of
shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the ownership limitation set forth in Section&nbsp;11(a) hereof) immediately before the
date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined for the participation in such Distribution;<I> provided</I>, <I>however</I>, to the
extent that the Holder&#146;s right to participate in any such Distribution would result in the Holder exceeding the ownership limitation set forth in Section&nbsp;11(a) hereof, then the Holder shall not be entitled to participate in such
Distribution to such extent (or in the beneficial ownership of any Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever,
as the delivery to such Holder of such portion would not result in the Holder exceeding the ownership limitation set forth in Section&nbsp;11(a) hereof. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Fundamental Transactions</U>. If, at any time while this Warrant is outstanding
(i)&nbsp;the Company effects any merger or consolidation of the Company with or into another Person, in which the Company is not the surviving entity, (ii)&nbsp;the Company effects any sale to another Person of all or substantially all of its assets
in one transaction or a series of related transactions, (iii)&nbsp;pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders of capital stock tender shares representing more than 50% of the voting power of
the capital stock of the Company and the Company or such other Person, as applicable, accepts such tender for payment, (iv)&nbsp;the Company consummates a stock purchase agreement or other business combination (including, without limitation, a
reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off</FONT> or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the voting power of the capital stock of the Company (except for
any such transaction in which the stockholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such Person immediately after the transaction) or (v)&nbsp;the Company effects
any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of
shares of Common Stock covered by Section&nbsp;9(a) above) (in any such case, a &#147;<B>Fundamental Transaction</B>&#148;), then following such Fundamental Transaction the Holder shall have the right to receive, upon exercise of this Warrant, the
same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the Number of Warrant
Shares without regard to any limitations on exercise contained herein (in the case of clause (iii)&nbsp;above, assuming it had tendered, and the offeror had accepted, such Warrant Shares) (the &#147;<B>Alternate Consideration</B>&#148;). The Company
shall not effect any Fundamental Transaction in which the Company is not the surviving entity or the Alternate Consideration includes securities of another Person unless (i)&nbsp;the Alternate Consideration is solely cash and the Company provides
for the simultaneous &#147;cashless exercise&#148; of this Warrant pursuant to Section&nbsp;10 below or (ii)&nbsp;prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity or other Person (including any
purchaser of assets of the Company) shall assume the obligation to deliver to the Holder such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under this
Warrant. The provisions of this paragraph (c)&nbsp;shall similarly apply to subsequent transactions analogous of a Fundamental Transaction type. Notwithstanding the foregoing, in the event of a Fundamental Transaction where the consideration payable
to holders of Common Stock consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities, then this Warrant shall automatically be deemed to be exercised in full in a &#147;cashless exercise&#148;
pursuant to Section&nbsp;10 below effective immediately prior to and contingent upon the consummation of such Fundamental Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Exercise Price</U>. Simultaneously with any adjustment to the Number of Warrant Shares pursuant to Section&nbsp;9 the Exercise Price
shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the increased or decreased Number of Warrant Shares shall be the same as the aggregate Exercise Price in effect
immediately prior to such adjustment. Notwithstanding the foregoing, in no event may the Exercise Price be adjusted below the par value of the Common Stock then in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Calculations</U>. All calculations under this Section&nbsp;9 shall be made to the nearest
<FONT STYLE="white-space:nowrap">one-hundredth</FONT> of one cent or the nearest whole share, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)<U> Notice of
Adjustments</U>. Upon the occurrence of each adjustment pursuant to this Section&nbsp;9, the Company at its expense will, at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this
Warrant and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable),
describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the
Company&#146;s transfer agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Notice of Corporate Events</U>. If, while this Warrant is outstanding, the Company
(i)&nbsp;declares a dividend or any other distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the
Company or any subsidiary, (ii)&nbsp;authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii)&nbsp;authorizes the voluntary dissolution, liquidation or winding up of
the affairs of the Company, then, except if such notice and the contents thereof shall be deemed to constitute material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company shall deliver to the Holder a notice of such
transaction at least ten </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(10)&nbsp;days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction; provided,
however, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action required to be described in such notice. In addition, if while this Warrant is outstanding, the Company authorizes or
approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction contemplated by Section&nbsp;9(c), other than a Fundamental Transaction under clause (iii)&nbsp;of Section&nbsp;9(c), then, except if
such notice and the contents thereof shall be deemed to constitute material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company shall deliver to the Holder a notice of such Fundamental Transaction at least ten (10)&nbsp;days
prior to the date such Fundamental Transaction is consummated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <I>Cashless Exercise</I>. Notwithstanding anything contained herein to
the contrary, this Warrant may only be exercised through a &#147;cashless exercise.&#148; Upon exercise, the Company shall issue to the Holder the number of Warrant Shares in an exchange of securities effected pursuant to Section&nbsp;3(a)(9) of the
Securities Act as determined as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">X = Y <FONT STYLE="white-space:nowrap">[(A-B)/A]</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">where: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;X&#148; equals the number of Warrant Shares to be
issued to the Holder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Y&#148; equals the total number of Warrant Shares with respect to which this Warrant is then being exercised; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;A&#148; equals the Closing Sale Price per share of Common Stock as of the Trading Day on the date immediately preceding the Exercise Date; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;B&#148; equals the Exercise Price per Warrant Share then in effect on the Exercise Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in
such a &#147;cashless exercise&#148; transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued (provided that the
Commission continues to take the position that such treatment is proper at the time of such exercise). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In no event will the exercise of this Warrant be
settled in cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <I>Limitations on Exercise</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant, and the Holder shall
not be entitled to exercise this Warrant (i)&nbsp;if immediately prior to the exercise, the Holder, its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of
Section&nbsp;13(d) of the Exchange Act, beneficially own an aggregate number of shares of Common Stock greater than [4.5] [4.99] [9.99] % (the &#147;<B>Maximum Percentage</B>&#148;) of the total number of issued and outstanding shares of Common
Stock of the Company without taking into account any Warrant Shares, or (ii)&nbsp;to the extent that immediately following the exercise, the Holder, its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated
with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act, would beneficially own in excess of the Maximum Percentage of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such
shares of Common Stock. Any portion of an exercise that would result in the issuance of shares in excess of the Maximum Percentage shall be treated as null and void ab initio. For purposes of this Warrant, in determining the number of outstanding
shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x)&nbsp;the Company&#146;s most recent Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Form
<FONT STYLE="white-space:nowrap">10-K,</FONT> as the case may be, filed with the Commission prior to the date hereof, (y)&nbsp;a more recent public announcement by the Company or (z)&nbsp;any other notice by the Company or its transfer agent setting
forth the number of shares of Common Stock outstanding. Upon the written request of the Holder, the Company shall within three (3)&nbsp;Trading Days confirm in writing or by electronic mail to the Holder the number of shares of Common Stock then
outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder since the date as of which such
number of outstanding shares of Common Stock was reported. By written notice to the Company, the Holder may from time to time increase or decrease the Maximum </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Percentage to any other percentage specified not in excess of 19.99% specified in such notice; provided that any such increase will not be effective until the sixty-first (61st) day after such
notice is delivered to the Company. For purposes of this Section&nbsp;11(a), the aggregate number of shares of Common Stock or voting securities beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of
Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act shall include the shares of Common Stock issuable upon the exercise of this Warrant with respect to which such determination is being
made, but shall exclude the number of shares of Common Stock which would be issuable upon (x)&nbsp;exercise of the remaining unexercised and <FONT STYLE="white-space:nowrap">non-cancelled</FONT> portion of this Warrant by the Holder and
(y)&nbsp;exercise or conversion of the unexercised, <FONT STYLE="white-space:nowrap">non-converted</FONT> or <FONT STYLE="white-space:nowrap">non-cancelled</FONT> portion of any other securities of the Company that do not have voting power
(including without limitation any securities of the Company which would entitle the holder thereof to acquire at any time Common Stock, including without limitation any debt, preferred stock, right, option, warrant or other instrument that is at any
time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock), is subject to a limitation on conversion or exercise analogous to the limitation contained herein and is beneficially owned
by the Holder or any of its Affiliates and other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act. For purposes of clarity, the Warrant Shares
issuable pursuant to the terms of this Warrant in excess of the Maximum Percentage shall not be deemed to be beneficially owned by the Holder for any purpose including for purposes of Section&nbsp;13(d) of the Exchange Act or Rule <FONT
STYLE="white-space:nowrap">16a-1(a)(1)</FONT> promulgated under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) This Section&nbsp;11 shall not restrict the number
of shares of Common Stock which a Holder may receive or beneficially own in order to determine the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated in
Section&nbsp;9(c) of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <I>No Fractional Shares</I>. No fractional Warrant Shares will be issued in connection with any
exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash the fair market value
(based on the Closing Sale Price) for any such fractional shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <I>Notices</I>. Any and all notices or other communications or
deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i)&nbsp;the date of transmission, if such notice or communication is delivered via confirmed
email prior to 5:30 P.M., New York City time, on a Trading Day, (ii)&nbsp;the next Trading Day after the date of transmission, if such notice or communication is delivered via confirmed <FONT STYLE="white-space:nowrap">e-mail</FONT> on a day that is
not a Trading Day or later than 5:30 P.M., New York City time, on any Trading Day, (iii)&nbsp;the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service specifying next business day delivery, or
(iv)&nbsp;upon actual receipt by the Person to whom such notice is required to be given, if by hand delivery. The addresses and <FONT STYLE="white-space:nowrap">e-mail</FONT> addresses for such communications shall be: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to the Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cabaletta Bio, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2929 Arch Street, Suite 600 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Philadelphia, PA 19104 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone: [___] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [___] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to the Holder, to its address or <FONT
STYLE="white-space:nowrap">e-mail</FONT> address set forth herein or on the books and records of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Or, in each of the above
instances, to such other address or <FONT STYLE="white-space:nowrap">e-mail</FONT> address as the recipient party has specified by written notice given to each other party at least five (5)&nbsp;days prior to the effectiveness of such change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <I>Warrant Agent</I>. The Company shall initially serve as warrant agent under this Warrant. Upon ten (10)&nbsp;days&#146; notice to the
Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or
any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor
warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder&#146;s last address as shown on the Warrant Register. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <I>Miscellaneous</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>No Rights as a Stockholder</U>. The Holder, solely in such Person&#146;s capacity as a holder of this Warrant, shall not be entitled to
vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person&#146;s capacity as the Holder of this
Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance
or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In
addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are
asserted by the Company or by creditors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Authorized Shares</U>. Except and to the extent as waived or consented to
by the Holder, the Company shall not by any action, including, without limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of
securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such
actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i)&nbsp;not increase the par value of any Warrant Shares
above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and
nonassessable Warrant Shares upon the exercise of this Warrant, and (iii)&nbsp;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be
necessary to enable the Company to perform its obligations under this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Successors and Assigns</U>. Subject to compliance
with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company without the written consent of the Holder, except to a successor in the event of a Fundamental Transaction. This Warrant
shall be binding on and inure to the benefit of the Company and the Holder and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and
the Holder any legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Amendment and Waiver</U>. Except as otherwise provided herein, this Warrant may be modified or amended or the provisions hereof waived
with the written consent of the Company and the Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Acceptance</U>. Receipt of this Warrant by the Holder shall constitute
acceptance of and agreement to all of the terms and conditions contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)<U> Governing Law; Jurisdiction</U>. ALL QUESTIONS
CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF.
EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION
HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY
CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY
MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY
RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit
or affect any of the provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Severability</U>. In case any one or more of the provisions of this Warrant shall be
invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder will attempt in good faith to agree
upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">REMAINDER OF PAGE INTENTIONALLY LEFT BLANK. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of
the date first indicated above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CABALETTA BIO, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF EXERCISE NOTICE </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[To
be executed by the Holder to purchase shares of Common Stock under the Warrant] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: (1)&nbsp;The undersigned is the Holder of Warrant
No. ___ (the &#147;Warrant&#148;) issued by Cabaletta Bio, Inc., a Delaware corporation (the &#147;Company&#148;). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The undersigned hereby exercises its right to purchase ___________ Warrant Shares pursuant to the Warrant.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Holder intends that payment of the Exercise Price shall be made as a &#147;Cashless Exercise&#148; under
Section&nbsp;10 of the Warrant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in
accordance with the terms of the Warrant. The Warrant Shares shall be delivered to the following DWAC Account Number: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving
effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section&nbsp;13(d) of the Securities Exchange Act of 1934, as amended) permitted to be
owned under Section&nbsp;11(a) of the Warrant to which this notice relates. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name&nbsp;of&nbsp;Holder:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Signature must conform in all respects to name of Holder as specified on the face of the Warrant) </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>4
<FILENAME>d828604dex42.htm
<DESCRIPTION>EX-4.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT TO PURCHASE COMMON STOCK OR <FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Number of Shares: [_________] (subject to adjustment) </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant No. [___]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">Original Issue Date: June [___], 2025</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cabaletta Bio, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), hereby certifies that, for good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [___________] or its registered assigns (the &#147;<B>Holder</B>&#148;) is entitled, subject to the terms set forth below, to purchase from the Company up to a
total of [______] shares of common stock, $0.00001 par value per share (the &#147;<B>Common Stock</B>&#148;), of the Company (each such share, a &#147;<B>Warrant Share</B>&#148; and all such shares, the &#147;<B>Warrant Shares</B>&#148;) at an
exercise price per share equal to $[&#149;] (the &#147;<B>Exercise Price</B>&#148;), in each case as adjusted from time to time as provided in Section&nbsp;9, upon surrender of this Warrant to Purchase Common Stock or
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the &#147;<B>Warrant</B>&#148;) at any time and from time to time on or after the date
hereof (the &#147;<B>Initial Exercise Date</B>&#148;) and on or prior to 5:00 p.m. (New York City time) on the <FONT STYLE="white-space:nowrap">15-month</FONT> anniversary of the date hereof (the &#147;<B>Termination Date</B>&#148;) but not
thereafter, subject to the following terms and conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <I>Definitions</I>. For purposes of this Warrant, the following terms shall
have the following meanings: (a) &#147;<B>Affiliate</B>&#148; means any Person directly or indirectly controlled by, controlling or under common control with, a Holder, as such terms are used in and construed under Rule 405 under the Securities Act,
but only for so long as such control shall continue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B>Commission</B>&#148; means the United States Securities and Exchange
Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Closing Sale Price</B>&#148; means, for any security as of any date, the last trade price for such security on
the Principal Trading Market for such security, as reported by Bloomberg L.P., or, if such Principal Trading Market begins to operate on an extended hours basis and does not designate the last trade price, then the last trade price of such security
prior to 4:00 P.M., New York City time, as reported by Bloomberg L.P., or if the security is not listed for trading on a national securities exchange or other trading market on the relevant date, the last quoted bid price for the security in the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the relevant date as reported by OTC Markets Group Inc. (or a similar organization or agency succeeding to its functions of reporting prices). If
the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually determined by the Company and the Holder.
If the Company and the Holder are unable to agree upon the fair market value of such security, then the Board of Directors of the Company shall use its good faith judgment to determine the fair market value. The Board of Directors&#146;
determination shall be binding upon all parties absent demonstrable error. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation
period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Reserved </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)
&#147;<B>Principal Trading Market</B>&#148; means the national securities exchange or other trading market on which the Common Stock is primarily listed on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Global
Select Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B>Registration Statement</B>&#148; means the Company&#146;s Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-3ASR</FONT> (File No <FONT STYLE="white-space:nowrap">333-278126),</FONT> as amended by that certain Post-Effective Amendment No.&nbsp;1 (No. <FONT STYLE="white-space:nowrap">333-278126)</FONT> and that certain
Post-Effective Amendment No.&nbsp;2 (No. <FONT STYLE="white-space:nowrap">333-278126),</FONT> as filed with the Commission on March&nbsp;31, 2025 and declared effective on March&nbsp;31, 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) &#147;<B>Securities Act</B>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) &#147;<B>Standard Settlement Period</B>&#148; means the standard settlement period, expressed in a number of Trading Days, for the
Company&#146;s primary trading market or quotation system with respect to the Common Stock that is in effect on the date of delivery of an applicable Exercise Notice, which as of the Original Issue Date is &#147;T+1&#148;. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) &#147;<B>Trading Day</B>&#148; means any weekday on which the Principal Trading Market
is open for trading. If the Common Stock is not listed or admitted for trading, &#147;Trading Day&#148; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking
institutions in New York City are authorized or required by law or other governmental action to close. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) &#147;<B>Trading
Market</B>&#148; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select
Market or the New York Stock Exchange (or any successors to any of the foregoing). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) &#147;<B>Transfer Agent</B>&#148; means Equiniti
Trust Company, LLC, the Company&#146;s transfer agent and registrar for the Common Stock, and any successor appointed in such capacity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) &#147;<B>VWAP</B>&#148; means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the
Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported
by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the OTCQB Venture Market (&#147;OTCQB&#148;) or the OTCQX Best Market (&#147;OTCQX&#148;) is not a Trading Market, the volume
weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are
then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value
of a share of Common Stock as determined by an independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be
paid by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <I>Issuance of Securities; Registration of Warrants</I>. The Warrant, as initially issued by the Company, is
offered and sold pursuant to the Registration Statement. As of the Original Issue Date, the Warrant Shares are issuable under the Registration Statement. Accordingly, the Warrant and, assuming issuance pursuant to the Registration Statement or an
exchange meeting the requirements of Section&nbsp;3(a)(9) of the Securities Act as in effect on the Original Issue Date, the Warrant Shares, are not &#147;restricted securities&#148; under Rule 144 promulgated under the Securities Act. The Company
shall register ownership of this Warrant, upon records to be maintained by the Company for that purpose (the &#147;<B>Warrant Register</B>&#148;), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any
assignee to which this Warrant is assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and
for all other purposes, absent actual notice to the contrary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <I>Registration of Transfers</I>. Subject to compliance with all
applicable securities laws, the Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer taxes
(if any). Upon any such registration or transfer, a new warrant to purchase Common Stock in substantially the form of this Warrant (any such new warrant, a &#147;<B>New Warrant</B>&#148;) evidencing the portion of this Warrant so transferred shall
be issued to the transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the
acceptance by such transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue and deliver at the Company&#146;s
own expense any New Warrant under this Section&nbsp;3. Until due presentment for registration of transfer, the Company may treat the registered Holder hereof as the owner and holder for all purposes, and the Company shall not be affected by any
notice to the contrary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <I>Exercise and Duration of Warrants</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) All or any part of this Warrant shall be exercisable by the registered Holder in any manner permitted by this Warrant (including
Section&nbsp;11) at any time and from time to time on or after the Initial Exercise Date and on or before the Termination Date. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Holder may exercise this Warrant by delivering to the Company (i)&nbsp;an exercise
notice, in the form attached as Schedule 1 hereto (the &#147;<B>Exercise Notice</B>&#148;), completed and duly signed, of the Holder&#146;s election to exercise this Warrant for, at the Holder&#146;s sole discretion, either (A)&nbsp;Warrant Shares
or <FONT STYLE="white-space:nowrap">(B)&nbsp;Pre-Funded</FONT> Warrants to purchase a number of shares of Common Stock equal to the number of Warrant Shares as to which this Warrant is being exercised in substantially the same form of <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant included in the Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the Securities and Exchange Commission on [DATE]
<FONT STYLE="white-space:nowrap">(&#147;Pre-Funded</FONT> Warrants&#148;) with an exercise price of $0.00001 per share of Common Stock and (ii)&nbsp;payment of the Exercise Price for the number of Warrant Shares as to which this Warrant is being
exercised (which may take the form of a &#147;cashless exercise&#148; if permitted by Section&nbsp;10 below and so indicated in the Exercise Notice pursuant to<U>&nbsp;Section</U><U></U><U>&nbsp;10</U>&nbsp;below), or, if this Warrant is being
exercised for <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, the aggregate Exercise Price, less $0.00001, multiplied by the number of Warrant Shares as to which this Warrant is being exercised. The date on which Exercise Notice is
delivered to the Company (as determined in accordance with the notice provisions hereof) is an <B>&#147;Exercise Date</B>.&#148; The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and
delivery of the Exercise Notice shall have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares, if any. <B>The Holder and any assignee, by
acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants hereunder, the number of
Warrant Shares and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <I>Delivery of Warrant Shares</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If this Warrant is being exercised for Warrant Shares, upon exercise of this Warrant, the Company shall, or shall cause the Transfer Agent
to, promptly (but in no event later than the number of Trading Days comprising the Standard Settlement Period following the Exercise Date), upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is
entitled pursuant to such exercise to the Holder&#146;s or its designee&#146;s balance account with The Depository Trust Company (&#147;<B>DTC</B>&#148;) through its Deposit Withdrawal Agent Commission system, or if the Transfer Agent is not
participating in the Fast Automated Securities Transfer Program or if the certificates are required to bear a legend regarding restriction on transferability, issue and dispatch by overnight courier to the address as specified in the Exercise
Notice, a certificate, registered in the Company&#146;s share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise. If this Warrant is being exercised
for <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, the Company shall issue and dispatch by overnight courier to the address specified in the Exercise Notice, <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to purchase a
number of shares of Common Stock equal to the number of Warrant Shares with respect to which this Warrant is being exercised. The Holder, or any natural person or legal entity (each, a &#147;<B>Person</B>&#148;) so designated by the Holder to
receive Warrant Shares or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, shall be deemed to have become the holder of record of such Warrant Shares or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants as of the Exercise Date,
irrespective of the date such Warrant Shares are credited to the Holder&#146;s DTC account or the date of delivery of the certificates evidencing such Warrant Shares or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, as the case may be.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If this Warrant is being exercised for Warrant Shares, iff the Company fails to deliver to the Holder a certificate representing the
required number of Warrant Shares in the manner required pursuant to <U>Section</U><U></U><U>&nbsp;5(a)</U> or fails to credit, or cause the Transfer Agent to credit, the Holder&#146;s DTC account for such number of Warrant Shares to which the
Holder is entitled within the Standard Settlement Period following the Exercise Date, and if after such Standard Settlement Period and prior to the receipt of such Warrant Shares, the Holder purchases (in an open market transaction or otherwise)
shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#147;<B><FONT STYLE="white-space:nowrap">Buy-In</FONT></B>&#148;), then the Company shall,
within one (1)&nbsp;Trading Day after the Holder&#146;s request promptly honor its obligation to deliver to the Holder a certificate or certificates representing such Warrant Shares and pay cash to the Holder in an amount equal to the excess (if
any) of Holder&#146;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased in the <FONT STYLE="white-space:nowrap">Buy-In</FONT> less the product of (A)&nbsp;the number of shares of Common Stock
purchased in the <FONT STYLE="white-space:nowrap">Buy-In,</FONT> times (B)&nbsp;the Closing Sale Price of a share of Common Stock on the Exercise Date. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To the extent permitted by law and subject to Section&nbsp;5(b), the Company&#146;s
obligations to issue and deliver Warrant Shares or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, as the case may be, in accordance with and subject to the terms hereof (including the limitations set forth in Section&nbsp;11 below) are
absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or
any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and
irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. Subject to
Section&nbsp;5(b), nothing herein shall limit the Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect
to the Company&#146;s failure to timely deliver shares of Common Stock or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants upon exercise of the Warrant as required pursuant to the terms hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <I>Charges, Taxes and Expenses</I>. Issuance and delivery of shares of Common Stock upon exercise of this Warrant shall be made without
charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties) in respect of the issuance of such shares, all of which taxes and expenses shall be paid by the
Company; <I>provided</I>, <I>however</I>, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any Warrant Shares or the Warrants in a name other than that of the Holder
or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <I>Replacement of Warrant</I>. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in
exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case)
and, in each case, a customary and reasonable contractual indemnity, if requested by the Company. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other
reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company&#146;s
obligation to issue the New Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <I>Reservation of Warrant Shares</I>. The Company covenants that it will, at all times while this
Warrant is outstanding, reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein
provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into account
the adjustments and restrictions of Section&nbsp;9). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and
validly authorized, issued and fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> The Company will take all such action as may be reasonably necessary to assure that such shares of Common Stock may be issued as provided herein
without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed. The Company further covenants that it will not, without the prior
written consent of the Holder, take any actions to increase the par value of the Common Stock at any time while this Warrant is outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <I>Certain Adjustments</I>. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant (the &#147;<B>Number of
Warrant Shares</B>&#148;) are subject to adjustment from time to time as set forth in this Section&nbsp;9. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Stock Dividends and
Splits</U>. If the Company, at any time while this Warrant is outstanding, (i)&nbsp;pays a stock dividend on its Common Stock or otherwise makes a distribution on any class of capital stock that is payable in shares of Common Stock,
(ii)&nbsp;subdivides its outstanding shares of Common Stock into a larger number of shares of Common Stock, (iii)&nbsp;combines its outstanding shares of Common Stock into a smaller number of shares of Common Stock or (iv)&nbsp;issues by
reclassification of shares of capital stock any additional shares of Common Stock of the Company, then in each such case the Number of Warrant Shares shall be multiplied by a fraction, the numerator of which shall be the number of shares of Common
Stock outstanding immediately after such event and the denominator of which shall be the number of shares of Common Stock outstanding immediately before such event. Any adjustment made pursuant to clause (i)&nbsp;of this paragraph shall become
effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution, provided, however, that if such record date shall have been fixed and such dividend is not fully paid on the date
fixed therefor, the Number of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Warrant Shares shall be recomputed accordingly as of the close of business on such record date and thereafter the Number of Warrant Shares shall be adjusted pursuant to this paragraph as of the
time of actual payment of such dividends. Any adjustment pursuant to clause (ii), (iii) or (iv)&nbsp;of this paragraph shall become effective immediately after the effective date of such subdivision, combination or issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Pro Rata Distributions</U>. If the Company, at any time while this Warrant is outstanding, distributes to all holders of Common Stock
for no consideration (i)&nbsp;evidences of its indebtedness, (ii)&nbsp;any security (other than a distribution of Common Stock covered by the preceding paragraph), (iii) rights or warrants to subscribe for or purchase any security (including Common
Stock), or (iv)&nbsp;cash or any other asset (in each case, a &#147;<B>Distribution</B>&#148;), other than a reclassification as to which Section&nbsp;9(c) applies, then in each such case, pursuant Section&nbsp;9(a), the Exercise Price shall be
decreased, effective immediately after the effective date of such Distribution, by the amount of cash and/or the fair market value (as determined by the Company&#146;s Board of Directors, in good faith) of any securities or other assets paid on each
share of Common Stock in respect of such Distribution in order that subsequent thereto upon exercise of the Warrants the Holder may obtain the equivalent benefit of such Distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Fundamental Transactions</U>. If, at any time while this Warrant is outstanding (i)&nbsp;the Company effects any merger or
consolidation of the Company with or into another Person, in which the Company is not the surviving entity or in which the stockholders of the Company immediately prior to such merger or consolidation do not own, directly or indirectly, at least 50%
of the voting power of the surviving entity immediately after such merger or consolidation, (ii)&nbsp;the Company effects any sale, transfer or disposition to another Person of all or substantially all of its assets in one transaction or a series of
related transactions, (iii)&nbsp;pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders of capital stock tender shares representing more than 50% of the voting power of the capital stock of the Company and
the Company or such other Person, as applicable, accepts such tender for payment, (iv)&nbsp;the Company consummates a stock purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, <FONT
STYLE="white-space:nowrap">spin-off</FONT> or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the voting power of the capital stock of the Company (except for any such transaction in which the
stockholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such Person immediately after the transaction) or (v)&nbsp;the Company effects any reclassification of the Common
Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by
Section&nbsp;9(a) above) (in any such case, a &#147;<B>Fundamental Transaction</B>&#148;), then following such Fundamental Transaction the Holder shall have the right to receive, upon exercise of this Warrant, the same amount and kind of securities,
cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the Number of Warrant Shares without regard to any
limitations on exercise contained herein (in the case of clause (iii)&nbsp;above, assuming it had tendered, and the offeror had accepted, such Warrant Shares) (the &#147;<B>Alternate Consideration</B>&#148;). The Company shall not effect any
Fundamental Transaction in which the Company is not the surviving entity or the Alternate Consideration includes securities of another Person unless (i)&nbsp;the Alternate Consideration is solely cash and the Company provides for the simultaneous
&#147;cashless exercise&#148; of this Warrant pursuant to Section&nbsp;10 below or (ii)&nbsp;prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity or other Person (including any purchaser of assets
of the Company) shall assume the obligation to deliver to the Holder such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of
this paragraph (c)&nbsp;shall similarly apply to subsequent transactions analogous of a Fundamental Transaction type. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding
anything to the contrary, in the event of a Fundamental Transaction (other than (x)&nbsp;any stock split or reverse stock split, (y)&nbsp;any transaction effected solely for the purpose of changing the jurisdiction of incorporation of the Company,
or (z)&nbsp;any holding company reorganization or parent-subsidiary merger not requiring stockholder approval pursuant to Sections 251(g) or 253 of the General Corporation Law of the State of Delaware (or any successor provisions thereof)), the
Company or any Successor Entity (as defined below) shall, at the Holder&#146;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public
announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the
date of the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consummation of such Fundamental Transaction, provided, however, that, if the Fundamental Transaction is not within the Company&#146;s control, including not approved by the Company&#146;s Board
of Directors, the Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion) at the Black Scholes Value of the unexercised portion of this Warrant, that is
being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are
given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental
Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &#147;<B>Black Scholes
Value</B>&#148; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &#147;OV&#148; function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for pricing
purposes and reflecting (A)&nbsp;a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date,
(B)&nbsp;an expected volatility equal to the greater of (i) 100% and (ii)&nbsp;the 100 day volatility, each obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following
the public announcement of the applicable Fundamental Transaction, (C)&nbsp;the underlying price per share used in such calculation shall be the greater of (i)&nbsp;the sum of the price per share being offered in cash, if any, plus the value of any <FONT
STYLE="white-space:nowrap">non-cash</FONT> consideration, if any, being offered in such Fundamental Transaction and (ii)&nbsp;the greater of (x)&nbsp;the last VWAP immediately prior to the public announcement of such Fundamental Transaction and
(y)&nbsp;the last VWAP immediately prior to the consummation of the Fundamental Transaction, (D)&nbsp;a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination
Date and (E)&nbsp;a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds within five Trading Days of the Holder&#146;s election (or, if later, on the effective date of the
Fundamental Transaction). The terms of any agreement pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this
<U>Section</U><U></U><U>&nbsp;9(c)</U> and insuring that this Warrant (or any such replacement security) will be similarly adjusted upon any subsequent Fundamental Transaction. The Company shall cause any successor entity in a Fundamental
Transaction in which the Company is not the survivor (the &#147;<B>Successor Entity</B>&#148;) to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this
<U>Section</U><U></U><U>&nbsp;9(c)</U> pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option
of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of
shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to
such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction
and the value of such shares of capital stock, such adjustments to the number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such
Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for the Company (so that from and
after the date of such Fundamental Transaction, the provisions of this Warrant referring to the &#147;Company&#148; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the
obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein. Notwithstanding the foregoing, and without limiting <U>Section</U><U></U><U>&nbsp;11</U> hereof, the Holder may
elect, at its sole option, by delivery of written notice to the Company to waive this <U>Section</U><U></U><U>&nbsp;9(c)</U> to permit a Fundamental Transaction without the assumption of this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Exercise Price</U>. Simultaneously with any adjustment to the Number of Warrant Shares pursuant to Section&nbsp;9 the Exercise Price
shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the increased or decreased Number of Warrant Shares shall be the same as the aggregate Exercise Price in effect
immediately prior to such adjustment. Notwithstanding the foregoing, in no event may the Exercise Price be adjusted below the par value of the Common Stock then in effect. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Calculations</U>. All calculations under this Section&nbsp;9 shall be made to the
nearest <FONT STYLE="white-space:nowrap">one-hundredth</FONT> of one cent or the nearest whole share, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)<U> Notice of
Adjustments</U>. Upon the occurrence of each adjustment pursuant to this Section&nbsp;9, the Company at its expense will promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate setting
forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such
adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Transfer Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Notice of Corporate Events</U>. If, while this Warrant is outstanding, the Company (i)&nbsp;declares a dividend or any other
distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any subsidiary,
(ii)&nbsp;authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii)&nbsp;authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company,
then, except if such notice and the contents thereof shall be deemed to constitute material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company shall deliver to the Holder a notice of such transaction at least ten
(10)&nbsp;days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction; provided, however, that the failure to deliver such notice or any
defect therein shall not affect the validity of the corporate action required to be described in such notice. In addition, if while this Warrant is outstanding, the Company authorizes or approves, enters into any agreement contemplating or solicits
stockholder approval for any Fundamental Transaction contemplated by Section&nbsp;9(c), other than a Fundamental Transaction under clause (iii)&nbsp;of Section&nbsp;9(c), then, except if such notice and the contents thereof shall be deemed to
constitute material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company shall deliver to the Holder a notice of such Fundamental Transaction at least ten (10)&nbsp;days prior to the date such Fundamental Transaction is
consummated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><U>(h)</U> <U>Voluntary Adjustment By Company.</U> Subject to the rules and regulations of the Principal Trading Market, the
Company may at any time during the term of this Warrant, reduce the then-current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <I>Cashless Exercise</I>. If at any time during the term of this Warrant the Registration Statement or another registration statement
registering the issuance of Warrant Shares is, for any reason, not effective at the time of exercise of this Warrant, this Warrant may be exercised through a &#147;cashless exercise.&#148; Upon exercise, the Company shall issue to the Holder the
number of Warrant Shares in an exchange of securities effected pursuant to Section&nbsp;3(a)(9) of the Securities Act as determined as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">X = Y <FONT
STYLE="white-space:nowrap">[(A-B)/A]</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">where: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;X&#148; equals the number of Warrant Shares to be issued to the Holder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Y&#148; equals the total number of Warrant Shares with respect to which this Warrant is then being exercised; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;A&#148; equals the Closing Sale Price per share of Common Stock as of the Trading Day on the date immediately preceding the Exercise Date; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;B&#148; equals the Exercise Price per Warrant Share then in effect on the Exercise Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in
such a &#147;cashless exercise&#148; transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the Original Issue Date (provided that the Commission continues
to take the position that such treatment is proper at the time of such exercise). In the event that the Registration Statement or another registration statement registering the issuance of Warrant Shares is, for any reason, not effective at the time
of exercise of this Warrant, then this Warrant may only be exercised through a cashless exercise, as set forth in this<U>&nbsp;Section</U><U></U><U>&nbsp;10</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise set forth herein, in no event will the exercise of this Warrant be
settled in cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <I>Limitations on Exercise</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant (other than for <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants), and the Holder shall not be entitled to exercise this Warrant (other than for <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants) (i)&nbsp;if immediately prior to the exercise, the
Holder, its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act, beneficially own an aggregate number of shares of Common Stock
greater than [4.5] [4.99] [9.99] % (the &#147;<B>Maximum Percentage</B>&#148;) of the total number of issued and outstanding shares of Common Stock of the Company without taking into account any Warrant Shares, or (ii)&nbsp;to the extent that
immediately following the exercise, the Holder, its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act, would beneficially own
in excess of the Maximum Percentage of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such shares of Common Stock. Any portion of an exercise that would result in the issuance of shares in excess
of the Maximum Percentage shall be treated as null and void ab initio. For purposes of this Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as
reflected in (x)&nbsp;the Company&#146;s most recent Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as the case may be, filed with the Commission prior to the Exercise Date, (y)&nbsp;a more
recent public announcement by the Company or (z)&nbsp;any other notice by the Company or its Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written request of the Holder, the Company shall within three
(3)&nbsp;Trading Days confirm in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the
conversion or exercise of securities of the Company, including this Warrant, by the Holder since the date as of which such number of outstanding shares of Common Stock was reported. By written notice to the Company, the Holder may from time to time
increase or decrease the Maximum Percentage to any other percentage specified not in excess of 19.99% specified in such notice; provided that any such increase will not be effective until the sixty-first (61st) day after such notice is delivered to
the Company. For purposes of this Section&nbsp;11(a), the aggregate number of shares of Common Stock or voting securities beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be
aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act shall include the shares of Common Stock issuable upon the exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (x)&nbsp;exercise of the remaining unexercised and non-cancelled portion of this Warrant by the Holder and (y)&nbsp;exercise or conversion of the unexercised, <FONT
STYLE="white-space:nowrap">non-converted</FONT> or <FONT STYLE="white-space:nowrap">non-cancelled</FONT> portion of any other securities of the Company that do not have voting power (including without limitation any securities of the Company which
would entitle the holder thereof to acquire at any time Common Stock, including without limitation any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or
otherwise entitles the holder thereof to receive, Common Stock), is subject to a limitation on conversion or exercise analogous to the limitation contained herein and is beneficially owned by the Holder or any of its Affiliates and other Persons
whose beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act. For purposes of clarity, the Warrant Shares issuable pursuant to the terms of this Warrant in excess of the
Maximum Percentage shall not be deemed to be beneficially owned by the Holder for any purpose including for purposes of Section&nbsp;13(d) of the Exchange Act or Rule <FONT STYLE="white-space:nowrap">16a-1(a)(1)</FONT> promulgated under the Exchange
Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) This Section&nbsp;11 shall not restrict the number of shares of Common Stock which a Holder may receive or beneficially own in
order to determine the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated in Section&nbsp;9(c) of this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <I>No Fractional Shares or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants</I>. No fractional Warrant Shares or fractional <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down
to the next whole number and the Company shall pay the Holder in cash the fair market value (based on the Closing Sale Price) for any such fractional shares. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <I>Notices</I>. Any and all notices or other communications or deliveries hereunder
(including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i)&nbsp;the date of transmission, if such notice or communication is delivered via confirmed email prior to 5:30
P.M., New York City time, on a Trading Day, (ii)&nbsp;the next Trading Day after the date of transmission, if such notice or communication is delivered via confirmed <FONT STYLE="white-space:nowrap">e-mail</FONT> on a day that is not a Trading Day
or later than 5:30 P.M., New York City time, on any Trading Day, (iii)&nbsp;the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service specifying next business day delivery, or (iv)&nbsp;upon actual
receipt by the Person to whom such notice is required to be given, if by hand delivery. The addresses and <FONT STYLE="white-space:nowrap">e-mail</FONT> addresses for such communications shall be: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to the Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cabaletta Bio, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2929 Arch Street, Suite 600 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Philadelphia, PA 19104 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone: [___] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [___] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to the Holder, to its address or <FONT
STYLE="white-space:nowrap">e-mail</FONT> address set forth herein or on the books and records of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Or, in each of the above
instances, to such other address or <FONT STYLE="white-space:nowrap">e-mail</FONT> address as the recipient party has specified by written notice given to each other party at least five (5)&nbsp;days prior to the effectiveness of such change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <I>Warrant Agent</I>. The Company shall initially serve as warrant agent under this Warrant. Upon ten (10)&nbsp;days&#146; notice to the
Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or
any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor
warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder&#146;s last address as shown on the Warrant Register. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <I>Miscellaneous</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>No Rights as a Stockholder</U>. Except as otherwise set forth in this Warrant, the Holder, solely in such Person&#146;s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share
capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person&#146;s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or
any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends
or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as
imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Authorized Shares; Further Assurances</U>. Except and to the extent as waived or consented to by the Holder, the Company shall not by
any action, including, without limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid
or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect
the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant,
and (iii)&nbsp;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant. Before taking any action which would result in an adjustment in the number of Warrant
Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction
thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Successors and Assigns</U>. Subject to compliance with applicable securities laws, this Warrant may be assigned by the
Holder. This Warrant may not be assigned by the Company without the written consent of the Holder, except to a successor in the event of a Fundamental Transaction. This Warrant shall be binding on and inure to the benefit of the Company and the
Holder and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action
under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Amendment and Waiver</U>. Except as otherwise provided herein, this Warrant may be modified or amended or the provisions hereof waived
with the written consent of the Company and the Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Acceptance</U>. Receipt of this Warrant by the Holder shall constitute
acceptance of and agreement to all of the terms and conditions contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)<U> Governing Law; Jurisdiction</U>. ALL QUESTIONS
CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF.
EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION
HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY
CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY
MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS
AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit
or affect any of the provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Severability</U>. In case any one or more of the provisions of this Warrant shall be
invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder will attempt in good faith to agree
upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">REMAINDER OF PAGE INTENTIONALLY LEFT BLANK. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of
the date first indicated above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CABALETTA&nbsp;BIO, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF EXERCISE NOTICE </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[To
be executed by the Holder to purchase shares of Common Stock under the Warrant] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: (1)&nbsp;The undersigned is the Holder of Warrant
No. ___ (the &#147;Warrant&#148;) issued by Cabaletta Bio, Inc., a Delaware corporation (the &#147;Company&#148;). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The undersigned hereby exercises its right to purchase ___________ Warrant Shares and ___________ <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants pursuant to the Warrant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Holder intends that payment of the Exercise Price shall be made as (check one): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cash Exercise with respect to Warrant Shares </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Cashless Exercise&#148; under<U>&nbsp;Section</U><U></U><U>&nbsp;10</U>&nbsp;of the Warrant with respect
to Warrant Shares </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cash Exercise with respect to <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Cashless Exercise&#148; under<U>&nbsp;Section</U><U></U><U>&nbsp;10</U>&nbsp;of the Warrant with respect
to <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Holder has elected a Cash Exercise, the Holder shall pay the sum of $ _____ in immediately available
funds to the Company in accordance with the terms of the Warrant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares or <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants determined in accordance with the terms of the Warrant. The Warrant Shares shall be delivered to the following DWAC Account Number: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving
effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section&nbsp;13(d) of the Securities Exchange Act of 1934, as amended) permitted to be
owned under Section&nbsp;11(a) of the Warrant to which this notice relates. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name&nbsp;of&nbsp;Holder:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Signature must conform in all respects to name of Holder as specified on the face of the Warrant) </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>5
<FILENAME>d828604dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">June 12, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cabaletta Bio, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2929 Arch Street, Suite 600 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Philadelphia, PA 19104 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Securities Registered under Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT></U>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as counsel to you in connection with your filing of a Registration Statement on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-3ASR</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-278126)</FONT> as amended by that certain Post-Effective Amendment No.&nbsp;1 to Form <FONT STYLE="white-space:nowrap">S-3</FONT> (No. <FONT
STYLE="white-space:nowrap">333-278126)</FONT> and that certain Post-Effective Amendment No.&nbsp;2 to Form <FONT STYLE="white-space:nowrap">S-3</FONT> (No. <FONT STYLE="white-space:nowrap">333-278126)</FONT> (as amended or supplemented, the
&#147;Registration Statement&#148;) filed on March&nbsp;31, 2025 with the Securities and Exchange Commission (the &#147;Commission&#148;) pursuant to the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), relating to the
registration of the offer by Cabaletta Bio, Inc., a Delaware corporation (the &#147;Company&#148;), of up to $400,000,000 of any combination of securities of the types specified therein. The Registration Statement was declared effective by the
Commission on March&nbsp;31, 2025. Reference is made to our opinion letter dated March&nbsp;31, 2025 and included as Exhibit&nbsp;5.1 to the Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are delivering this supplemental opinion letter in connection with the prospectus supplement (the &#147;Prospectus Supplement&#148;) filed on June&nbsp;11,
2025 by the Company with the Commission pursuant to Rule&nbsp;424 under the Securities Act. The Prospectus Supplement relates to the offering by the Company of up to (i) 39,200,000 shares of the Company&#146;s common stock, par value $0.00001 per
share (the &#147;Common Stock&#148;), (ii) <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants (the <FONT STYLE="white-space:nowrap">&#147;Pre-Funded</FONT> Warrants&#148;) to purchase up to 10,800,000 shares of Common Stock and
(iii)&nbsp;warrants to purchase 50,000,000 shares of Common Stock (the &#147;Warrants&#148;) (such shares issuable upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and the Warrants, the &#147;Warrant Shares&#148; and
together with the Common Stock, the &#147;Shares&#148;) covered by the Registration Statement. The Shares include an over-allotment option granted to the underwriters of the offering to purchase 7,500,000 shares of Common Stock and 7,500,000
Warrants. The Shares, Warrants and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are being sold to the several underwriters named in, and pursuant to, an underwriting agreement among the Company and such underwriters (the
&#147;Underwriting Agreement&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinion
set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company. For purposes of the opinion set
forth in paragraph 3 below, we have assumed that before the Warrant Shares are issued, the Company does not issue shares of Common Stock or reduce the total number of shares of Common Stock the Company is authorized to issue under its certificate of
incorporation such that the number of unissued shares of Common Stock authorized under the Company&#146;s certificate of incorporation is less than the number of Warrant Shares. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cabaletta Bio, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June 12, 2025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 2 </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The opinions set forth below are limited to the Delaware General Corporation Law, and with respect to opinion
paragraph 2, the law of the State of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the foregoing, we are of the opinion that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Shares have been duly authorized and, when delivered and paid for in accordance with the terms of the
Underwriting Agreement, will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and the Warrants have been duly authorized and
executed by the Company and, when delivered and paid for in accordance with the terms of the Underwriting Agreement, will be valid and binding obligations of the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assuming sufficient authorized but unissued shares of Common Stock are available for issuance when the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and Warrants are exercised, the Warrant Shares, when issued upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and/or Warrants in accordance with the terms of the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and/or Warrants, will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The opinions expressed above are subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other similar laws of general
application affecting the rights and remedies of creditors and to general principles of equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion letter and the opinion it contains shall be
interpreted in accordance with the Core Opinion Principles as published in 74 <I>Business Lawyer</I> 815 (Summer 2019). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the
inclusion of this opinion as Exhibit&nbsp;5.1 to the Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and to the references to our firm under the caption &#147;Legal Matters&#148; in the Registration Statement. In giving our
consent, we do not admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations thereunder. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Goodwin Procter LLP</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GOODWIN PROCTER <SMALL>LLP</SMALL></P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>d828604dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g828604g0611224604895.jpg" ALT="LOGO" STYLE="width:2.86458in;height:0.392361in;">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cabaletta Bio Announces Pricing of Public Offering of Securities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PHILADELPHIA, June&nbsp;11, 2025 &#151; Cabaletta Bio, Inc. (&#147;Cabaletta&#148; or the &#147;Company&#148;) (Nasdaq: CABA), a clinical-stage biotechnology
company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced today the pricing of an underwritten public offering consisting of (i) 39,200,000 shares of
its common stock and accompanying warrants to purchase an aggregate of 39,200,000 shares of common stock (or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants in lieu thereof) and (ii)&nbsp;in lieu of common stock, to certain investors, <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase an aggregate of up to 10,800,000 shares of its common stock and accompanying warrants to purchase an aggregate of 10,800,000 shares of common stock (or
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants in lieu thereof), at an exercise price of $0.00001 per <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. Cabaletta also granted the underwriters a
<FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to an additional 15,000,000 shares of common stock and/or warrants at the public offering price, less underwriting discounts and commissions. The common stock and <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants are being sold in combination with an accompanying warrant to purchase one share of common stock (or a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant in lieu thereof) issued for each
share of common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant sold. The accompanying warrant has an exercise price of $2.50 per share, is immediately exercisable from the date of issuance and will expire fifteen months from the
date of issuance. The combined offering price of each share of common stock and accompanying common stock warrant is $2.00. The combined offering price of each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant and accompanying common stock
warrant is $1.99999. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of the shares, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and accompanying common stock warrants in the
offering are being sold by Cabaletta. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $100&nbsp;million, excluding any exercise of the
underwriters&#146; option to purchase additional shares and/or warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies, TD Cowen and Cantor are acting as joint book-running managers for the
offering. The offering is expected to close on or about June&nbsp;12, 2025, subject to customary closing conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of common stock, <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants and common stock warrants and shares of common stock issuable upon the exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and common stock warrants are being offered by
Cabaletta pursuant to a shelf registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-278126),</FONT> as amended by that certain Post-Effective Amendment No.&nbsp;1 to Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (No. <FONT STYLE="white-space:nowrap">333-278126)</FONT> and that certain Post-Effective Amendment No.&nbsp;2 to Form <FONT STYLE="white-space:nowrap">S-3</FONT> (No.
<FONT STYLE="white-space:nowrap">333-278126),</FONT> as filed with the U.S. Securities and Exchange Commission (SEC) on March&nbsp;31, 2025 and declared effective on March&nbsp;31, 2025. A preliminary prospectus supplement relating to and describing
the terms of the offering was filed with the SEC on June&nbsp;12, 2025. The final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and may also be obtained, when
available, from: Jefferies LLC by mail at Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) <FONT STYLE="white-space:nowrap">821-7388,</FONT> or by email at
prospectus_department@jefferies.com; TD Securities (USA) LLC, by mail at 1 Vanderbilt Avenue, New York, NY 10017, by telephone at (833) <FONT STYLE="white-space:nowrap">297-2926</FONT> or by email at TD.ECM_Prospectus@tdsecurities.com; Cantor
Fitzgerald&nbsp;&amp; Co. by mail at Attention: Capital Markets, 110 East 59th Street, New York 10022 or by email at prospectus@cantor.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press
release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such state or jurisdiction. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Cabaletta Bio </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed
specifically for patients with autoimmune diseases. The CABA<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> platform encompasses two complementary strategies which aim to advance the discovery and development of engineered T cell
therapies with the potential to become deep and durable, perhaps curative, treatments for a broad range of autoimmune diseases. The lead CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy is prioritizing the development of rese-cel,
a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">4-1BB-containing</FONT></FONT> fully human <FONT STYLE="white-space:nowrap">CD19-CAR</FONT> T cell investigational therapy. Rese-cel is currently being evaluated in the RESET<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology and dermatology. Cabaletta Bio&#146;s headquarters and labs are
located in Philadelphia, PA.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains &#147;forward-looking statements&#148; of Cabaletta Bio within the meaning of the Private Securities Litigation Reform Act of 1995,
as amended, including without limitation, express or implied statements regarding: Cabaletta&#146;s business plans and objectives as a whole; Cabaletta&#146;s ability to realize its vision of launching the first curative targeted cell therapy
designed specifically for patients with autoimmune diseases; Cabaletta&#146;s beliefs and expectations regarding its anticipated public offering; uncertainties related to market conditions and statements regarding the timing, size and expected
proceeds of the anticipated offering; and the safety, tolerability, efficacy, advancement and success of Cabaletta&#146;s clinical programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any
forward-looking statements in this press release are based on management&#146;s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties related to completion of the public offering on the anticipated terms, or at all, include, but are not limited to, market conditions and
the satisfaction of customary closing conditions related to the public offering. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Cabaletta&#146;s actual results to differ from those
contained in the forward-looking statements, see the section entitled &#147;Risk Factors&#148; in Cabaletta&#146;s most recent annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on March&nbsp;31, 2025 and our subsequent
quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Cabaletta&#146;s other filings with the SEC, including those
contained or incorporated by reference in the preliminary prospectus supplement related to the public offering to be filed with the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anup Marda </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">investors@cabalettabio.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>caba-20250611.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 6/12/2025 8:17:27 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2024"
  xmlns:caba="http://www.cabalettabio.com/20250611"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.cabalettabio.com/20250611"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" namespace="http://xbrl.sec.gov/naics/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="caba-20250611_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="caba-20250611_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.cabalettabio.com//20250611/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>caba-20250611_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 6/12/2025 8:17:27 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>caba-20250611_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 6/12/2025 8:17:27 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cabalettabio.com//20250611/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="caba-20250611.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com//20250611/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g828604g0611224604895.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g828604g0611224604895.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  E 0\# 2(  A$! Q$!_\0
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M\5TCUWC'->7&%-'^,D2VN$2]A+2J.F:ZF_\ B!X9L;)KC^U[6; RJ12AV;Z
M5YEH.K7NN?%:SU*Z@>&.=28%8?P=J&PI0=FV=5J_/QETG_KW-9GQ0OY!XJT>
MV:VDNH(_WOD)_P M#6IJ_P#R632?^O<U<^(NB7LOV/7M,0O=Z>V\H!RR]Z3O
M8<6E)7*4?Q)U*- B>$+]548  K+\1>+[[Q#HT]A-X0OP9!\K$9VGL:ZO0OB/
MX>U.R5KF_@LKA1B2&X<(0?QK+\2^/ENWCTCPG,+O49V \V$;EC'KGI1\QK1_
M")9O>GX.W$=_%)'-' R$2#!P.E;WPV_Y$33_ /=-2ZO87TO@*YM)Y#<7IMB'
M;'WFQSTK"^&7B'3I/#5OIDEU'%?0$H\+MANO8&FM&3+WH.W<K>*O^2K:!_NF
MK7Q:N)$\/6MHC%4N;E4D.>U4?'\HTGQOH6LW"D6:'8\@'"UN>+;&V\:>%)%T
MNZBGFB(EA:-@?F':EW&OLLZ31K&#3M(M;:W0+&D8  'M4NI6D-]IMQ;W"!XI
M$(8&N&\)?$/3VLAINNSK8:C;#RY%N#L#8]":D\5?$72K6QDM='N4O]0F4I&E
ML0X!/<D4[JQ'))S*WPBG=++5-.+%HK6Y(CSV%=WK7_(%OO\ K@_\J\V^"_FB
M#5_/!$OG#>#USWKTG6O^0)??]<'_ )4X[!55IL\K\ ^!=(\0>'FO;Q[H2^<R
MXBF*C ]JLZ[\._\ A&8CK_A^[E^T6?[QHYOFRHZ\U+\-_%6AZ1X9:VO]2@MY
MO/9MCM@XJ]XK^(FDW&D3Z9HLAO[Z[0Q(L*D@9XZU74QT-=M9'B#X87>I;=K2
MV4F]?1@"#5+P+.]M\)UN8_OQ13NOU!:GV.C3:%\)[JRN/]>+.5Y!Z$@G'ZT_
MX:Q)<?#BT@D&8Y!*K#U!9LT 0?">QBC\+-J)^:YO9W>60]3@D8/Y9_&O0.U>
M3>&]9;X>ZM<^'==#1V$DIDM;HCY<'U/I_*NRO?'?AFQLFN&UBUE &52&0.S>
MP I#.:6%='^-\45IA(M2LS),B],X;^J _C7IE>:>";:]\1>*KOQGJ$#00NOD
MV4;==O3/Y9_,UZ70 E<_KOA70M:4S:CIL,TF,;\;7_[Z'-%%)E0W,^Q^&_A2
MRFWQZ3&[@Y!E9G _ G%=5'&D,:I&BJB_*%48 %%%)#DR.]T^UU"V:WO((YX7
MX*2*"*Y5/AMX16;SUT>/=N^Z9'*_EFBBAA%Z&]/H.E3/:&2QA)LSNM\+@1GV
M ^E:N!C%%%4B6<QJ?@OPYK;?:;[2XGE)Y=24)^I7&:M:#X6T/18_,TW3H8&;
MJV-S?]]'FBBI6Y5W8WATK.U+2-/U:V:WO[2*XB_NR+G'T]/PHHJB48=K\.?"
MEE="6+2(BX.1YC,X'X,2*VO[$TQM0AOS9Q?:HEVQR8Y4>@HHI(IMBR:3I\NJ
M)J,EJC7D2[4F.<@5HX!&#113).8U'P%X9UBY::[TJ(S \NC,A/UVD5>T7PUH
MVAQN--L(H#W8#+'ZD\T45*W*<I6W-@CC%<]+X1T!]7COSIL2WB-N$J$KSZX'
M%%%-B1L7^G6>I6K6][;QSPMU21<BJ6B>&]*T*.1=+M5MUE.74,2#^9HHH0="
MMJ?A30?$6)M1TR*23IO&5;\Q@TW3/!N@:"&EL-,ACD ^^<LWYDDBBB@:;-'3
M=&T[2VG-C:I 96W2%?XCZFKLL:31M%(H9'!5@>XHHIHEF#_P@/A7.?[$ML_C
M_C5W3/#>BZ6WG6&F6T$A'WU0;A^)YHHH$:%Q;Q75M)!.@DBD4JZGH0>U0Z?I
M]IIEDMK90+# A.U%Z#/-%% $>I:3I^JVC0ZA9Q7,0_AD7./H>WX5BVOP[\*V
BMQYT6D1%QR/,9G4?@3BBB@#IHPJ($10JKP .U2T44 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 11, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001759138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 11,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CABALETTA BIO, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-1685768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2929 Arch Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Philadelphia<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(267)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">759-3100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.00001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CABA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d828604d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com//20250611/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>caba-20250611.xsd</File>
    <File>caba-20250611_lab.xml</File>
    <File>caba-20250611_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="d828604d8k.htm">d828604d8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d828604d8k.htm": {
   "nsprefix": "caba",
   "nsuri": "http://www.cabalettabio.com/20250611",
   "dts": {
    "schema": {
     "local": [
      "caba-20250611.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "caba-20250611_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "caba-20250611_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "d828604d8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.cabalettabio.com//20250611/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-06-11_to_2025-06-11",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d828604d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-06-11_to_2025-06-11",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d828604d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.cabalettabio.com//20250611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.cabalettabio.com//20250611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.cabalettabio.com//20250611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.cabalettabio.com//20250611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.cabalettabio.com//20250611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.cabalettabio.com//20250611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.cabalettabio.com//20250611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.cabalettabio.com//20250611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.cabalettabio.com//20250611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.cabalettabio.com//20250611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.cabalettabio.com//20250611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.cabalettabio.com//20250611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.cabalettabio.com//20250611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.cabalettabio.com//20250611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.cabalettabio.com//20250611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.cabalettabio.com//20250611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.cabalettabio.com//20250611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.cabalettabio.com//20250611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.cabalettabio.com//20250611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.cabalettabio.com//20250611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.cabalettabio.com//20250611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.cabalettabio.com//20250611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.cabalettabio.com//20250611/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001193125-25-139517-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-139517-xbrl.zip
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M@RX B?[^TC0I:"O/.V6VGFK=%1184V]@NOTB>W54IYV%I\?U!\+3W>+G8O
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M\#UK.T676?C28*N-P( 2G]3C)4T>?R]Q'[QRFMV=29[/^+:%;0O^.A)3+:_
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M.*=<\-@@STH#TT$N$WE7B[17F#,A%Z6JEY0L[5)SN,_S:Z- NE=AP5:/5EJ
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MVMW9^RT'>[-:[0]\7_Y\/]BD*H@D,RA! >@X%P:7R1^D+R\L+1:%]-[?@FO
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M5])K%OV(5P;Q9 ^^7C3[3]^"U7?ME#:#3%V*JFZX.HH; 0\S=@4T70PBN$Y
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MV51</PLIAAH\$O D(^O2A>N<(?)\;3#VBV5%6@6Q4QR(#=L,QHFUL3?^?*\
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M;S:'XYUE/\JMRK7Z5D)9EJNPC6<\,S/VU(RFG,5!?Z(+"IX_S<:H\R@5A3#
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M0"X5B+.,:E,3S-BU+K.\E ,9"'&:G!=3*KU&WP9SQVHE28=+]RT,RU7<C3O
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M-\<?7AS_9\)\N3X;Z%-#O34*_=4O]W,3S((@]6ONB;OY)*%!4=#\?!LQ](A
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ML@S99]BYC+ *SA)PWS>YZ/Z<Z!8"OMU R>NG,6 *.3!E7$EKOQS;&%]@D?X
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M(F/=\(Y&*TN7G87K;N=R7V/)^"JNEK,1&W+1 )S37U2%(MY03LF;\D@[_'D
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M?&DCT>Q>T5<(Q2\\DMM/AH^>R(%T='H:6'E30+ST&34C1/X-[SC&W5[!'S;
M_7!:[_MIQ0T7*\T<T;-DUB7(#PK^061@,Y&=&81EF$[8)(N5OZV9YQN6M]AD
M"I[?:=T&RKWX8^B$$WH^I-"9]:KO*L'!D,U$W5ZC+ >_RG]QY7@!%)@_<6W)
M3PZO/]I EBL'Z$]W@/TS\Z1LMGP-R]6D7XXC7!Q#>CAE_\&GC&)0""8X+>:
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ML(!Q09'<)DV_C;AE1(+#5*=IV386 !3?K@%ZRQ8)?)8B%@$#"A!=VBQ?KD;
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M<4X7/E'K@0?,E*,"SJ#/-8S4%FI@2FJX@'-HB7/I@:'B@VPU*)P:AR"C8FZ
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M[J1MVCN'@-VU62W*1M*F(Y6<CT1=9CXK-97W>SW;W6MF49RIY#"YZ\<^"0:
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M.N1>>1K,4[RM,HU:!H&)/L7)*MI<<]S78M\O;WK>K7';909 *.#82V> ._P
M* $0&!9P2+F]7X103\A*LV%&>8#M3.SMS-,<46 ( HK/!7A;+%D@?N6\FTL\
M(,!O_ KO/./V/,P+I)93Q8;H1(FIJ=?2A&XY3I-,XB40LA$\C[._#[,OS/#=
M5PCE@.R"($!H&^S-TQ2UDM/@</,$A*@4L#*>\4NUPXY!0$F([J=+%(2(YH9(
MY0MD2=/@+%UE>3 .\YC/:9H"Q( H!=,(Y1E\HVJ+M/&D>O?IS-U)LZ$I\C.D
MR">;[V'Y98I\C1WCAG%.#=>8%SN/F3_C+ ( W&? A!? DAML5 P.ATN1\NI7
M%@PSX0M9-(_.D4M[!_W'*J7U@>)B3MM=E,U8FHTUK.5*WI,"H]F P38FZ0HU
M..%!BA6M6;$/S./1OB!%'KS-4A ;418/6HC@01[#?0F1TY\"\?TWLRO\Y92D
M8SC.2101C. 04?"=K1*2=.@V\#3X*P$D;V\&_1GC>_F.@525X)&-\:_Y9#4/
MU<F%]G6!3R"=%C$^D/&&"',URX4WHM,4QP;D58)CQ70^-@8DD<$7-";3U['P
MH##.%$A9+ 88+E8%2)) IJ=10;R<P6D+OWAO\#/SBLUFHS];\SLSCX0T%)3<
M3[,H8D&Q>@W^!JRKMY>&V10?."!.EV:Y+Y?S_H!5T:FACH0S@&KQ^VIZ2M(<
M+$'OK'H%F\&H<BZDE"]>-1OJ=<8:#=$Q,F X"]H:?D?GB>Q@G./$TVA!7),
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M!'XZBY?E+!@R&HXM%_34N)K<:-Z9Q^C=9/>G&!^0J@:OHBP1AS?KP%))%]Q
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M1)Z0WUX3X/WZ\=[QP6?X\MWH_>'N_P!02P,$%     @ KC#,6CL07#VN"@
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M3V0\U]_CN32ZY"Q*IT.4X)06I?[BCE@V #?DL26^SU-MIZXHXBF-(IC;V])
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M#P  9#@R.#8P-&0X:RYH=&U02P$"% ,4    " "N,,Q: GR+EH*X   :O0,
M$               @ $I*   9#@R.#8P-&1E>#$Q+FAT;5!+ 0(4 Q0    (
M *XPS%K4$D^ 8#D  $GX   0              "  =G@  !D.#(X-C T9&5X
M-#$N:'1M4$L! A0#%     @ KC#,6J!J9V(C0P  2RX! !
M ( !9QH! &0X,C@V,#1D97@T,BYH=&U02P$"% ,4    " "N,,Q:.Q!</:X*
M  !"*P  $               @ &X70$ 9#@R.#8P-&1E>#4Q+FAT;5!+ 0(4
M Q0    ( *XPS%J!NYZT/@T  -8I   1              "  91H 0!D.#(X
C-C T9&5X.3DQ+FAT;5!+!08     "0 ) #@"   !=@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>d828604d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="caba-20250611.xsd" xlink:type="simple"/>
    <context id="duration_2025-06-11_to_2025-06-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
        </entity>
        <period>
            <startDate>2025-06-11</startDate>
            <endDate>2025-06-11</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-351">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-06-11_to_2025-06-11"
      id="Hidden_dei_EntityCentralIndexKey">0001759138</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-362">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-363">2025-06-11</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-364">CABALETTA BIO, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-365">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-366">001-39103</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-367">82-1685768</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-368">2929 Arch Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-369">Suite 600</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-370">Philadelphia</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-371">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-372">19104</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-373">(267)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-374">759-3100</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-375">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-376">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-377">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-378">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-379">Common Stock, par value $0.00001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-380">CABA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-381">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-06-11_to_2025-06-11" id="ixv-382">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
